<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8532670</article-id><article-id pub-id-type="doi">10.3390/antibiotics10101254</article-id><article-id pub-id-type="publisher-id">antibiotics-10-01254</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Looking Back to <italic toggle="yes">Amycolatopsis</italic>: History of the Antibiotic Discovery and Future Prospects</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4799-1318</contrib-id><name><surname>Kisil</surname><given-names>Olga V.</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9632-6854</contrib-id><name><surname>Efimenko</surname><given-names>Tatiana A.</given-names></name><xref rid="c1-antibiotics-10-01254" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3131-1031</contrib-id><name><surname>Efremenkova</surname><given-names>Olga V.</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Simal-Gandara</surname><given-names>Jesus</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Barros</surname><given-names>Lillian</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Lage</surname><given-names>Miguel A. Prieto</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-10-01254">Gause Institute of New Antibiotics, 119021 Moscow, Russia; <email>olvv@mail.ru</email> (O.V.K.); <email>ovefr@yandex.ru</email> (O.V.E.)</aff><author-notes><corresp id="c1-antibiotics-10-01254"><label>*</label>Correspondence: <email>efimen@inbox.ru</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2021</year></pub-date><volume>10</volume><issue>10</issue><elocation-id>1254</elocation-id><history><date date-type="received"><day>15</day><month>8</month><year>2021</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The emergence of antibiotic-resistant pathogenic bacteria in recent decades leads us to an urgent need for the development of new antibacterial agents. The species of the genus <italic toggle="yes">Amycolatopsis</italic> are known as producers of secondary metabolites that are used in medicine and agriculture. The complete genome sequences of the <italic toggle="yes">Amycolatopsis</italic> demonstrate a wide variety of biosynthetic gene clusters, which highlights the potential ability of actinomycetes of this genus to produce new antibiotics. In this review, we summarize information about antibiotics produced by <italic toggle="yes">Amycolatopsis</italic> species. This knowledge demonstrates the prospects for further study of this genus as an enormous source of antibiotics.</p></abstract><kwd-group><kwd>antibiotics</kwd><kwd>antimicrobial compounds</kwd><kwd>genus <italic toggle="yes">Amycolatopsis</italic></kwd><kwd>glycopeptide antibiotics</kwd><kwd>polyene antibiotics</kwd><kwd>rifamycins</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-10-01254"><title>1. Introduction</title><p>The science of antibiotics was formed in the twentieth century. About a hundred years ago, Alexander Fleming described the suppression of bacterial growth in an agar medium under the action of a certain substance released into the environment by a fungus colony growing nearby. This fungus was <italic toggle="yes">Penicillium chrysogenum</italic>, and the first discovered antibiotic was called penicillin. In the 1940s, an active search for natural antimicrobial compounds among representatives of various groups of organisms began. In 1952, Zelman Waxman introduced the term &#x0201c;antibiotics&#x0201d;. By the 1960s, all the major groups of currently known antibiotics had been discovered. Unlike the previous half-century period, during which all the main classes of antibiotics were described, in the twenty-first century the effectiveness of the search for new natural antibiotics has significantly decreased. An additional problem was the emergence of antibiotic-resistant microorganisms. The emergence of antibiotic resistance was a natural biological response to antimicrobial drug use, which created selective pressure that promoted the selection, survival and reproduction of microorganism-resistant strains. The spread of antibiotic-resistant microorganisms reduces the effectiveness of prevention and treatment of infectious and parasitic diseases in humans, animals and plants, leads to an increase in the severity and duration of these diseases, an increase in mortality among the population, and the death of animals and plants. The decline in the effectiveness of existing clinically important antibiotics has motivated researchers to search for new molecules with antimicrobial properties to overcome antimicrobial resistance. The phylum <italic toggle="yes">Actinobacteria</italic> represents one of the most diverse groups of microorganisms recognized within the domain Bacteria. Among the phylum <italic toggle="yes">Actinobacteria</italic>, the genus <italic toggle="yes">Streptomyces</italic> is the source of 70&#x02013;80% of all secondary metabolites; in addition, the important producers of antibiotics are the <italic toggle="yes">Amycolatopsis</italic>, <italic toggle="yes">Actinoplanes</italic>, <italic toggle="yes">Micromonospora</italic> and <italic toggle="yes">Saccharopolyspora</italic> genera [<xref rid="B1-antibiotics-10-01254" ref-type="bibr">1</xref>]. In our review we focus on antibiotics produced by genus <italic toggle="yes">Amycolatopsis</italic>, including the history of their discovery, the emergence of resistance, and the current state of the new drug discovery problem.</p></sec><sec id="sec2-antibiotics-10-01254"><title>2. The History and Genomic Analysis of <italic toggle="yes">Amycolatopsis</italic></title><p>The history of the genus <italic toggle="yes">Amycolatopsis</italic> is closely connected with the history of the discovery of antibiotics. The genus <italic toggle="yes">Amycolatopsis</italic> was previously widely used as one of the most effective sources of producers of secondary metabolites with antibacterial, antifungal, or antiviral properties and continues to be the focus of attention when searching for new drugs today [<xref rid="B2-antibiotics-10-01254" ref-type="bibr">2</xref>,<xref rid="B3-antibiotics-10-01254" ref-type="bibr">3</xref>,<xref rid="B4-antibiotics-10-01254" ref-type="bibr">4</xref>]. In the golden era of antibiotics in the 1950s, vancomycin and related glycopeptides (<italic toggle="yes">Amycolatopsis orientalis</italic>) and rifamycin (<italic toggle="yes">Amycolatopsis mediterranei</italic>) were discovered. In addition to antibiotic production, the importance of <italic toggle="yes">Amycolatopsis</italic> strains in industry and ecology, namely bioremediation (heavy metal immobilization, herbicide, and polymer biodegradation) and bioconversion (wuxistatin and vanillin production) was reported [<xref rid="B2-antibiotics-10-01254" ref-type="bibr">2</xref>,<xref rid="B5-antibiotics-10-01254" ref-type="bibr">5</xref>,<xref rid="B6-antibiotics-10-01254" ref-type="bibr">6</xref>]. Some members of the genus <italic toggle="yes">Amycolatopsis</italic> were initially misidentified as <italic toggle="yes">Streptomyces</italic> or <italic toggle="yes">Nocardia</italic>. Only in 1986 did Lechevalier finally recognize <italic toggle="yes">Amycolatopsis</italic> as a unique genus of nocardioform actinomycetes, that lack mycolic acids but contain meso-diaminopimelic acid, arabinose, and galactose in the peptidoglycan of the cell wall [<xref rid="B7-antibiotics-10-01254" ref-type="bibr">7</xref>]. <italic toggle="yes">A. orientalis</italic> was the first recorded species of this genus. The <italic toggle="yes">Amycolatopsis</italic> strains are widespread and are isolated mainly from soil [<xref rid="B8-antibiotics-10-01254" ref-type="bibr">8</xref>]. In addition, the <italic toggle="yes">Amycolatopsis</italic> strains have been isolated from medieval alum slate mine [<xref rid="B9-antibiotics-10-01254" ref-type="bibr">9</xref>], lichen <bold>[<xref rid="B10-antibiotics-10-01254" ref-type="bibr">10</xref>]</bold>, ocean sediment [<xref rid="B11-antibiotics-10-01254" ref-type="bibr">11</xref>], vegetable matter [<xref rid="B12-antibiotics-10-01254" ref-type="bibr">12</xref>], insects [<xref rid="B13-antibiotics-10-01254" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-10-01254" ref-type="bibr">14</xref>], clinical sources [<xref rid="B15-antibiotics-10-01254" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-10-01254" ref-type="bibr">16</xref>], and equine placentas [<xref rid="B17-antibiotics-10-01254" ref-type="bibr">17</xref>]. Only four <italic toggle="yes">Amycolatopsis</italic> species are known to have pathogenic properties [<xref rid="B15-antibiotics-10-01254" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-10-01254" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-10-01254" ref-type="bibr">17</xref>].</p><p>As of 2021, the number of officially accepted and published species of the genus <italic toggle="yes">Amycolatopsis</italic> is 83 (<xref rid="antibiotics-10-01254-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B18-antibiotics-10-01254" ref-type="bibr">18</xref>]. The genome sequences of 120 <italic toggle="yes">Amycolatopsis</italic> strains have been assembled, among them 71 assembled from type material [<xref rid="B19-antibiotics-10-01254" ref-type="bibr">19</xref>]. The genomic studies have revealed that <italic toggle="yes">Amycolatopsis</italic> species have genomes from 5.62 Mb (<italic toggle="yes">A. granulosa</italic> DSM 45669) to 10.94 Mb (<italic toggle="yes">A. anabasis</italic> EGI 650086) (on average, approximately 8.5&#x02013;9 Mb), circular chromosome, and a high DNA GC content (of 66&#x02013;75 mol%.) The pan-genome analysis revealed a core genome of 1212 genes with an accessory genome of 27,483 genes and 33,342 unique genes [<xref rid="B20-antibiotics-10-01254" ref-type="bibr">20</xref>,<xref rid="B21-antibiotics-10-01254" ref-type="bibr">21</xref>]. Due to such a significant pan-genome, <italic toggle="yes">Amycolatopsis</italic> species have an extensive adaptive capacity. A major part of the accessory and unique genes of the <italic toggle="yes">Amycolatopsis</italic> strains are involved in secondary metabolite biosynthesis [<xref rid="B20-antibiotics-10-01254" ref-type="bibr">20</xref>,<xref rid="B22-antibiotics-10-01254" ref-type="bibr">22</xref>].</p><p>The diversity of secondary metabolites in bacteria is highly dependent on the genus and is mainly organized into several diverse clusters called biosynthetic gene clusters (BGCs), which contain biosynthesis genes in close physical proximity [<xref rid="B23-antibiotics-10-01254" ref-type="bibr">23</xref>,<xref rid="B24-antibiotics-10-01254" ref-type="bibr">24</xref>,<xref rid="B25-antibiotics-10-01254" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-10-01254" ref-type="bibr">26</xref>]. BGCs encoding for closely related biosynthetic pathways are summarized under the term gene cluster families. All members of the cluster either produce or possess biosynthetic genes for the production of the corresponding class of antibiotics. BGCs of various genera of actinobacteria retrieved from the repository MIBiG (Minimum Information about a Biosynthetic Gene cluster) are presented in <xref rid="antibiotics-10-01254-t001" ref-type="table">Table 1</xref>. The correlation between average total genome length and number of BGCs puts <italic toggle="yes">Amycolatopsis</italic> in second place among rare actinobacteria species.</p><p>Phylogenetic trees constructed with the oxyB monooxygenase gene (essential for glycopeptides production) or with the AHBA synthase gene (essential for ansamycins production) demonstrate that all strains with correspondent genes are grouped into individual cluster families [<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]. So, <italic toggle="yes">Amycolatopsis</italic> type strains that produce, or have the potential to produce, a particular class of antibiotic are phylogenetically related. Owing to this phylogenetic clustering, it is possible to predict the antibiotic-production ability of a novel <italic toggle="yes">Amycolatopsis</italic> strain by its association in the tree, constructed with the antibiotic biosynthetic gene sequences. It should be noted that the presence of these genes does not necessarily mean that the strains will produce the antibiotic. The genes may not be expressed at all in the strain (silent genes) or may only be expressed under specific conditions (e.g., under particular environmental conditions, such as the type of media used for the antibacterial testing). Furthermore, if the genes are expressed, the antibiotic may not have activity against the strains used in the antibacterial screening tests. It is interesting to note that antibiotic biosynthetic genes in several <italic toggle="yes">Amycolatopsis</italic> type strains that are not known to produce antibiotics have been detected.</p></sec><sec id="sec3-antibiotics-10-01254"><title>3. <italic toggle="yes">Amycolatopsis</italic> Genomic Potential for Antibiotic Production</title><p>Today, understanding of the BGC system functioning, together with next generation sequencing, allows us to predict detection of new antibiotics. In 2006, genomic scanning analyses of <italic toggle="yes">A. orientalis</italic> ATCC 43491, deposited as a vancomycin producer, revealed the presence of genetic loci to produce at least ten secondary metabolites other than vancomycin [<xref rid="B28-antibiotics-10-01254" ref-type="bibr">28</xref>]. Screening of culture liquids led to the isolation of a novel linear polyene antibiotic 13-hydroxy-2,12,14,16,22-pentam ethyl-28-(<italic toggle="yes">N</italic>-methyl-guanidino)octacosa-2,4,6,8,10,14,20,24-octaenoic acid (2-hydroxy-5-oxo-cyclopent-1-enyl)-amide, ECO-0501), which exhibited antibacterial activity against several resistant Gram-positive pathogens.</p><p>Bacterial genome sequences are checked for regions that are likely to encode the production of secondary metabolites. Now researchers are faced with another problem: in BGC it is easy to identify bioinformatics, but how do we get them to produce antibiotics in the laboratory? Xu et al. reported a method for activating silent BGCs in diverse microorganisms [<xref rid="B29-antibiotics-10-01254" ref-type="bibr">29</xref>]. This approach relies on elicitor screening to induce the secondary metabolome of a given strain and imaging mass spectrometry to visualize the resulting metabolomes in response to ~500 conditions. Because it does not require challenging genetic, cloning, or culturing procedures, this method can be used with both sequenced and unsequenced bacteria. Application of this method to <italic toggle="yes">Amycolatopsis keratiniphila</italic> NRRL B24117 allowed the discovery of nine glycopeptide chemotype metabolites with potentially therapeutic bioactivities. Keratinimicins A and C showed potent antibacterial activity against numerous Gram-positive pathogens, with minimal inhibitory concentrations (MICs) akin to those of vancomycin against streptococci, <italic toggle="yes">Clostridium difficile</italic>, and <italic toggle="yes">Enterococcus faecalis</italic>.</p><p>On the one hand, the detection of ECO-0501 and keratinimicins is a worthy example of using the genome scanning method to identify and isolate a new class of antibacterial preparations. However, on the other hand, genomic mining has not become a key technology for the extraction of natural secondary metabolites. Most natural product BGC identified in bacterial genomic and metagenomic sequencing efforts are silent under laboratory growth conditions. Kim et al. presented a BGC activation method where the gene clusters are disassembled at interoperonic regions in vitro using CRISPR/Cas9 and then reassembled with PCR-amplified, short DNAs carrying synthetic promoters, using transformation-assisted recombination in yeast [<xref rid="B30-antibiotics-10-01254" ref-type="bibr">30</xref>]. This is <italic toggle="yes">in vitro</italic> disassembly/<italic toggle="yes">in vivo</italic> reassembly method was used for the activation of the atolypene BGC from the genome of the cultured actinomycete <italic toggle="yes">Amycolatopsis tolypomycina</italic> NRRL B-24205.30, which led to the characterization of two bacterial cyclic sesterterpenes, atolypene A and B, which are moderately cytotoxic to human cancer cell lines.</p><p>The most significant antibiotics from the <italic toggle="yes">Amycolatopsis</italic> genus were isolated by the traditional method, which involves isolation and cultivation of actinobacteria from the soil, screening for inhibitory activity in a test tube, and isolation of the leading molecules. The most currently known antibiotics isolated from <italic toggle="yes">Amycolatopsis</italic> are summarized in <xref rid="antibiotics-10-01254-t002" ref-type="table">Table 2</xref>. There are more than 100 compounds of <italic toggle="yes">Amycolatopsis</italic> origin with described antibacterial activity and/or proven antibiotic biosynthesis gene presence. The most productive species are <italic toggle="yes">A. orientalis</italic> (12 antibiotics), <italic toggle="yes">A. mediterranei</italic> (5 antibiotics), and <italic toggle="yes">A. sulphurea</italic> (3 antibiotics). Among the antibiotics produced by <italic toggle="yes">Amycolatopsis</italic>, there are two main commercially significant groups: glycopeptides and polyketides. Further in the text of this review we will discuss this division.</p></sec><sec id="sec4-antibiotics-10-01254"><title>4. Glycopeptide Antibiotics</title><p>Glycopeptides are glycosylated non-ribosomal peptides produced by a various group of actinomycetes. Glycopeptide antibiotics have a common structure representing a heptapeptide containing aromatic amino acids that have undergone extensive oxidative cross-linking to form macrocycles and carry in various positions such motifs as sugar residues, chlorine atoms, and lipid chains [<xref rid="B124-antibiotics-10-01254" ref-type="bibr">124</xref>]. Among actinobacteria, <italic toggle="yes">A. orientalis</italic> is a well-known producer of glycopeptide antibiotics (<xref rid="antibiotics-10-01254-t002" ref-type="table">Table 2</xref>).</p><p>Chen et al. proposed the dividing of glycopeptide antibiotics produced by <italic toggle="yes">Amycolatopsis</italic> into three classes, based on residue type at positions 1 and 3 of the heptapeptide: (I) Compounds containing aliphatic residues (vancomycin, balhimycin, eremomycin, chloroeremomycin, orienticin, norvancomycin). Vancomycin and balhimycin contain two sugar residues, while eremomycin and orienticin contain three sugar residues. (II) Compounds containing aromatic residues (avoparcin). (III) Compounds with aromatic residues that are covalently joined to each other (ristocetin) [<xref rid="B3-antibiotics-10-01254" ref-type="bibr">3</xref>]. The structures of the main glycopeptide antibiotics are presented in <xref rid="antibiotics-10-01254-f002" ref-type="fig">Figure 2</xref>.</p><sec id="sec4dot1-antibiotics-10-01254"><title>4.1. Vancomycin</title><p>In 1952, a missionary in Borneo sent a soil sample to his friend Dr. E.K. Cornfield, an organic chemist at Eli Lilly and Company [<xref rid="B125-antibiotics-10-01254" ref-type="bibr">125</xref>]. The microorganism isolated from this sample (previously identified as <italic toggle="yes">Streptomyces orientalis</italic>) produced a substance (&#x0201c;compound 05865&#x0201d;) that was active against most Gram-positive organisms, including penicillin-resistant <italic toggle="yes">S. aureus</italic>. &#x00422;he original product, obtained by fermentation, contained considerable (up to 70%) amounts of impurities, and had a brown color, earning it the nickname &#x0201c;Mississippi Mud&#x0201d; [<xref rid="B126-antibiotics-10-01254" ref-type="bibr">126</xref>]. The resulting drug was named &#x0201c;vancomycin&#x0201d;, a term derived from the word &#x0201c;vanquish&#x0201d; [<xref rid="B127-antibiotics-10-01254" ref-type="bibr">127</xref>]. The <italic toggle="yes">A. orientalis</italic> type strain was used for the biological preparation of vancomycin. However, <italic toggle="yes">A. orientalis</italic> is also a producer of natural derivatives of vancomycin, <italic toggle="yes">N</italic>-demethylvancomycin and <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-demethylvancomycin, which demonstrate significant antibacterial activity [<xref rid="B87-antibiotics-10-01254" ref-type="bibr">87</xref>,<xref rid="B91-antibiotics-10-01254" ref-type="bibr">91</xref>]. Subsequently, numerous mutant strains of <italic toggle="yes">A. orientalis</italic> were developed for the industrial production of vancomycin, giving a high yield of the drug [<xref rid="B128-antibiotics-10-01254" ref-type="bibr">128</xref>]. In 1958, there was a growing problem of drug-resistant staphylococci, so the US Food and Drug Administration granted vancomycin a &#x0201c;fast track approval&#x0201d; in the absence of an effective alternative [<xref rid="B126-antibiotics-10-01254" ref-type="bibr">126</xref>,<xref rid="B129-antibiotics-10-01254" ref-type="bibr">129</xref>]. However, methicillin, the first semisynthetic penicillin, was also licensed for clinical use in 1958. The pronounced ototoxicity and nephrotoxicity, most likely due to impurities contained in early vancomycin lots, did not allow its widespread use for treatment. A special place among adverse reactions is occupied by the &#x0201c;red man&#x0201d; syndrome, which is characterized by a combination of erythema, pruritis, hypotension, and angioedema. The occurrence of &#x0201c;red man&#x0201d; syndrome is associated with the degranulation of mast cells and basophils caused by the administration of rapid infusions of the first dose of the drug [<xref rid="B130-antibiotics-10-01254" ref-type="bibr">130</xref>]. The aversion to vancomycin is associated with the emergence of methicillin-resistant, and broadly, beta-lactam resistant <italic toggle="yes">S. aureus</italic>, and the introduction of chromatographic purification methods. Chromatographically purified dosage forms of vancomycin with a content of at least 90&#x02013;95% of the active substance are characterized by low toxicity, and today vancomycin is considered as a relatively safe drug with some minor side effects. Vancomycin and related glycopeptides are considered antibiotics of last resort for the treatment of life-threatening infections caused by all clinically significant Gram-positive human pathogens, such as <italic toggle="yes">Clostridium</italic> spp., <italic toggle="yes">Enterococcus</italic> spp., <italic toggle="yes">Lactobacillus</italic> spp., <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">S. aureus</italic> (including methicillin-resistant strains of <italic toggle="yes">S. aureus,</italic> MRSA), etc [<xref rid="B124-antibiotics-10-01254" ref-type="bibr">124</xref>,<xref rid="B131-antibiotics-10-01254" ref-type="bibr">131</xref>]. During the vancomycin biosynthesis, seven amino acid precursors are assembled to form a linear heptapeptide, which is then modified, including cyclization, halogenation, methylation, and glycosylation [<xref rid="B132-antibiotics-10-01254" ref-type="bibr">132</xref>,<xref rid="B133-antibiotics-10-01254" ref-type="bibr">133</xref>,<xref rid="B134-antibiotics-10-01254" ref-type="bibr">134</xref>] (<xref rid="app1-antibiotics-10-01254" ref-type="app">Figure S1</xref>). Both methylation and demethylation do not affect the antibacterial activity of vancomycin and its derivatives <italic toggle="yes">in vitro</italic>. As for glycosylation, despite aglucovancomycin showing a slightly higher bioactivity than that of vancomycin <italic toggle="yes">in vitro</italic>, the <italic toggle="yes">in vivo</italic> activity was five-fold lower than that of vancomycin [<xref rid="B135-antibiotics-10-01254" ref-type="bibr">135</xref>]. This indicates that part of the sugar may play an important role in giving improved pharmacokinetic properties [<xref rid="B135-antibiotics-10-01254" ref-type="bibr">135</xref>]. Chlorination has not been sufficiently studied, although it is assumed that it improves the dimerization of glycopeptides, which, in turn, can positively enhance antimicrobial activity [<xref rid="B133-antibiotics-10-01254" ref-type="bibr">133</xref>]. The biosynthesis pathways of balhimycin and chloroeremomycin are similar to vancomycin [<xref rid="B3-antibiotics-10-01254" ref-type="bibr">3</xref>].</p></sec><sec id="sec4dot2-antibiotics-10-01254"><title>4.2. Eremomycin</title><p>Eremomycin was isolated at the Gause Institute of New Antibiotics (Russia) from the cultural liquid of the actinomycete <italic toggle="yes">Nocardia orientalis</italic> INA 238, later clarified as <italic toggle="yes">A. orientalis</italic> [<xref rid="B136-antibiotics-10-01254" ref-type="bibr">136</xref>]. Eremomycin is closely related to vancomycin but differs in sugar residue and chlorine content. Monodechlorovancomycinic acid was detected in eremomycin. The antibacterial spectrum of eremomycin is close to that of ristomycin and vancomycin. However, the <italic toggle="yes">in vitro</italic> antibacterial activity of eremomycin is 2&#x02013;10 times higher than that of ristomycin and vancomycin. <italic toggle="yes">In vivo</italic> studies showed that eremomycin is less toxic than vancomycin and ristomycin. It does not cause damage to local tissues after intramuscular injections. The chemotherapeutic indices of eremomycin in the treatment of staphylococcal and streptococcal sepsis in albino mice exceeded 10 times those of vancomycin [<xref rid="B137-antibiotics-10-01254" ref-type="bibr">137</xref>]. The pharmacokinetic parameters of eremomycin, teicoplanin, and vancomycin were compared after their intravenous administration to rats at the same dose. The antibacterial activity of eremomycin against methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) was 4 times higher than that of vancomycin [<xref rid="B138-antibiotics-10-01254" ref-type="bibr">138</xref>]. Currently, the ability to produce eremomycin is shown not only for <italic toggle="yes">A. orientalis</italic> but also for <italic toggle="yes">A. umgeniensis</italic> [<xref rid="B121-antibiotics-10-01254" ref-type="bibr">121</xref>].</p></sec><sec id="sec4dot3-antibiotics-10-01254"><title>4.3. Norvancomycin</title><p>Norvancomycin was isolated from <italic toggle="yes">A. orientalis</italic> CPCC200066 (originally named wan-23) from a soil sample in China in 1959 [<xref rid="B93-antibiotics-10-01254" ref-type="bibr">93</xref>]. This strain was first discovered for its ability to produce an antibiotic that resembles the glycopeptide antibiotic vancomycin, and in 1983 it was confirmed as norvancomycin. The chemical structure of norvancomycin is almost the same as that of vancomycin, except for an absent methyl group at the N-terminus. Norvancomycin is effective for the treatment of bacterial infections caused by Gram-positive cocci and bacilli, especially infections of MRSA and methicillin-resistant <italic toggle="yes">S. epidermidis</italic> (MRSE) [<xref rid="B92-antibiotics-10-01254" ref-type="bibr">92</xref>]. The complete genome sequence of <italic toggle="yes">A. orientalis</italic> CPCC200066 has been obtained [<xref rid="B93-antibiotics-10-01254" ref-type="bibr">93</xref>]. Norvancomycin is widely used in China to treat severe infections such as endocarditis and osteomyelitis.</p></sec><sec id="sec4dot4-antibiotics-10-01254"><title>4.4. Balhimycin</title><p>Balhimycin was isolated from the fermentation broth of a <italic toggle="yes">Amycolatopsis</italic> sp. Y-86, 21022, later clarified as <italic toggle="yes">A. balhimycina.</italic> It differs from vancomycin only in its glycosylation pattern [<xref rid="B55-antibiotics-10-01254" ref-type="bibr">55</xref>]. Balhimycin is very similar in activity to vancomycin, but it shows higher activity towards anaerobic bacteria. Most knowledge on glycopeptide biosynthetic pathways comes from studies on <italic toggle="yes">A. balhimycina</italic> as this species, among glycopeptide producers, is genetically more amenable [<xref rid="B139-antibiotics-10-01254" ref-type="bibr">139</xref>]. <italic toggle="yes">A. balhimycina</italic> is positioned as a model producing strain for production of improved derivatives of glycopeptide antibiotics by molecular genetic methods [<xref rid="B140-antibiotics-10-01254" ref-type="bibr">140</xref>].</p></sec><sec id="sec4dot5-antibiotics-10-01254"><title>4.5. Ristocetin (Ristomycin)</title><p>Ristocetin was isolated from <italic toggle="yes">A. orientalis</italic> subsp. <italic toggle="yes">lurida</italic> [<xref rid="B41-antibiotics-10-01254" ref-type="bibr">41</xref>,<xref rid="B73-antibiotics-10-01254" ref-type="bibr">73</xref>]. It was first discovered as a mixture of two closely related components, designated ristocetin A and ristocetin B. Although these two ristocetins have the same antimicrobial spectrum, ristocetin B is 3&#x02013;4 times more active than ristocetin A. The commercial preparation of this antibiotic is the mixture of ristocetin A and ristocetin B [<xref rid="B141-antibiotics-10-01254" ref-type="bibr">141</xref>]. Ristocetin A and B are specific against Gram-positive bacteria, including mycobacteria. Since the toxic side effects of ristocetin include thrombocytopenia and platelet agglutination, it is only used for laboratory diagnosis of von Willebrand disease. Von Willebrand disease is a mucosal bleeding caused by platelet and collagen binding [<xref rid="B142-antibiotics-10-01254" ref-type="bibr">142</xref>]. One of the strategies to new antibiotics discovery is to evaluate the genetic capacity of the secondary metabolite-producing strains and to activate silent BGC. <italic toggle="yes">A. japonicum</italic> does not produce antibiotics under standard laboratory conditions. To activate a possible silent glycopeptide cluster, Spohn et al. introduced a gene encoding the transcriptional activator of balhimycin biosynthesis, the <italic toggle="yes">bbr</italic> gene from <italic toggle="yes">A. balhimycina</italic> (<italic toggle="yes">bbr</italic><sub>Aba</sub>), into <italic toggle="yes">A. japonicum</italic>. The resulting recombinant strain of <italic toggle="yes">A. japonicum</italic>/pRM4-<italic toggle="yes">bbr</italic><sub>Aba</sub> synthesizes ristomycin A [<xref rid="B62-antibiotics-10-01254" ref-type="bibr">62</xref>].</p></sec><sec id="sec4dot6-antibiotics-10-01254"><title>4.6. Avoparcin and Emergence of Vancomycin Resistance</title><p>Avoparcin (avotan) was isolated from <italic toggle="yes">A. coloradensis</italic> (formerly <italic toggle="yes">Streptomyces candidus</italic>) in 1968 [<xref rid="B56-antibiotics-10-01254" ref-type="bibr">56</xref>]. It is chemically similar to vancomycin and is a mixture of components. The commercial product consists of a mixture of &#x003b1;- and &#x003b2;-avoparcin, which differ only in the presence of an additional aromatic chlorine atom in the &#x003b2; component [<xref rid="B143-antibiotics-10-01254" ref-type="bibr">143</xref>,<xref rid="B144-antibiotics-10-01254" ref-type="bibr">144</xref>]. Avoparcin has been widely used as a feed additive to promote the growth of cattle, pigs, and chickens. The presence of vancomycin-resistant bacterial strains in humans who were first admitted to the hospital and had never previously taken antibiotics suggested that these strains could have been transmitted through the food chain, as a result of the use of avaporcin in animal feed. The presence of various strains of vancomycin-resistant enterococci strains in animal and human feces in areas where avoparcin was used has been well documented [<xref rid="B145-antibiotics-10-01254" ref-type="bibr">145</xref>]. So, avoparcin was banned in Europe in 1997 by the Commission of the European Union, after which many researchers reported decreased prevalence of vancomycin-resistant enterococci strains in livestock. However, these strains never completely disappeared [<xref rid="B146-antibiotics-10-01254" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-10-01254" ref-type="bibr">147</xref>].</p><p>Antimicrobial activity of glycopeptides is based on binding to the bacterial cell envelope, and not to the target protein, as in the case of most antibiotics. Glycopeptides bind to the <italic toggle="yes">D</italic>-alanyl-<italic toggle="yes">D</italic>-alanine (<italic toggle="yes">D</italic>-Ala-<italic toggle="yes">D</italic>-Ala) dipeptide terminus of the growing peptidoglycan on the outer surface of the bacterial cytoplasmic membrane [<xref rid="B148-antibiotics-10-01254" ref-type="bibr">148</xref>]. This, in turn, interferes with the maturation of the peptidoglycan layer, sequestering the substrate from transpeptidation and/or transglycosylation reactions at the late extracellular stages of peptidoglycan cross-linking. Subsequently, the replicating bacteria cannot survive due to an incomplete and damaged cell wall, which makes them vulnerable to osmotic pressure [<xref rid="B124-antibiotics-10-01254" ref-type="bibr">124</xref>]. Due to a different cell wall morphology, namely the presence of an external lipopolysaccharide membrane impervious to large biomolecules, Gram-negative bacteria are protected from vancomycin [<xref rid="B149-antibiotics-10-01254" ref-type="bibr">149</xref>]. Glycopeptide-resistant organisms replace the <italic toggle="yes">D</italic>-Ala-<italic toggle="yes">D</italic>-Ala terminus with <italic toggle="yes">D</italic>-alanyl-<italic toggle="yes">D</italic>-lactate (<italic toggle="yes">D</italic>-Ala-<italic toggle="yes">D</italic>-Lac) or <italic toggle="yes">D</italic>-alanyl-<italic toggle="yes">D</italic>-serine (<italic toggle="yes">D</italic>-Ala-<italic toggle="yes">D</italic>-Ser), thus markedly reducing antibiotic affinity for the cellular target [<xref rid="B150-antibiotics-10-01254" ref-type="bibr">150</xref>]. Resistance manifests itself in enterococci and staphylococci mainly through the expression of <italic toggle="yes">van</italic> genes encoding proteins that reprogram cell wall biosynthesis and thus evade the action of the antibiotic [<xref rid="B124-antibiotics-10-01254" ref-type="bibr">124</xref>].</p><p>The emergence of vancomycin resistance was compared to all other antibiotics. In 1986, vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic> was found in England and France, followed by vancomycin-resistant <italic toggle="yes">E. faecalis</italic> detected in the United States next year [<xref rid="B151-antibiotics-10-01254" ref-type="bibr">151</xref>]. Vancomycin-resistant enterococci (VRE) are categorized as opportunistic pathogens that are selected for when other bacteria die off. The determinants of resistance in enterococci are encoded in the plasmid-borne transposons, which increases the vancomycin resistance spreading among Gram-positive species through horizontal gene transfer [<xref rid="B152-antibiotics-10-01254" ref-type="bibr">152</xref>,<xref rid="B153-antibiotics-10-01254" ref-type="bibr">153</xref>]. The transfer of <italic toggle="yes">van</italic> genes from enterococci to other Gram-positive bacteria, such as staphylococci, has been shown [<xref rid="B154-antibiotics-10-01254" ref-type="bibr">154</xref>]. The first case of <italic toggle="yes">S. aureus</italic> resistance to vancomycin was detected in 2002 for a dialysis patient in Michigan co-infected with the vancomycin-resistant <italic toggle="yes">E. faecalis</italic> [<xref rid="B129-antibiotics-10-01254" ref-type="bibr">129</xref>,<xref rid="B155-antibiotics-10-01254" ref-type="bibr">155</xref>]. The origin of the genes associated with vancomycin-resistance in enterococci is unknown, but the selection pressure on bacteria was clearly favorable for their occurrence. At the same time, the use of avoparcin in livestock farming has created a hospitable environment for the emergence of vancomycin-resistant enterococci strains. However, it is possible that actinomycetes are the original source of the <italic toggle="yes">van</italic> genes. Most antibiotic-producing bacteria have self-defense strategies and immunity from the effects of these chemical weapons. The simultaneous presence of the antibiotic synthesis and antibiotic resistance genes makes it possible to regulate the bacterial self-resistance [<xref rid="B156-antibiotics-10-01254" ref-type="bibr">156</xref>]. It has been hypothesized that the enterococci vancomycin-resistance genes originated from glycopeptide-producing organisms where they are presumably needed to avoid bacterial suicide [<xref rid="B157-antibiotics-10-01254" ref-type="bibr">157</xref>,<xref rid="B158-antibiotics-10-01254" ref-type="bibr">158</xref>]. Then, the resistance genes were transferred to organisms with the same GC content (for example, <italic toggle="yes">Paenibacillus popilliae</italic>), and then to enterococci. In support of this hypothesis, van-like genes which have similarity to <italic toggle="yes">vanA</italic> and <italic toggle="yes">vanB</italic> have been found in several glycopeptide producers such as <italic toggle="yes">A. orientalis</italic> and <italic toggle="yes">A. balhimycina</italic>.</p></sec></sec><sec id="sec5-antibiotics-10-01254"><title>5. Polyketide Antibiotics</title><p>In addition to glycopeptide antibiotics, the genus <italic toggle="yes">Amycolatopsis</italic> is a well-known producer of polyketide antibiotics. Their structures range widely and include cyclic, acyclic, small, large, simple, and complex molecules (<xref rid="antibiotics-10-01254-f003" ref-type="fig">Figure 3</xref>). Among the polyketide antibiotics produced by genus <italic toggle="yes">Amycolatopsis</italic>, rifamycins, chelocardin, tolypomycin, kanglemicin A, macrothermycins A-D, van&#x00441;oresmycin, tetracenomycin X, and rifamorpholines A-E should be listed (<xref rid="antibiotics-10-01254-t002" ref-type="table">Table 2</xref>). These antibiotics are united by their bacterial biosynthetic pathway: all of them are obtained through a polyketide precursor, which is different in the case of each antibiotic. The most commercially demanded of them is rifamycin, which belongs to the ansamycin polyketides. Ansamycins get their name from the characteristic configuration of their molecule carbon skeleton, which has a basket-shaped architecture, consisting of an aromatic naphthalene (or benzene) core and a long aliphatic bridge in the shape of a handle (latin, <italic toggle="yes">ansa</italic>) connecting two non-adjacent positions of the core. The resulting molecules are very rigid and compact, which leads to unique chemical properties and specific biological effects [<xref rid="B159-antibiotics-10-01254" ref-type="bibr">159</xref>].</p><sec id="sec5dot1-antibiotics-10-01254"><title>5.1. Rifamycin&#x02019;s Discovery and Structure</title><p>In 1957, in France, from a soil sample in Saint-Raphael, a strain was isolated which was classified as <italic toggle="yes">Streptomyces mediterranei</italic>, later as <italic toggle="yes">Nocardia mediterranei</italic>, and finally as <italic toggle="yes">Amycolatopsis mediterranei</italic> ATCC 13685/DSM 43304/ME 83/973. The strain was cultured in shaking flasks and the cultural liquid showed high activity against Gram-positive bacteria <italic toggle="yes">Mycobacterium tuberculosis</italic>. In addition, it demonstrated limited activity against some Gram-negative bacteria [<xref rid="B79-antibiotics-10-01254" ref-type="bibr">79</xref>]. Thus, one of the earliest antibiotics was discovered, rifamycin, named after the Italian movie &#x0201c;Le Riffi&#x0201d; [<xref rid="B160-antibiotics-10-01254" ref-type="bibr">160</xref>]. The original strain <italic toggle="yes">A. mediterranei</italic> ATCC 13685 produced a mixture of several rifamycin antibiotics. The only component of this extract that could be isolated in pure crystalline form by the addition of sodium diethylbarbiturate was rifamycin B, secondary in biological activity. The rifamycin B molecule consists of two main parts: the naphthoquinone ring and a 24-member aliphatic chain with 5 methyl groups (<xref rid="antibiotics-10-01254-f003" ref-type="fig">Figure 3</xref>(<bold>1</bold>)). Due to the importance of rifamycin, the producer strain <italic toggle="yes">A. mediterranei</italic> was selected in order to create strains capable of producing large amounts of rifamycin B, or its biologically active natural derivatives [<xref rid="B161-antibiotics-10-01254" ref-type="bibr">161</xref>]. Later, a mutant strain, <italic toggle="yes">A. mediterranei</italic> ATCC 21789, producing single rifamycin B without any barbiturate salt addition, was isolated [<xref rid="B162-antibiotics-10-01254" ref-type="bibr">162</xref>].</p><p>All ansamycins are assembled by the polyketide pathway, using 3-amino-5-hydroxybenzoic acid (AHBA) as the starting unit [<xref rid="B163-antibiotics-10-01254" ref-type="bibr">163</xref>]. The earliest macrocyclic precursor in the biosynthesis of rifamycin is proansamycin X (<xref rid="app1-antibiotics-10-01254" ref-type="app">Figure S2</xref>). It had never been isolated and identified, therefore, it is to some extent hypothetical [<xref rid="B163-antibiotics-10-01254" ref-type="bibr">163</xref>,<xref rid="B164-antibiotics-10-01254" ref-type="bibr">164</xref>]. Proansamycin X dehydrogenation leads to the formation of biologically inactive rifamycin W. Further post-translational modifications lead to the production rifamycin SV, and rifamycin S [<xref rid="B165-antibiotics-10-01254" ref-type="bibr">165</xref>]. Rifamycins W, S, and SV are key intermediates in biosynthesis and are precursors of many other natural derivatives of rifamycins: B, R, G, Q, P, Z, O, L, Y, etc. <xref rid="antibiotics-10-01254-t003" ref-type="table">Table 3</xref> summarizes the rifamycin derivatives produced by genus <italic toggle="yes">Amycolatopsis</italic> and shows their bioactivity and biosynthetic precursors. Some of these derivatives, together with ketides accumulated by <italic toggle="yes">A. mediterranei</italic>, can be considered as waste metabolites, resulting from enzymatic reactions with the formation of biologically active rifamycins. The most stable component in the rifamycin complex is rifamycin B. Reversible oxidation of the quinone core, followed by hydrolytic loss of the glycolic acid fragment of rifamycin B, leads to the production of significantly more active rifamycins S and SV. Rifamycin SV quickly stood out among the first available natural rifamycins due to its antibacterial activity and low toxicity. Rifamycin SV was the first rifamycin used in clinical practice but was only effective when injected intravenously [<xref rid="B166-antibiotics-10-01254" ref-type="bibr">166</xref>]. Rifamycin S was half as weak as rifamycin SV [<xref rid="B167-antibiotics-10-01254" ref-type="bibr">167</xref>]. The poor bioavailability and poor pharmacokinetic properties of rifamycin SV, combined with the understanding of structure&#x02013;activity relationships, initiated a chemical campaign to develop a more potent and orally bioavailable drug. In 1965, Dow-Lepetit Research Laboratories (Milan, Italy) developed <italic toggle="yes">rifampicin</italic> (3-(4-methyl-piperazinyl-iminomethyl) rifamycin SV), which is the most important and widely used semi-synthetic antibiotic of the rifamycin group in medicine (<xref rid="app1-antibiotics-10-01254" ref-type="app">Figure S2</xref>) [<xref rid="B168-antibiotics-10-01254" ref-type="bibr">168</xref>].</p></sec><sec id="sec5dot2-antibiotics-10-01254"><title>5.2. Mechanism of Rifampicin Action and Occurrence of Resistance</title><p>The antibiotic activity of rifamycins on the bacterial cell has been most widely studied for rifampicin. Rifampicin (and other rifamycins) binds in the rifamycin-binding pocket to the &#x003b2;-subunit of RNA polymerase in the immediate vicinity of the catalytic site and sterically blocks the expansion of the RNA chain [<xref rid="B167-antibiotics-10-01254" ref-type="bibr">167</xref>]. The collision of RNA and rifampicin occurs when the RNA reaches a length of 3&#x02013;4 nucleotides, after which the RNA is released from the promoter complex in the form of an interrupted transcript. The length of the abortive RNA product may be affected at the C3 substituent of a particular rifamycin&#x02019;s derivative. Eukaryotic cell polymerases are less sensitive to the antibiotic compared to the bacterial ones. Binding constants for prokaryotic RNA polymerases are about 10<sup>&#x02212;8</sup> M whereas those for eukaryotic enzymes are at least 10,000 fold weaker [<xref rid="B167-antibiotics-10-01254" ref-type="bibr">167</xref>]. Due to their high selectivity for their molecular target, rifamycins have become a safe and effective drug [<xref rid="B78-antibiotics-10-01254" ref-type="bibr">78</xref>]. At present, rifampicin is still the first-line treatment for diseases such as tuberculosis, leprosy, and various infections associated with the biofilm formation. It is important to note that natural rifamycins have significant activity only against Gram-positive bacteria because of the hydrophobic nature of their large molecule.</p><p>The main practical rifamycin application is associated with its activity against mycobacteria. Tuberculosis is second (just after AIDS) among the world&#x02019;s most common causes of death from infectious diseases [<xref rid="B188-antibiotics-10-01254" ref-type="bibr">188</xref>]. WHO estimates that 8&#x02013;10 million new cases of tuberculosis occur worldwide each year. A third of the world&#x02019;s population is infected by <italic toggle="yes">M. tuberculosis</italic>, the etiological agent of tuberculosis [<xref rid="B189-antibiotics-10-01254" ref-type="bibr">189</xref>,<xref rid="B190-antibiotics-10-01254" ref-type="bibr">190</xref>]. However, long periods of use and poor medical supervision have resulted in rifamycin-resistant <italic toggle="yes">M. tuberculosis</italic> strains [<xref rid="B191-antibiotics-10-01254" ref-type="bibr">191</xref>]. The primary mechanism of resistance to rifampicin (and other rifamycins) consists of rapid selection of resistant mutants (amino acids substitutions) in the rifampicin-binding pocket of RNA polymerase, which results in antibiotic affinity decreasing. Another way to decrease antibiotic affinity is the enzymatic modification of rifamycin by C-21 and C-23 hydroxyl groups [<xref rid="B192-antibiotics-10-01254" ref-type="bibr">192</xref>]. Altogether, these modifications generate the rifamicyn resistome, which negatively affects this class of antibiotics. In 2016, there were 600,000 reported new cases of resistance to rifamycin, of which 490,000 were caused by multidrug-resistant <italic toggle="yes">M. tuberculosis</italic> strains [<xref rid="B78-antibiotics-10-01254" ref-type="bibr">78</xref>,<xref rid="B193-antibiotics-10-01254" ref-type="bibr">193</xref>].</p></sec><sec id="sec5dot3-antibiotics-10-01254"><title>5.3. Polyketide Backbone Rearrangement</title><p>Despite obtaining a large number of rifamycin derivatives by semi-synthetic approaches (more than 750 rifamycin derivatives have been studied) the possibility of chemically introducing structural modifications is limited because of the structural complexity of the rifamycin molecule [<xref rid="B160-antibiotics-10-01254" ref-type="bibr">160</xref>,<xref rid="B169-antibiotics-10-01254" ref-type="bibr">169</xref>]. Unfortunately, no new drug has been developed for tuberculosis in recent decades [<xref rid="B167-antibiotics-10-01254" ref-type="bibr">167</xref>]. Today, to achieve structural diversity, researchers have switched to a combinatorial biosynthetic approach&#x02014;mutasynthesis. Knowledge of the biosynthesis of rifamycins allows the rational genetic manipulation of <italic toggle="yes">A. mediterranei</italic> to obtain new natural antibiotics.</p><p>Nigam et al., by replacing the substituted acyltransferase domain of module 6 of rifamycin polyketide synthase with that of module 2 of rapamycin polyketide synthase, obtained the semisynthetic derivatives 24-desmethylrifamycin B and 24-desmethylrifamycin SV. These compounds have proven effective against a number of pathogenic bacteria, including several rifampicin-resistant <italic toggle="yes">M. tuberculosis</italic> strains [<xref rid="B194-antibiotics-10-01254" ref-type="bibr">194</xref>].</p><p>Posttranslational modifications at the last stages of the biosynthetic pathway of rifamycins play an important role in expanding the structural diversity and, as a consequence, biological activity of the final rifamycin metabolites. <xref rid="antibiotics-10-01254-t003" ref-type="table">Table 3</xref> shows that the early intermediates on the pathway of rifampicin biosynthesis do not have any biological activity. The proposed earliest macrocyclic precursor in rifamycin biosynthesis, proansamycin X, undergoes dehydration to form protorifamycins or undergoes dehydrogenation to form rifamycin W. Rifamycin W undergoes a rearrangement of the polyketide backbone to produce rifamycin B. However, the progress of genetic engineering allows us to look at inactive rhymaicins X and W as potential sources for structural modifications in the hope of new drugs discovery. Shi et al. in 2021 constructed the mutant strain <italic toggle="yes">Amycolatopsis mediterranei</italic> S699 <italic toggle="yes">&#x00394;rif-orf5</italic> by in-frame deleting the <italic toggle="yes">rif-orf5</italic> gene (involved in the polyketide backbone rearrangement mechanism) to afford thirteen rifamycin W congeners including seven new ones [<xref rid="B195-antibiotics-10-01254" ref-type="bibr">195</xref>]. Compounds 1&#x02013;3 exhibited antibacterial activity against <italic toggle="yes">Staphylococcus aureus</italic>. A year earlier, Ye et al. constructed mutant strain <italic toggle="yes">A. mediterranei</italic> S699<italic toggle="yes">&#x00394;rifT</italic> by deleting the <italic toggle="yes">rifT</italic> gene, encoding NADH-dependent dehydrogenase, presumably responsible for the dehydrogenation of proansamycin X. The mutant strain successfully produced eleven 8-deoxy-rifamycin derivatives and seven known analogs. For four of them, antibacterial activity against <italic toggle="yes">S. aureus</italic> was shown [<xref rid="B196-antibiotics-10-01254" ref-type="bibr">196</xref>].</p></sec></sec><sec id="sec6-antibiotics-10-01254"><title>6. Old New Polyenes</title><p>A promising approach to searching for effective antibiotics is to look back and re-examine the molecules that previously demonstrated antibacterial activity but for various reasons did not receive further development.</p><sec id="sec6dot1-antibiotics-10-01254"><title>6.1. Kanglemycin A</title><p>As well as rifamycins, <italic toggle="yes">A. mediterranei</italic> produces another ansamycin&#x02014;kanglemycin A (KglA). KglA was originally isolated from the fermentation broth of <italic toggle="yes">Nocardia mediterranei</italic> var. <italic toggle="yes">kanglensis</italic> 1741&#x02013;64 [<xref rid="B77-antibiotics-10-01254" ref-type="bibr">77</xref>]. There was only limited information about its biological activity until 2018, when Mosaei et al. described in detail the mechanism of KglA action [<xref rid="B78-antibiotics-10-01254" ref-type="bibr">78</xref>]. This antibiotic contains two important and unusual ansa bridge modifications: a pendant 2,2-dimethyl succinic acid side chain at C20 and a unique sugar moiety (&#x003b2;-O-3,4-O,O&#x02019;-methylene digitoxose) at C27. As a result, KglA exhibits an altered binding conformation with RNA polymerase (larger binding surface) in comparison to known rifamycins and their semisynthetic derivatives. The mechanism of KglA action also differs from rifampicin, as KglA inhibits RNA synthesis even after the first phosphodiester bond formation. This leads to the phenomenon where KglA is effective against rifampicin-resistant pathogens [<xref rid="B78-antibiotics-10-01254" ref-type="bibr">78</xref>,<xref rid="B197-antibiotics-10-01254" ref-type="bibr">197</xref>].</p></sec><sec id="sec6dot2-antibiotics-10-01254"><title>6.2. Chelocardin (Otherwise Known as Cetocycline or Cetotetrine)</title><p>Another polyenes antibiotic produced by <italic toggle="yes">Amycolatopsis</italic> that has regained interest in recent years is atypical tetracycline chelocardin. Isolated from <italic toggle="yes">A. sulphurea</italic> (formerly <italic toggle="yes">N. sulphurea</italic>), chelocardin was&#x000a0;first described in the 1970s [<xref rid="B116-antibiotics-10-01254" ref-type="bibr">116</xref>,<xref rid="B198-antibiotics-10-01254" ref-type="bibr">198</xref>]. It is structurally related to tetracyclines and contains a 9-methyl group, aromatic ring, unsubstituted 4-ammonia group, and the methyl group replacing the 2-ammonia group. At low concentrations, like classical tetracyclines, chelocardin prevents bacterial growth by inhibition of peptidyl transferase biosynthesis. At higher concentrations, the bacterial membrane is the main antibiotic target of chelocardin [<xref rid="B199-antibiotics-10-01254" ref-type="bibr">199</xref>]. The application of the biosynthetic engineering approach made it possible to design a recombinant <italic toggle="yes">A. sulphurea</italic> producing a new chelocardin analogue with carboxamido moiety of tetracyclines (an important structural feature for its bioactivity). 2-Carboxamido-2-deacetyl-chelocardin showed significantly improved antimicrobial activity against a collection of well-characterized multidrug-resistant clinical isolates from the ESKAPE panel [<xref rid="B118-antibiotics-10-01254" ref-type="bibr">118</xref>,<xref rid="B200-antibiotics-10-01254" ref-type="bibr">200</xref>,<xref rid="B201-antibiotics-10-01254" ref-type="bibr">201</xref>].</p></sec><sec id="sec6dot3-antibiotics-10-01254"><title>6.3. Vancoresmycin</title><p>Vancoresmycin is an understudied natural product antibiotic consisting of a terminal tetramic acid moiety linked to a linear, highly oxygenated, stereochemically complex polyketide chain. It was isolated from the fermentation broth of the <italic toggle="yes">Amycolatopsis</italic> sp. ST 101170 in 2002 [<xref rid="B122-antibiotics-10-01254" ref-type="bibr">122</xref>]. The species name <italic toggle="yes">A. vancoresmycina</italic> was proposed by Wink et al. who isolated it from Indian soil [<xref rid="B65-antibiotics-10-01254" ref-type="bibr">65</xref>]. In 2013 the genome of the strain <italic toggle="yes">A. vancoresmycina</italic> DSM 44592 was sequenced [<xref rid="B202-antibiotics-10-01254" ref-type="bibr">202</xref>]. Vancoresmycin shows minimal inhibitory concentrations against a range of clinically relevant, antibiotic-resistant Gram-positive bacteria. It selectively targets the cytoplasmic membrane of Gram-positive bacteria via a concentration-dependent depolarization mechanism [<xref rid="B123-antibiotics-10-01254" ref-type="bibr">123</xref>].</p></sec><sec id="sec6dot4-antibiotics-10-01254"><title>6.4. Rifamycin O</title><p>Some studies return attention to the natural metabolites of rifampicin, which were not tested in time due to the establishment of rifampicins B, S, and SV for clinical purposes (<xref rid="antibiotics-10-01254-t003" ref-type="table">Table 3</xref>). In 2020 it was shown that rifamycin O, which is fundamentally different from other rifamycins in positions C1 and C4, showed significant activity <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> against <italic toggle="yes">M. abscessus.</italic> It is the most difficult-to-treat nontuberculous mycobacteria because of internal and acquired resistance mechanisms and <italic toggle="yes">M. abscessus</italic> cell wall is 10&#x02013;20 times less permeable than that of <italic toggle="yes">M. tuberculosis</italic> [<xref rid="B183-antibiotics-10-01254" ref-type="bibr">183</xref>].</p></sec></sec><sec id="sec7-antibiotics-10-01254"><title>7. Antibiotics Produced by <italic toggle="yes">Amycolatopsis</italic> Isolated from Poorly Studied Ecological Habitats</title><p>While metagenomics and high-throughput sequencing tools reveal the species diversity of microbial communities and identify genetic clusters for the production of antibiotics that have not been detected by cultured approaches, the isolation of a monoculture of microorganisms is still important for the detection of bioactive compounds. However, in order to effectively obtain <italic toggle="yes">Actinobacteria</italic> for the discovery of new drugs, it is necessary to estimate where to search for new producers in terms of geography and specific ecological systems [<xref rid="B203-antibiotics-10-01254" ref-type="bibr">203</xref>]. The main hopes for new antibiotic discoveries are related to microorganisms isolated from extreme or unusual environments that are characterized by challenging conditions such as aridity, high salinity, low nutrient sources, extreme temperatures, and especially the complex composition of microorganism species. Other alternative promising sources of specialized metabolites are the microbiota of diverse eukaryotic hosts, including plants, insects, sponges, and humans. The evolution of microorganisms from such habitats follows a special path, due to geographical and/or genetic isolation and adaptation to extreme conditions. Therefore, it is likely to find among such endemic species unique metabolisms, the products of which are new antibiotics. In the last five years, several new antibiotics produced by various <italic toggle="yes">Amycolatopsis</italic> strains have been isolated and described. Most of them are located in special environmental conditions. Recent studies of lichen-associated <italic toggle="yes">Amycolatopsis</italic> metabolites have led to the isolation of amycophthalazinone A [<xref rid="B44-antibiotics-10-01254" ref-type="bibr">44</xref>], 2-carbamoyl-3-hydroxy-1,4-naphthoquinone [<xref rid="B45-antibiotics-10-01254" ref-type="bibr">45</xref>], and amycolasporin C [<xref rid="B61-antibiotics-10-01254" ref-type="bibr">61</xref>]. Amycophthalazinone A is the first example of a naturally occurring phthalazinone derivative. Amycophthalazinone A exhibits potent inhibitory activity against <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">Salmonella typhi</italic> (MIC 32 &#x003bc;g/mL) [<xref rid="B44-antibiotics-10-01254" ref-type="bibr">44</xref>]. The antimicrobial activity test shows that 2-carbamoyl-3-hydroxy-1,4-naphthoquinone has significant inhibitory effects on bacterial pathogens MRSA (MIC 2 &#x003bc;g/mL) and fungal pathogens of <italic toggle="yes">Botrytis cinerea</italic> and <italic toggle="yes">Fusarium graminearum</italic> (MICs 1 &#x003bc;g/mL) [<xref rid="B45-antibiotics-10-01254" ref-type="bibr">45</xref>]. Amycolasporin C shows activity against <italic toggle="yes">Bacillus subtilis, S. aureus,</italic> and <italic toggle="yes">Escherichia coli</italic> (MIC 25 &#x003bc;g/mL) [<xref rid="B61-antibiotics-10-01254" ref-type="bibr">61</xref>]. The sponge-associated marine bacteria produce more antibiotic substances through competition for space and nutrients. Amycolactam, isolated from the <italic toggle="yes">A. saalfeldensis</italic>, is the bacterial indole alkaloid related to the cyclopiazonic acid class [<xref rid="B32-antibiotics-10-01254" ref-type="bibr">32</xref>]. The biological activities of amycolactam were evaluated in antibacterial and antifungal assays against various pathogenic microbes, but the compound did not exhibit significant inhibitory activities. Amycolactam displays significant cytotoxicity against the gastric cancer cell line and the colon cancer cell line, with IC<sub>50</sub> values of 0.8 and 2.0 &#x003bc;M, respectively. Bacteria, through antibiotics, often provide chemical defenses that selectively inhibit insect microbial competitors and pathogens. Macrotermycins A and C from the termite-associated <italic toggle="yes">Amycolatopsis</italic> sp. M39 have antibacterial activity against human-pathogenic <italic toggle="yes">S. aureus</italic>&#x000a0;(MIC 1.5 and 10 &#x003bc;g/mL, respectively) [<xref rid="B14-antibiotics-10-01254" ref-type="bibr">14</xref>]. <italic toggle="yes">Amycolatopsis</italic> sp. HCa4 isolated from the gut of locusts (<italic toggle="yes">Locusta migratoria</italic>) produces amycolamycin A which is selectively cytotoxic to the M231 breast cancer cell line [<xref rid="B204-antibiotics-10-01254" ref-type="bibr">204</xref>] and rifamorpholines A-E [<xref rid="B13-antibiotics-10-01254" ref-type="bibr">13</xref>]. Rifamorpholines represent the new subclass of rifamycin antibiotics with an unprecedented 5/6/6/6 fused tetracyclic ring system and an unusually modified polyketide chain. Rifamorpholine B (<xref rid="antibiotics-10-01254-f003" ref-type="fig">Figure 3</xref>) shows activity against MRSA (MIC 4 &#x000b5;g/mL).</p></sec><sec sec-type="conclusions" id="sec8-antibiotics-10-01254"><title>8. Conclusions</title><p>Medical success in the treatment of many diseases is associated with the development and widespread use of antibiotics, biologically active substances of natural origin, and their chemical analogues with antimicrobial, antitumor, antiviral, and immunomodulatory properties. At the beginning of the birth of the science of antibiotics, which began with the discovery of penicillin in 1928, the search for new antibiotics has been carried out in a variety of organisms. Later it was shown that most antibiotics are formed by fungi and bacteria living in species-enriched biocenoses, primarily in the soil. It was found that the main producers of antibiotics are actinobacteria. Actinobacteria produce two-thirds of all known antibiotics used in the clinic today. Among actinobacteria, representatives of the genus <italic toggle="yes">Streptomyces</italic> are the champions in a number of identified antibiotics. Unfortunately, at present, the discovery of new natural antibiotics is not as effective as it was in the &#x0201c;golden era of antibiotics&#x0201d; (1940s&#x02013;1970s). The study of rare genera of actinobacteria, which are not as thoroughly studied as <italic toggle="yes">Streptomyces</italic>, is promising for the search for new antibiotics. Among such genera, the genus <italic toggle="yes">Amycolatopsis</italic> is particularly interesting, since its representatives form antibiotics of different chemical structures, including two especially important medical antibiotics, vancomycin and rifamycin, and their analogues. The sequencing of the first complete bacterial genome in 1995 opened a new page of possibilities for antibacterial drug discoverers. The combination of next-generation sequencing technologies, comparative genomics, and studies of the role of specific gene expression provides effective opportunities for activating the BGCs that <italic toggle="yes">Amycolatopsis</italic> is so full of. Silent BGCs are a treasure trove of potential new antibiotics. An alternative approach to the search for new antibiotics is to optimize the structural scaffolds with proven antibacterial activity by genetically engineering strains producing commercially significant antibiotics, such as <italic toggle="yes">A. mediterranei</italic> and <italic toggle="yes">A. orientalis</italic>. Transformation of compounds such as rapamycin through the application of biosynthetic engineering can deliver novel drug candidates. Every year, the genus <italic toggle="yes">Amycolatopsis</italic> opens up new prospects for obtaining new antibiotics. In the past five years, more than a dozen new antibiotics produced by strains of various species of <italic toggle="yes">Amycolatopsis</italic> have been isolated and described. The results of our review show that members of the genus <italic toggle="yes">Amycolatopsis</italic> are still a valuable source of new antibiotics, and our task is to correctly reveal and use this potential.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-antibiotics-10-01254"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/article/10.3390/antibiotics10101254/s1">https://www.mdpi.com/article/10.3390/antibiotics10101254/s1</uri>, Figure S1: Biosynthetic pathway of vancomycin [<xref rid="B132-antibiotics-10-01254" ref-type="bibr">132</xref>,<xref rid="B133-antibiotics-10-01254" ref-type="bibr">133</xref>]. Figure S2: (A) Biosynthetic pathway of rifamycin B [<xref rid="B163-antibiotics-10-01254" ref-type="bibr">163</xref>,<xref rid="B164-antibiotics-10-01254" ref-type="bibr">164</xref>]. (B) Chemical structure of rifampicin.</p><supplementary-material id="antibiotics-10-01254-s001" position="float" content-type="local-data"><media xlink:href="antibiotics-10-01254-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, O.V.E. and O.V.K.; writing&#x02014;original draft preparation, O.V.K.; writing&#x02014;review and editing, T.A.E.; project administration, O.V.E. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-10-01254"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ventura</surname><given-names>M.</given-names></name>
<name><surname>Canchaya</surname><given-names>C.</given-names></name>
<name><surname>Tauch</surname><given-names>A.</given-names></name>
<name><surname>Chandra</surname><given-names>G.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>G.F.</given-names></name>
<name><surname>Chater</surname><given-names>K.F.</given-names></name>
<name><surname>van Sinderen</surname><given-names>D.</given-names></name>
</person-group><article-title>Genomics of <italic toggle="yes">Actinobacteria</italic>: Tracing the evolutionary history of an ancient phylum</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2007</year><volume>71</volume><fpage>495</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00005-07</pub-id><pub-id pub-id-type="pmid">17804669</pub-id></element-citation></ref><ref id="B2-antibiotics-10-01254"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Hou</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
</person-group><article-title>Secondary Metabolites of the Genus <italic toggle="yes">Amycolatopsis</italic>: Structures, Bioactivities and Biosynthesis</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>1884</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26071884</pub-id><?supplied-pmid 33810439?><pub-id pub-id-type="pmid">33810439</pub-id></element-citation></ref><ref id="B3-antibiotics-10-01254"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
<name><surname>Shen</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
</person-group><article-title>Progress in understanding the genetic information and biosynthetic pathways behind <italic toggle="yes">Amycolatopsis</italic> antibiotics, with implications for the continued discovery of novel drugs</article-title><source>ChemBioChem</source><year>2016</year><volume>17</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1002/cbic.201500542</pub-id><?supplied-pmid 26503579?><pub-id pub-id-type="pmid">26503579</pub-id></element-citation></ref><ref id="B4-antibiotics-10-01254"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumari</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Lal</surname><given-names>R.</given-names></name>
</person-group><article-title>Genetics and genomics of the genus <italic toggle="yes">Amycolatopsis</italic></article-title><source>Indian J. Microbiol.</source><year>2016</year><volume>56</volume><fpage>233</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s12088-016-0590-8</pub-id><pub-id pub-id-type="pmid">27407288</pub-id></element-citation></ref><ref id="B5-antibiotics-10-01254"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x000e1;vila Costa</surname><given-names>J.S.</given-names></name>
<name><surname>Amoroso</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Current biotechnological applications of the genus <italic toggle="yes">Amycolatopsis</italic></article-title><source>World J. Microbiol. Biotechnol.</source><year>2014</year><volume>30</volume><fpage>1919</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1007/s11274-014-1622-3</pub-id><pub-id pub-id-type="pmid">24557749</pub-id></element-citation></ref><ref id="B6-antibiotics-10-01254"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Penkhrue</surname><given-names>W.</given-names></name>
<name><surname>Sujarit</surname><given-names>K.</given-names></name>
<name><surname>Kudo</surname><given-names>T.</given-names></name>
<name><surname>Ohkuma</surname><given-names>M.</given-names></name>
<name><surname>Masaki</surname><given-names>K.</given-names></name>
<name><surname>Aizawa</surname><given-names>T.</given-names></name>
<name><surname>Pathom-Aree</surname><given-names>W.</given-names></name>
<name><surname>Khanongnuch</surname><given-names>C.</given-names></name>
<name><surname>Lumyong</surname><given-names>S.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis oliviviridis</italic> sp. <italic toggle="yes">nov.</italic>, a novel polylactic acid-bioplastic-degrading actinomycete isolated from paddy soil</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2018</year><volume>68</volume><fpage>1448</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1099/ijsem.0.002682</pub-id><?supplied-pmid 29517482?><pub-id pub-id-type="pmid">29517482</pub-id></element-citation></ref><ref id="B7-antibiotics-10-01254"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lechevalier</surname><given-names>M.P.</given-names></name>
<name><surname>Prauser</surname><given-names>H.</given-names></name>
<name><surname>Labeda</surname><given-names>D.P.</given-names></name>
<name><surname>Ruan</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Two new genera of nocardioform actinomycetes: <italic toggle="yes">Amycolata</italic> gen. nov. and <italic toggle="yes">Amycolatopsis</italic> gen. nov</article-title><source>Int. J. Syst. Bacteriol.</source><year>1986</year><volume>36</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1099/00207713-36-1-29</pub-id></element-citation></ref><ref id="B8-antibiotics-10-01254"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>S.K.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Guan</surname><given-names>T.W.</given-names></name>
<name><surname>Lee</surname><given-names>J.C.</given-names></name>
<name><surname>Kim</surname><given-names>C.J.</given-names></name>
<name><surname>Li</surname><given-names>W.J.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis halophila</italic> sp. nov., a halophilic actinomycete isolated from a salt lake</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2010</year><volume>60</volume><issue-part>Pt 5</issue-part><fpage>1073</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.012427-0</pub-id><pub-id pub-id-type="pmid">19666809</pub-id></element-citation></ref><ref id="B9-antibiotics-10-01254"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carlsohn</surname><given-names>M.R.</given-names></name>
<name><surname>Growth</surname><given-names>I.</given-names></name>
<name><surname>Tan</surname><given-names>G.Y.A.</given-names></name>
<name><surname>Sch&#x000fc;tze</surname><given-names>B.</given-names></name>
<name><surname>Saluz</surname><given-names>H.P.</given-names></name>
<name><surname>Munder</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Wink</surname><given-names>J.</given-names></name>
<name><surname>Goodfellow</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis saalfeldensis</italic> sp. nov., a novel actinomycete isolated from a medieval alum slate mine</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2007</year><volume>57</volume><issue-part>Pt 7</issue-part><fpage>1640</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.64903-0</pub-id><pub-id pub-id-type="pmid">17625209</pub-id></element-citation></ref><ref id="B10-antibiotics-10-01254"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e1;nchez-Hidalgo</surname><given-names>M.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>I.</given-names></name>
<name><surname>D&#x000ed;az-Mu&#x000f1;oz</surname><given-names>C.</given-names></name>
<name><surname>Mart&#x000ed;nez</surname><given-names>G.</given-names></name>
<name><surname>Genilloud</surname><given-names>O.</given-names></name>
</person-group><article-title>Comparative genomics and biosynthetic potential analysis of two lichen-isolated <italic toggle="yes">Amycolatopsis</italic> strains</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>369</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00369</pub-id><pub-id pub-id-type="pmid">29593664</pub-id></element-citation></ref><ref id="B11-antibiotics-10-01254"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bian</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Song</surname><given-names>F.H.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Dai</surname><given-names>H.Q.</given-names></name>
<name><surname>Ren</surname><given-names>B.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Z.H.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Amycolatopsis marina</italic> sp. nov., an actinomycete isolated from an ocean sediment</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2009</year><volume>59</volume><issue-part>Pt 3</issue-part><fpage>477</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.000026-0</pub-id><?supplied-pmid 19244425?><pub-id pub-id-type="pmid">19244425</pub-id></element-citation></ref><ref id="B12-antibiotics-10-01254"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodfellow</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Minnikin</surname><given-names>D.E.</given-names></name>
<name><surname>Whitehead</surname><given-names>D.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.-H.</given-names></name>
<name><surname>Mattinson-Rose</surname><given-names>A.D.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis sacchari</italic> sp. nov., a moderately thermophilic actinomycete isolated from vegetable matter</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2001</year><volume>51</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1099/00207713-51-1-187</pub-id><pub-id pub-id-type="pmid">11211259</pub-id></element-citation></ref><ref id="B13-antibiotics-10-01254"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>Y.S.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>Z.K.</given-names></name>
<name><surname>Deng</surname><given-names>X.Z.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Jiao</surname><given-names>R.H.</given-names></name>
<name><surname>Tan</surname><given-names>R.X.</given-names></name>
<name><surname>Ge</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Rifamorpholines A&#x02013;E, potential antibiotics from locust-associated actinobacteria <italic toggle="yes">Amycolatopsis</italic> sp. Hca4</article-title><source>Org. Biomol. Chem.</source><year>2017</year><volume>15</volume><fpage>3909</fpage><lpage>3916</lpage><pub-id pub-id-type="doi">10.1039/C7OB00614D</pub-id><?supplied-pmid 28422262?><pub-id pub-id-type="pmid">28422262</pub-id></element-citation></ref><ref id="B14-antibiotics-10-01254"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beemelmanns</surname><given-names>C.</given-names></name>
<name><surname>Ramadhar</surname><given-names>T.R.</given-names></name>
<name><surname>Kim</surname><given-names>K.H.</given-names></name>
<name><surname>Klassen</surname><given-names>J.L.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Wyche</surname><given-names>T.P.</given-names></name>
<name><surname>Hou</surname><given-names>Y.</given-names></name>
<name><surname>Poulsen</surname><given-names>M.</given-names></name>
<name><surname>Bugni</surname><given-names>T.S.</given-names></name>
<name><surname>Currie</surname><given-names>C.R.</given-names></name>
<etal/>
</person-group><article-title>Macrotermycins A-D, glycosylated macrolactams from a termite-associated <italic toggle="yes">Amycolatopsis</italic> sp. M39</article-title><source>Org. Lett.</source><year>2017</year><volume>19</volume><fpage>1000</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.6b03831</pub-id><?supplied-pmid 28207275?><pub-id pub-id-type="pmid">28207275</pub-id></element-citation></ref><ref id="B15-antibiotics-10-01254"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Pa&#x0015b;ciak</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Xie</surname><given-names>Q.</given-names></name>
<name><surname>Gamian</surname><given-names>A.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis palatopharyngis</italic> sp. nov., a potentially pathogenic actinomycete isolated from a human clinical source</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2004</year><volume>54</volume><issue-part>Pt 2</issue-part><fpage>359</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.02685-0</pub-id><?supplied-pmid 15023943?><pub-id pub-id-type="pmid">15023943</pub-id></element-citation></ref><ref id="B16-antibiotics-10-01254"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>G.Y.A.</given-names></name>
<name><surname>Goodfellow</surname><given-names>M.</given-names></name>
</person-group><article-title>Amycolatopsis</article-title><source>Bergey&#x02019;s Manual of Systematic Bacteriology</source><person-group person-group-type="editor">
<name><surname>Whitman</surname><given-names>W.B.</given-names></name>
</person-group><publisher-name>John Wiley &#x00026; Sons</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2015</year><fpage>1</fpage><lpage>40</lpage></element-citation></ref><ref id="B17-antibiotics-10-01254"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Labeda</surname><given-names>D.P.</given-names></name>
<name><surname>Donahue</surname><given-names>J.M.</given-names></name>
<name><surname>Williams</surname><given-names>N.M.</given-names></name>
<name><surname>Sells</surname><given-names>S.F.</given-names></name>
<name><surname>Henton</surname><given-names>M.M.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis kentuckyensis</italic> sp. nov., <italic toggle="yes">Amycolatopsis lexingtonensis</italic> sp. nov. and <italic toggle="yes">Amycolatopsis pretoriensis</italic> sp. nov., isolated from equine placentas</article-title><source>Int. J. Syst. Evol. Microbiol</source><year>2003</year><volume>53</volume><issue-part>Pt 5</issue-part><fpage>1601</fpage><lpage>1605</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.02691-0</pub-id><?supplied-pmid 13130055?><pub-id pub-id-type="pmid">13130055</pub-id></element-citation></ref><ref id="B18-antibiotics-10-01254"><label>18.</label><element-citation publication-type="webpage"><article-title>LPSN&#x02014;List of Prokaryotic Names with Standing in Nomenclature</article-title><comment>Available online: <ext-link xlink:href="http://www.bacterio.net/amycolatopsis.html" ext-link-type="uri">http://www.bacterio.net/amycolatopsis.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-06-22">(accessed on 22 June 2021)</date-in-citation></element-citation></ref><ref id="B19-antibiotics-10-01254"><label>19.</label><element-citation publication-type="gov"><article-title>The National Center for Biotechnology Information (Assembly)</article-title><comment>Available online: <ext-link xlink:href="www.ncbi.nlm.nih.gov/assembly" ext-link-type="uri">www.ncbi.nlm.nih.gov/assembly</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-06-22">(accessed on 22 June 2021)</date-in-citation></element-citation></ref><ref id="B20-antibiotics-10-01254"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adamek</surname><given-names>M.</given-names></name>
<name><surname>Alanjary</surname><given-names>M.</given-names></name>
<name><surname>Sales-Ortells</surname><given-names>H.</given-names></name>
<name><surname>Goodfellow</surname><given-names>M.</given-names></name>
<name><surname>Bull</surname><given-names>A.T.</given-names></name>
<name><surname>Winkler</surname><given-names>A.</given-names></name>
<name><surname>Wibberg</surname><given-names>D.</given-names></name>
<name><surname>Kalinowski</surname><given-names>J.</given-names></name>
<name><surname>Ziemert</surname><given-names>N.</given-names></name>
</person-group><article-title>Comparative genomics reveals phylogenetic distribution patterns of secondary metabolites in <italic toggle="yes">Amycolatopsis</italic> species</article-title><source>BMC Genomics</source><year>2018</year><volume>19</volume><elocation-id>426</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-018-4809-4</pub-id><pub-id pub-id-type="pmid">29859036</pub-id></element-citation></ref><ref id="B21-antibiotics-10-01254"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sangal</surname><given-names>V.</given-names></name>
<name><surname>Goodfellow</surname><given-names>M.</given-names></name>
<name><surname>Blom</surname><given-names>J.</given-names></name>
<name><surname>Tan</surname><given-names>G.Y.A.</given-names></name>
<name><surname>Klenk</surname><given-names>H.P.</given-names></name>
<name><surname>Sutcliffe</surname><given-names>I.C.</given-names></name>
</person-group><article-title>Revisiting the taxonomic status of the biomedically and industrially important genus <italic toggle="yes">Amycolatopsis</italic>, using a phylogenomic approach</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2281</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02281</pub-id><pub-id pub-id-type="pmid">30319584</pub-id></element-citation></ref><ref id="B22-antibiotics-10-01254"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>G.Y.</given-names></name>
<name><surname>Ward</surname><given-names>A.C.</given-names></name>
<name><surname>Goodfellow</surname><given-names>M.</given-names></name>
</person-group><article-title>Exploration of <italic toggle="yes">Amycolatopsis</italic> diversity in soil using genus-specific primers and novel selective media</article-title><source>Syst. Appl. Microbiol.</source><year>2006</year><volume>29</volume><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1016/j.syapm.2006.01.007</pub-id><pub-id pub-id-type="pmid">16466884</pub-id></element-citation></ref><ref id="B23-antibiotics-10-01254"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doroghazi</surname><given-names>J.R.</given-names></name>
<name><surname>Metcalf</surname><given-names>W.W.</given-names></name>
</person-group><article-title>Comparative genomics of actinomycetes with a focus on natural product biosynthetic genes</article-title><source>BMC Genomics</source><year>2013</year><volume>14</volume><elocation-id>611</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-14-611</pub-id><pub-id pub-id-type="pmid">24020438</pub-id></element-citation></ref><ref id="B24-antibiotics-10-01254"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Everest</surname><given-names>G.J.</given-names></name>
<name><surname>le Roes-Hill</surname><given-names>M.</given-names></name>
<name><surname>Rohland</surname><given-names>J.</given-names></name>
<name><surname>Enslin</surname><given-names>S.</given-names></name>
<name><surname>Meyers</surname><given-names>P.R.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis roodepoortensis</italic> sp. nov. and <italic toggle="yes">Amycolatopsis speibonae</italic> sp. nov.: Antibiotic-producing actinobacteria isolated from South African soils</article-title><source>J. Antibiot. (Tokyo)</source><year>2014</year><volume>67</volume><fpage>813</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1038/ja.2014.79</pub-id><pub-id pub-id-type="pmid">24961711</pub-id></element-citation></ref><ref id="B25-antibiotics-10-01254"><label>25.</label><element-citation publication-type="webpage"><article-title>Minimum Information about a Biosynthetic Gene cluster</article-title><comment>Available online: <ext-link xlink:href="http://mibig.secondarymetabolites.org" ext-link-type="uri">http://mibig.secondarymetabolites.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-06-22">(accessed on 22 June 2021)</date-in-citation></element-citation></ref><ref id="B26-antibiotics-10-01254"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Medema</surname><given-names>M.H.</given-names></name>
<name><surname>Kottmann</surname><given-names>R.</given-names></name>
<name><surname>Yilmaz</surname><given-names>P.</given-names></name>
<name><surname>Cummings</surname><given-names>M.</given-names></name>
<name><surname>Biggins</surname><given-names>J.B.</given-names></name>
<name><surname>Blin</surname><given-names>K.</given-names></name>
<name><surname>de Bruijn</surname><given-names>I.</given-names></name>
<name><surname>Chooi</surname><given-names>Y.H.</given-names></name>
<name><surname>Claesen</surname><given-names>J.</given-names></name>
<name><surname>Coates</surname><given-names>R.C.</given-names></name>
<etal/>
</person-group><article-title>Minimum information about a biosynthetic gene cluster</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1890</pub-id><pub-id pub-id-type="pmid">26284661</pub-id></element-citation></ref><ref id="B27-antibiotics-10-01254"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Everest</surname><given-names>G.J.</given-names></name>
<name><surname>Meyers</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Evaluation of the antibiotic biosynthetic potential of the genus <italic toggle="yes">Amycolatopsis</italic> and description of <italic toggle="yes">Amycolatopsis circi</italic> sp. nov., <italic toggle="yes">Amycolatopsis equina</italic> sp. nov. and <italic toggle="yes">Amycolatopsis hippodromi</italic> sp. nov</article-title><source>J. Appl. Microbiol.</source><year>2011</year><volume>111</volume><fpage>300</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2011.05058.x</pub-id><pub-id pub-id-type="pmid">21615633</pub-id></element-citation></ref><ref id="B28-antibiotics-10-01254"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banskota</surname><given-names>A.H.</given-names></name>
<name><surname>Mcalpine</surname><given-names>J.B.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>D.</given-names></name>
<name><surname>Ibrahim</surname><given-names>A.</given-names></name>
<name><surname>Aouidate</surname><given-names>M.</given-names></name>
<name><surname>Piraee</surname><given-names>M.</given-names></name>
<name><surname>Alarco</surname><given-names>A.M.</given-names></name>
<name><surname>Farnet</surname><given-names>C.M.</given-names></name>
<name><surname>Zazopoulos</surname><given-names>E.</given-names></name>
</person-group><article-title>Genomic analyses lead to novel secondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class</article-title><source>J. Antibiot. (Tokyo)</source><year>2006</year><volume>59</volume><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/ja.2006.74</pub-id><?supplied-pmid 17136886?><pub-id pub-id-type="pmid">17136886</pub-id></element-citation></ref><ref id="B29-antibiotics-10-01254"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>F.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Davis</surname><given-names>K.M.</given-names></name>
<name><surname>Moon</surname><given-names>K.</given-names></name>
<name><surname>Bushin</surname><given-names>L.B.</given-names></name>
<name><surname>Seyedsayamdost</surname><given-names>M.R.</given-names></name>
</person-group><article-title>A genetics-free method for high-throughput discovery of cryptic microbial metabolites</article-title><source>Nat. Chem. Biol.</source><year>2019</year><volume>15</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0193-2</pub-id><?supplied-pmid 30617293?><pub-id pub-id-type="pmid">30617293</pub-id></element-citation></ref><ref id="B30-antibiotics-10-01254"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.H.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Ahmadi</surname><given-names>M.K.</given-names></name>
<name><surname>Montiel</surname><given-names>D.</given-names></name>
<name><surname>Ternei</surname><given-names>M.A.</given-names></name>
<name><surname>Brady</surname><given-names>S.F.</given-names></name>
</person-group><article-title>Atolypenes, Tricyclic Bacterial Sesterterpenes Discovered Using a Multiplexed In Vitro Cas9-TAR Gene Cluster Refactoring Approach</article-title><source>ACS Synth Biol.</source><year>2019</year><volume>8</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.8b00361</pub-id><pub-id pub-id-type="pmid">30575381</pub-id></element-citation></ref><ref id="B31-antibiotics-10-01254"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hopp</surname><given-names>D.C.</given-names></name>
<name><surname>Rabenstein</surname><given-names>J.</given-names></name>
<name><surname>Rhea</surname><given-names>J.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Romari</surname><given-names>K.</given-names></name>
<name><surname>Clarke</surname><given-names>M.</given-names></name>
<name><surname>Francis</surname><given-names>L.</given-names></name>
<name><surname>Irigoyen</surname><given-names>M.</given-names></name>
<name><surname>Milanowski</surname><given-names>D.</given-names></name>
<name><surname>Luche</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Mutactimycin E, a new anthracycline antibiotic with Gram-positive activity</article-title><source>J. Antibiot. (Tokyo)</source><year>2008</year><volume>61</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1038/ja.2008.95</pub-id><?supplied-pmid 19168982?><pub-id pub-id-type="pmid">19168982</pub-id></element-citation></ref><ref id="B32-antibiotics-10-01254"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.H.</given-names></name>
<name><surname>Shin</surname><given-names>Y.</given-names></name>
<name><surname>Bae</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>B.Y.</given-names></name>
<name><surname>Lee</surname><given-names>S.K.</given-names></name>
<name><surname>Oh</surname><given-names>K.B.</given-names></name>
<name><surname>Shin</surname><given-names>J.</given-names></name>
<name><surname>Oh</surname><given-names>D.C.</given-names></name>
</person-group><article-title>A new benzofuran glycoside and indole alkaloids from a sponge-associated rare actinomycete, <italic toggle="yes">Amycolatopsis</italic> sp.</article-title><source>Mar. Drugs.</source><year>2014</year><volume>12</volume><fpage>2326</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.3390/md12042326</pub-id><?supplied-pmid 24759001?><pub-id pub-id-type="pmid">24759001</pub-id></element-citation></ref><ref id="B33-antibiotics-10-01254"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bauermeister</surname><given-names>A.</given-names></name>
<name><surname>Calil</surname><given-names>F.A.</given-names></name>
<name><surname>Pinto</surname><given-names>F.d.C.L.</given-names></name>
<name><surname>Medeiros</surname><given-names>T.C.T.</given-names></name>
<name><surname>Almeida</surname><given-names>L.C.</given-names></name>
<name><surname>Silva</surname><given-names>L.J.</given-names></name>
<name><surname>de Melo</surname><given-names>I.S.</given-names></name>
<name><surname>Zucchi</surname><given-names>T.D.</given-names></name>
<name><surname>Costa-Lotufo</surname><given-names>L.V.</given-names></name>
<name><surname>Moraes</surname><given-names>L.A.B.</given-names></name>
</person-group><article-title>Pradimicin-IRD from <italic toggle="yes">Amycolatopsis</italic> sp. IRD-009 and its antimicrobial and cytotoxic activities</article-title><source>Nat. Prod. Res.</source><year>2019</year><volume>33</volume><fpage>1713</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1080/14786419.2018.1434639</pub-id><pub-id pub-id-type="pmid">29451013</pub-id></element-citation></ref><ref id="B34-antibiotics-10-01254"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Izuta</surname><given-names>S.</given-names></name>
<name><surname>Kosaka</surname><given-names>S.</given-names></name>
<name><surname>Kawai</surname><given-names>M.</given-names></name>
<name><surname>Miyano</surname><given-names>R.</given-names></name>
<name><surname>Matsuo</surname><given-names>H.</given-names></name>
<name><surname>Matsumoto</surname><given-names>A.</given-names></name>
<name><surname>Nonaka</surname><given-names>K.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>&#x0014c;mura</surname><given-names>S.</given-names></name>
<name><surname>Nakashima</surname><given-names>T.</given-names></name>
</person-group><article-title>Dipyrimicin A and B, microbial compounds isolated from Amycolatopsis sp. K16-0194</article-title><source>J. Antibiot. (Tokyo)</source><year>2018</year><volume>71</volume><fpage>535</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1038/s41429-018-0028-0</pub-id><pub-id pub-id-type="pmid">29463887</pub-id></element-citation></ref><ref id="B35-antibiotics-10-01254"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitscher</surname><given-names>L.A.</given-names></name>
<name><surname>H&#x000f6;gberg</surname><given-names>T.</given-names></name>
<name><surname>Drake</surname><given-names>S.D.</given-names></name>
<name><surname>Burgstahler</surname><given-names>A.W.</given-names></name>
<name><surname>Jackson</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Sheldon</surname><given-names>R.I.</given-names></name>
<name><surname>Gracey</surname><given-names>H.E.</given-names></name>
<name><surname>Kohl</surname><given-names>W.</given-names></name>
<name><surname>Theriault</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Isolation and structural determination of siderochelin C, a fermentation product of an unusual <italic toggle="yes">Actinomycetes</italic> sp.</article-title><source>J. Antibiot. (Tokyo)</source><year>1984</year><volume>37</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.37.1260</pub-id><?supplied-pmid 6501097?><pub-id pub-id-type="pmid">6501097</pub-id></element-citation></ref><ref id="B36-antibiotics-10-01254"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>C.H.</given-names></name>
<name><surname>Ye</surname><given-names>F.W.</given-names></name>
<name><surname>Shen</surname><given-names>Y.M.</given-names></name>
</person-group><article-title>Siderochelins with anti-mycobacterial activity from <italic toggle="yes">Amycolatopsis</italic> sp. LZ149</article-title><source>Chin. J. Nat. Med.</source><year>2015</year><volume>13</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S1875-5364(15)60009-7</pub-id><pub-id pub-id-type="pmid">25660291</pub-id></element-citation></ref><ref id="B37-antibiotics-10-01254"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimanaka</surname><given-names>K.</given-names></name>
<name><surname>Kinoshita</surname><given-names>N.</given-names></name>
<name><surname>Iinuma</surname><given-names>H.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Novel antibiotics, amythiamicins. I. Taxonomy, fermentation, isolation, physico-chemical properties, and antimicrobial activity</article-title><source>J. Antibiot. (Tokyo)</source><year>1994</year><volume>47</volume><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.47.668</pub-id><?supplied-pmid 8040071?><pub-id pub-id-type="pmid">8040071</pub-id></element-citation></ref><ref id="B38-antibiotics-10-01254"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimanaka</surname><given-names>K.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Iinuma</surname><given-names>H.</given-names></name>
<name><surname>Naganawa</surname><given-names>H.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Novel antibiotics, amythiamicins. III. Structure elucidations of amythiamicins A, B and C</article-title><source>J. Antibiot. (Tokyo)</source><year>1994</year><volume>47</volume><fpage>1153</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.47.1153</pub-id><?supplied-pmid 7961166?><pub-id pub-id-type="pmid">7961166</pub-id></element-citation></ref><ref id="B39-antibiotics-10-01254"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwun</surname><given-names>M.J.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>D.R.</given-names></name>
<name><surname>Suh</surname><given-names>J.W.</given-names></name>
<name><surname>Hong</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Draft genome sequence of ristocetin-producing strain <italic toggle="yes">Amycolatopsis</italic> sp. strain MJM2582 isolated in South Korea</article-title><source>Genome Announc.</source><year>2014</year><volume>2</volume><fpage>e01091-14</fpage><pub-id pub-id-type="doi">10.1128/genomeA.01091-14</pub-id></element-citation></ref><ref id="B40-antibiotics-10-01254"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Truman</surname><given-names>A.W.</given-names></name>
<name><surname>Kwun</surname><given-names>M.J.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>S.H.</given-names></name>
<name><surname>Suh</surname><given-names>J.W.</given-names></name>
<name><surname>Hong</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Antibiotic resistance mechanisms inform discovery: Identification and characterization of a novel amycolatopsis strain producing ristocetin</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>5687</fpage><lpage>5895</lpage><pub-id pub-id-type="doi">10.1128/AAC.03349-14</pub-id><pub-id pub-id-type="pmid">25022591</pub-id></element-citation></ref><ref id="B41-antibiotics-10-01254"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grundy</surname><given-names>W.E.</given-names></name>
<name><surname>Sinclair</surname><given-names>A.C.</given-names></name>
<name><surname>Theriault</surname><given-names>R.J.</given-names></name>
<name><surname>Goldstein</surname><given-names>A.W.</given-names></name>
<name><surname>Rickher</surname><given-names>C.J.</given-names></name>
<name><surname>Warren</surname><given-names>H.B.</given-names><suffix>Jr.</suffix></name>
<name><surname>Oliver</surname><given-names>T.J.</given-names></name>
<name><surname>Sylvester</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Ristocetin, microbiologic properties</article-title><source>Antibiot. Annu.</source><year>1956</year><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">13425450</pub-id></element-citation></ref><ref id="B42-antibiotics-10-01254"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Igarashi</surname><given-names>M.</given-names></name>
<name><surname>Sawa</surname><given-names>R.</given-names></name>
<name><surname>Kinoshita</surname><given-names>N.</given-names></name>
<name><surname>Hashizume</surname><given-names>H.</given-names></name>
<name><surname>Nakagawa</surname><given-names>N.</given-names></name>
<name><surname>Homma</surname><given-names>Y.</given-names></name>
<name><surname>Nishimura</surname><given-names>Y.</given-names></name>
<name><surname>Akamatsu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Pargamicin A, a novel cyclic peptide antibiotic from <italic toggle="yes">Amycolatopsis</italic> sp.</article-title><source>J. Antibiot. (Tokyo)</source><year>2008</year><volume>61</volume><fpage>387</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/ja.2008.54</pub-id><pub-id pub-id-type="pmid">18667787</pub-id></element-citation></ref><ref id="B43-antibiotics-10-01254"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hashizume</surname><given-names>H.</given-names></name>
<name><surname>Iijima</surname><given-names>K.</given-names></name>
<name><surname>Yamashita</surname><given-names>K.</given-names></name>
<name><surname>Kimura</surname><given-names>T.</given-names></name>
<name><surname>Wada</surname><given-names>S.I.</given-names></name>
<name><surname>Sawa</surname><given-names>R.</given-names></name>
<name><surname>Igarashi</surname><given-names>M.</given-names></name>
</person-group><article-title>Valgamicin C, a novel cyclic depsipeptide containing the unusual amino acid cleonine, and related valgamicins A, T and V produced by <italic toggle="yes">Amycolatopsis</italic> sp. ML1-hF4</article-title><source>J. Antibiot. (Tokyo)</source><year>2017</year><volume>71</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/ja.2017.135</pub-id></element-citation></ref><ref id="B44-antibiotics-10-01254"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>K.X.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>J.X.</given-names></name>
<name><surname>Huang</surname><given-names>R.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>S.H.</given-names></name>
</person-group><article-title>A new phthalazinone derivative and a new isoflavonoid glycoside from lichen-associated <italic toggle="yes">Amycolatopsis</italic> sp.</article-title><source>Fitoterapia</source><year>2019</year><volume>135</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2019.04.011</pub-id><pub-id pub-id-type="pmid">31028818</pub-id></element-citation></ref><ref id="B45-antibiotics-10-01254"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>R.</given-names></name>
<name><surname>Jiang</surname><given-names>B.</given-names></name>
<name><surname>Zheng</surname><given-names>K.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
</person-group><article-title>Diverse secondary metabolites from a lichen-derived <italic toggle="yes">Amycolatopsis</italic> strain</article-title><source>Curr. Microbiol.</source><year>2020</year><volume>77</volume><fpage>2104</fpage><lpage>2110</lpage><pub-id pub-id-type="doi">10.1007/s00284-020-02049-5</pub-id><pub-id pub-id-type="pmid">32468182</pub-id></element-citation></ref><ref id="B46-antibiotics-10-01254"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pishchany</surname><given-names>G.</given-names></name>
<name><surname>Mevers</surname><given-names>E.</given-names></name>
<name><surname>Ndousse-Fetter</surname><given-names>S.</given-names></name>
<name><surname>Horvath</surname><given-names>D.J.</given-names><suffix>Jr.</suffix></name>
<name><surname>Paludo</surname><given-names>C.R.</given-names></name>
<name><surname>Silva-Junior</surname><given-names>E.A.</given-names></name>
<name><surname>Koren</surname><given-names>S.</given-names></name>
<name><surname>Skaar</surname><given-names>E.P.</given-names></name>
<name><surname>Clardy</surname><given-names>J.</given-names></name>
<name><surname>Kolter</surname><given-names>R.</given-names></name>
</person-group><article-title>Amycomicin is a potent and specific antibiotic discovered with a targeted interaction screen</article-title><source>Proc. Natl. Acad. Sci. USA.</source><year>2018</year><volume>115</volume><fpage>10124</fpage><lpage>10129</lpage><pub-id pub-id-type="doi">10.1073/pnas.1807613115</pub-id><?supplied-pmid 30228116?><pub-id pub-id-type="pmid">30228116</pub-id></element-citation></ref><ref id="B47-antibiotics-10-01254"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dasari</surname><given-names>V.R.</given-names></name>
<name><surname>Muthyala</surname><given-names>M.K.</given-names></name>
<name><surname>Nikku</surname><given-names>M.Y.</given-names></name>
<name><surname>Donthireddy</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Novel pyridinium compound from marine actinomycete, <italic toggle="yes">Amycolatopsis alba</italic> var. nov. DVR D4 showing antimicrobial and cytotoxic activities <italic toggle="yes">in vitro</italic></article-title><source>Microbiol. Res.</source><year>2012</year><volume>167</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2011.12.003</pub-id><?supplied-pmid 22293027?><pub-id pub-id-type="pmid">22293027</pub-id></element-citation></ref><ref id="B48-antibiotics-10-01254"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kunimoto</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Esumi</surname><given-names>H.</given-names></name>
<name><surname>Yamazaki</surname><given-names>Y.</given-names></name>
<name><surname>Kinoshita</surname><given-names>N.</given-names></name>
<name><surname>Honma</surname><given-names>Y.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Ohsono</surname><given-names>M.</given-names></name>
<name><surname>Ishizuka</surname><given-names>M.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Kigamicins, novel antitumor antibiotics. I. Taxonomy, isolation, physico-chemical properties and biological activities</article-title><source>J. Antibiot. (Tokyo)</source><year>2003</year><volume>56</volume><fpage>1004</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.56.1004</pub-id><?supplied-pmid 15015727?><pub-id pub-id-type="pmid">15015727</pub-id></element-citation></ref><ref id="B49-antibiotics-10-01254"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
</person-group><article-title>Carbamothioic S-acid derivative and kigamicins, the activated production of silent metabolites in <italic toggle="yes">Amycolatopsis alba</italic> DSM 44262&#x00394;<italic toggle="yes">abm9</italic> elicited by N-acetyl-D-glucosamine</article-title><source>Nat. Prod. Res.</source><year>2019</year><volume>20</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1080/14786419.2019.1696792</pub-id></element-citation></ref><ref id="B50-antibiotics-10-01254"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Identification of the Bacterial Maytansinoid Gene Cluster <italic toggle="yes">asc</italic> Provides Insights into the Post-PKS Modifications of Ansacarbamitocin Biosynthesis</article-title><source>Org. Lett.</source><year>2019</year><volume>21</volume><fpage>5823</fpage><lpage>5826</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.9b01891</pub-id><pub-id pub-id-type="pmid">31299158</pub-id></element-citation></ref><ref id="B51-antibiotics-10-01254"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Omura</surname><given-names>S.</given-names></name>
<name><surname>Tanaka</surname><given-names>H.</given-names></name>
<name><surname>Tanaka</surname><given-names>Y.</given-names></name>
<name><surname>Spiri-Nakagawa</surname><given-names>P.</given-names></name>
<name><surname>Oiwa</surname><given-names>R.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Matsuyama</surname><given-names>K.</given-names></name>
<name><surname>Iwai</surname><given-names>Y.</given-names></name>
</person-group><article-title>Studies on bacterial cell wall inhibitors. VII. Azureomycins A and B, new antibiotics produced by <italic toggle="yes">Pseudonocardia azurea</italic> nov. sp. Taxonomy of the producing organism, isolation, characterization and biological properties</article-title><source>J. Antibiot. (Tokyo)</source><year>1979</year><volume>32</volume><fpage>985</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.32.985</pub-id><pub-id pub-id-type="pmid">528377</pub-id></element-citation></ref><ref id="B52-antibiotics-10-01254"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khatri</surname><given-names>I.</given-names></name>
<name><surname>Subramanian</surname><given-names>S.</given-names></name>
<name><surname>Mayilraj</surname><given-names>S.</given-names></name>
</person-group><article-title>Genome sequencing and annotation of <italic toggle="yes">Amycolatopsis azurea</italic> DSM 43854(T)</article-title><source>Genom. Data.</source><year>2014</year><volume>12</volume><fpage>44</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.gdata.2013.12.003</pub-id></element-citation></ref><ref id="B53-antibiotics-10-01254"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobashi</surname><given-names>K.</given-names></name>
<name><surname>Matsuda</surname><given-names>N.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Naganawa</surname><given-names>H.</given-names></name>
<name><surname>Takita</surname><given-names>T.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Novel antifungal antibiotics octacosamicins A and B. I. Taxonomy, fermentation and isolation, physico-chemical properties and biological activities</article-title><source>J. Antibiot. (Tokyo)</source><year>1988</year><volume>41</volume><fpage>1525</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.41.1525</pub-id><pub-id pub-id-type="pmid">3198488</pub-id></element-citation></ref><ref id="B54-antibiotics-10-01254"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobashi</surname><given-names>K.</given-names></name>
<name><surname>Naganawa</surname><given-names>H.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Takita</surname><given-names>T.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Novel antifungal antibiotics octacosamicins A and B. II. The structure elucidation using various NMR spectroscopic methods</article-title><source>J. Antibiot. (Tokyo)</source><year>1988</year><volume>41</volume><fpage>1533</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.41.1533</pub-id><pub-id pub-id-type="pmid">3198489</pub-id></element-citation></ref><ref id="B55-antibiotics-10-01254"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nadkarni</surname><given-names>S.R.</given-names></name>
<name><surname>Patel</surname><given-names>M.V.</given-names></name>
<name><surname>Chatterjee</surname><given-names>S.</given-names></name>
<name><surname>Vijayakumar</surname><given-names>E.K.</given-names></name>
<name><surname>Desikan</surname><given-names>K.R.</given-names></name>
<name><surname>Blumbach</surname><given-names>J.</given-names></name>
<name><surname>Ganguli</surname><given-names>B.N.</given-names></name>
<name><surname>Limbert</surname><given-names>M.</given-names></name>
</person-group><article-title>Balhimycin, a new glycopeptide antibiotic produced by <italic toggle="yes">Amycolatopsis</italic> sp. Y-86,21022. Taxonomy, production, isolation and biological activity</article-title><source>J. Antibiot. (Tokyo)</source><year>1994</year><volume>47</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.47.334</pub-id><pub-id pub-id-type="pmid">8175486</pub-id></element-citation></ref><ref id="B56-antibiotics-10-01254"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kunstmann</surname><given-names>M.P.</given-names></name>
<name><surname>Mitscher</surname><given-names>L.A.</given-names></name>
<name><surname>Porter</surname><given-names>J.N.</given-names></name>
<name><surname>Shay</surname><given-names>A.J.</given-names></name>
<name><surname>Darken</surname><given-names>M.A.</given-names></name>
</person-group><article-title>LL-AV290, a new antibiotic. I. Fermentation, isolation, and characterization</article-title><source>Antimicrob. Agents Chemother.</source><year>1968</year><volume>8</volume><fpage>242</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">5735366</pub-id></element-citation></ref><ref id="B57-antibiotics-10-01254"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellestad</surname><given-names>G.A.</given-names></name>
<name><surname>Swenson</surname><given-names>W.</given-names></name>
<name><surname>McGahren</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Epimerization and stereochemistry of avoparcin</article-title><source>J. Antibiot. (Tokyo)</source><year>1983</year><volume>36</volume><fpage>1683</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.36.1683</pub-id><?supplied-pmid 6662809?><pub-id pub-id-type="pmid">6662809</pub-id></element-citation></ref><ref id="B58-antibiotics-10-01254"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acar</surname><given-names>J.</given-names></name>
<name><surname>Casewell</surname><given-names>M.</given-names></name>
<name><surname>Freeman</surname><given-names>J.</given-names></name>
<name><surname>Friis</surname><given-names>C.</given-names></name>
<name><surname>Goossens</surname><given-names>H.</given-names></name>
</person-group><article-title>Avoparcin and virginiamycin as animal growth promoters: A plea for science in decision-making</article-title><source>Clin. Microbiol. Infect.</source><year>2000</year><volume>6</volume><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1046/j.1469-0691.2000.00128.x</pub-id><pub-id pub-id-type="pmid">11168181</pub-id></element-citation></ref><ref id="B59-antibiotics-10-01254"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neu</surname><given-names>H.C.</given-names></name>
<name><surname>Chin</surname><given-names>N.X.</given-names></name>
<name><surname>Niu</surname><given-names>W.W.</given-names></name>
</person-group><article-title>In vitro activity of the new glycopeptide decaplanin</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>1992</year><volume>11</volume><fpage>458</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1007/BF01961864</pub-id><?supplied-pmid 1330562?><pub-id pub-id-type="pmid">1330562</pub-id></element-citation></ref><ref id="B60-antibiotics-10-01254"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wink</surname><given-names>J.</given-names></name>
<name><surname>Gandhi</surname><given-names>J.</given-names></name>
<name><surname>Kroppenstedt</surname><given-names>R.M.</given-names></name>
<name><surname>Seibert</surname><given-names>G.</given-names></name>
<name><surname>Str&#x000e4;ubler</surname><given-names>B.</given-names></name>
<name><surname>Schumann</surname><given-names>P.</given-names></name>
<name><surname>Stackebrandt</surname><given-names>E.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis decaplanina</italic> sp. nov., a novel member of the genus with unusual morphology</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2004</year><volume>54</volume><issue-part>Pt 1</issue-part><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.02586-0</pub-id><?supplied-pmid 14742486?><pub-id pub-id-type="pmid">14742486</pub-id></element-citation></ref><ref id="B61-antibiotics-10-01254"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Aobulikasimu</surname><given-names>N.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Cao</surname><given-names>B.</given-names></name>
<name><surname>Lin</surname><given-names>B.</given-names></name>
<name><surname>Guan</surname><given-names>P.</given-names></name>
<name><surname>Mu</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Han</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Amycolasporins and dibenzoyls from lichen-associated <italic toggle="yes">Amycolatopsis hippodrome</italic> and their antibacterial and anti-inflammatory activities</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>83</volume><fpage>3545</fpage><lpage>3553</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.0c00547</pub-id><pub-id pub-id-type="pmid">33216556</pub-id></element-citation></ref><ref id="B62-antibiotics-10-01254"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spohn</surname><given-names>M.</given-names></name>
<name><surname>Kirchner</surname><given-names>N.</given-names></name>
<name><surname>Kulik</surname><given-names>A.</given-names></name>
<name><surname>Jochim</surname><given-names>A.</given-names></name>
<name><surname>Wolf</surname><given-names>F.</given-names></name>
<name><surname>Muenzer</surname><given-names>P.</given-names></name>
<name><surname>Borst</surname><given-names>O.</given-names></name>
<name><surname>Gross</surname><given-names>H.</given-names></name>
<name><surname>Wohlleben</surname><given-names>W.</given-names></name>
<name><surname>Stegmann</surname><given-names>E.</given-names></name>
</person-group><article-title>Overproduction of Ristomycin A by activation of a silent gene cluster in <italic toggle="yes">Amycolatopsis japonicum</italic> MG417-CF17</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>6185</fpage><lpage>6196</lpage><pub-id pub-id-type="doi">10.1128/AAC.03512-14</pub-id><?supplied-pmid 25114137?><pub-id pub-id-type="pmid">25114137</pub-id></element-citation></ref><ref id="B63-antibiotics-10-01254"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navarro-Mu&#x000f1;oz</surname><given-names>J.C.</given-names></name>
<name><surname>Selem-Mojica</surname><given-names>N.</given-names></name>
<name><surname>Mullowney</surname><given-names>M.W.</given-names></name>
<name><surname>Kautsar</surname><given-names>S.A.</given-names></name>
<name><surname>Tryon</surname><given-names>J.H.</given-names></name>
<name><surname>Parkinson</surname><given-names>E.I.</given-names></name>
<name><surname>De Los Santos</surname><given-names>E.L.C.</given-names></name>
<name><surname>Yeong</surname><given-names>M.</given-names></name>
<name><surname>Cruz-Morales</surname><given-names>P.</given-names></name>
<name><surname>Abubucker</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>A computational framework to explore large-scale biosynthetic diversity</article-title><source>Nat. Chem. Biol.</source><year>2020</year><volume>16</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/s41589-019-0400-9</pub-id><pub-id pub-id-type="pmid">31768033</pub-id></element-citation></ref><ref id="B64-antibiotics-10-01254"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shorin</surname><given-names>V.A.</given-names></name>
<name><surname>Yudinstev</surname><given-names>S.D.</given-names></name>
<name><surname>Kunrat</surname><given-names>I.A.</given-names></name>
<name><surname>Goldberg</surname><given-names>L.E.</given-names></name>
<name><surname>Pevzner</surname><given-names>N.S.</given-names></name>
<name><surname>Brazhnikova</surname><given-names>M.G.</given-names></name>
<name><surname>Lomakina</surname><given-names>N.N.</given-names></name>
<name><surname>Oparysheva</surname><given-names>E.F.</given-names></name>
</person-group><article-title>New antibiotics, actinoidin</article-title><source>Antibiotiki</source><year>1957</year><volume>2</volume><fpage>44</fpage><lpage>49</lpage><comment>(In Russian)</comment></element-citation></ref><ref id="B65-antibiotics-10-01254"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wink</surname><given-names>J.M.</given-names></name>
<name><surname>Kroppenstedt</surname><given-names>R.M.</given-names></name>
<name><surname>Ganguli</surname><given-names>B.N.</given-names></name>
<name><surname>Nadkarni</surname><given-names>S.R.</given-names></name>
<name><surname>Schumann</surname><given-names>P.</given-names></name>
<name><surname>Seibert</surname><given-names>G.</given-names></name>
<name><surname>Stackebrandt</surname><given-names>E.</given-names></name>
</person-group><article-title>Three new antibiotics producing species of the genus <italic toggle="yes">Amycolatopsis, Amycolatopsis balhimycina</italic> sp. nov., <italic toggle="yes">A. tolypomycina</italic> sp. nov., <italic toggle="yes">A. vancoresmycina</italic> sp. nov., and description of <italic toggle="yes">Amycolatopsis keratiniphila</italic> subsp. <italic toggle="yes">keratiniphila</italic> subsp. nov. and <italic toggle="yes">A. keratiniphila</italic> subsp. <italic toggle="yes">nogabecina</italic> subsp. nov</article-title><source> Syst. Appl. Microbiol.</source><year>2003</year><volume>26</volume><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1078/072320203322337290</pub-id><pub-id pub-id-type="pmid">12747408</pub-id></element-citation></ref><ref id="B66-antibiotics-10-01254"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>A.K.</given-names></name>
<name><surname>Celozzi</surname><given-names>E.</given-names></name>
<name><surname>Kong</surname><given-names>Y.</given-names></name>
<name><surname>Pelak</surname><given-names>B.A.</given-names></name>
<name><surname>Kropp</surname><given-names>H.</given-names></name>
<name><surname>Stapley</surname><given-names>E.O.</given-names></name>
<name><surname>Hendlin</surname><given-names>D.</given-names></name>
</person-group><article-title>Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies</article-title><source>Antimicrob. Agents Chemother.</source><year>1972</year><volume>2</volume><fpage>287</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1128/AAC.2.4.287</pub-id><pub-id pub-id-type="pmid">4670502</pub-id></element-citation></ref><ref id="B67-antibiotics-10-01254"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stapley</surname><given-names>E.O.</given-names></name>
<name><surname>Jackson</surname><given-names>M.</given-names></name>
<name><surname>Hernandez</surname><given-names>S.</given-names></name>
<name><surname>Zimmerman</surname><given-names>S.B.</given-names></name>
<name><surname>Currie</surname><given-names>S.A.</given-names></name>
<name><surname>Mochales</surname><given-names>S.</given-names></name>
<name><surname>Mata</surname><given-names>J.M.</given-names></name>
<name><surname>Woodruff</surname><given-names>H.B.</given-names></name>
<name><surname>Hendlin</surname><given-names>D.</given-names></name>
</person-group><article-title>Cephamycins, a new family of beta-lactam antibiotics. I. Production by actinomycetes, including <italic toggle="yes">Streptomyces lactamdurans</italic> sp. n</article-title><source>Antimicrob. Agents Chemother.</source><year>1972</year><volume>2</volume><fpage>122</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1128/AAC.2.3.122</pub-id><?supplied-pmid 4790552?><pub-id pub-id-type="pmid">4790552</pub-id></element-citation></ref><ref id="B68-antibiotics-10-01254"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barreiro</surname><given-names>C.</given-names></name>
<name><surname>Pisabarro</surname><given-names>A.</given-names></name>
<name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Characterization of the ribosomal rrnD operon of the cephamycin-producer <italic toggle="yes">&#x02019;Nocardia lactamdurans&#x02019;</italic> shows that this actinomycete belongs to the genus <italic toggle="yes">Amycolatopsis</italic></article-title><source>Syst. Appl. Microbiol.</source><year>2000</year><volume>23</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S0723-2020(00)80041-7</pub-id><pub-id pub-id-type="pmid">10879974</pub-id></element-citation></ref><ref id="B69-antibiotics-10-01254"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liras</surname><given-names>P.</given-names></name>
<name><surname>Demain</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Enzymology of beta-lactam compounds with cephem structure produced by actinomycete</article-title><source>Methods Enzymol.</source><year>2009</year><volume>458</volume><fpage>401</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(09)04816-2</pub-id><pub-id pub-id-type="pmid">19374992</pub-id></element-citation></ref><ref id="B70-antibiotics-10-01254"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wax</surname><given-names>R.</given-names></name>
<name><surname>Maises</surname><given-names>W.</given-names></name>
<name><surname>Weston</surname><given-names>R.</given-names></name>
<name><surname>Birnbaum</surname><given-names>J.</given-names></name>
</person-group><article-title>Efrotomycin, a new antibiotic from <italic toggle="yes">Streptomyces lactamdurans</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1976</year><volume>29</volume><fpage>670</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.29.670</pub-id><pub-id pub-id-type="pmid">950325</pub-id></element-citation></ref><ref id="B71-antibiotics-10-01254"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theriault</surname><given-names>R.J.</given-names></name>
<name><surname>Rasmussen</surname><given-names>R.R.</given-names></name>
<name><surname>Kohl</surname><given-names>W.L.</given-names></name>
<name><surname>Prokop</surname><given-names>J.F.</given-names></name>
<name><surname>Hutch</surname><given-names>T.B.</given-names></name>
<name><surname>Barlow</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Benzanthrins A and B, a new class of quinone antibiotics. I. Discovery, fermentation and antibacterial activity</article-title><source>J. Antibiot. (Tokyo)</source><year>1986</year><volume>39</volume><fpage>1509</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.39.1509</pub-id><?supplied-pmid 3793619?><pub-id pub-id-type="pmid">3793619</pub-id></element-citation></ref><ref id="B72-antibiotics-10-01254"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rasmussen</surname><given-names>R.R.</given-names></name>
<name><surname>Nuss</surname><given-names>M.E.</given-names></name>
<name><surname>Scherr</surname><given-names>M.H.</given-names></name>
<name><surname>Mueller</surname><given-names>S.L.</given-names></name>
<name><surname>McAlpine</surname><given-names>J.B.</given-names></name>
<name><surname>Mitscher</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Benzanthrins A and B, a new class of quinone antibiotics. II. Isolation, elucidation of structure and potential antitumor activity</article-title><source>J. Antibiot. (Tokyo)</source><year>1986</year><volume>39</volume><fpage>1515</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.39.1515</pub-id><?supplied-pmid 3793620?><pub-id pub-id-type="pmid">3793620</pub-id></element-citation></ref><ref id="B73-antibiotics-10-01254"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Philip</surname><given-names>J.E.</given-names></name>
<name><surname>Schenck</surname><given-names>J.R.</given-names></name>
<name><surname>Hargie</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Ristocetins A and B, two new antibiotics; isolation and properties</article-title><source>Antibiot. Annu.</source><year>1957</year><fpage>699</fpage><lpage>705</lpage></element-citation></ref><ref id="B74-antibiotics-10-01254"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>G.D.</given-names></name>
<name><surname>Carr</surname><given-names>S.A.</given-names></name>
<name><surname>Rottschaefer</surname><given-names>S.</given-names></name>
<name><surname>Jeffs</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Structural characterization of glycopeptide antibiotics related to vancomycin by fast atom bombardment mass spectrometry</article-title><source>J. Antibiot. (Tokyo)</source><year>1985</year><volume>38</volume><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.38.713</pub-id><?supplied-pmid 4019316?><pub-id pub-id-type="pmid">4019316</pub-id></element-citation></ref><ref id="B75-antibiotics-10-01254"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Amexanthomycins A-J, pentangular polyphenols produced by <italic toggle="yes">Amycolatopsis mediterranei</italic> S699&#x02206;<italic toggle="yes">rifA</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>689</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1007/s00253-017-8648-z</pub-id><?supplied-pmid 29181568?><pub-id pub-id-type="pmid">29181568</pub-id></element-citation></ref><ref id="B76-antibiotics-10-01254"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ueno</surname><given-names>M.</given-names></name>
<name><surname>Iijima</surname><given-names>M.</given-names></name>
<name><surname>Masuda</surname><given-names>T.</given-names></name>
<name><surname>Kinoshita</surname><given-names>N.</given-names></name>
<name><surname>Iinuma</surname><given-names>H.</given-names></name>
<name><surname>Naganawa</surname><given-names>H.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Ishizuka</surname><given-names>M.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Dethymicin, a novel immunosuppressant isolated from an <italic toggle="yes">Amycolatopsis</italic>. Fermentation, isolation, physico-chemical properties and biological activities</article-title><source>J. Antibiot. (Tokyo)</source><year>1992</year><volume>45</volume><fpage>1819</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.45.1819</pub-id><?supplied-pmid 1490872?><pub-id pub-id-type="pmid">1490872</pub-id></element-citation></ref><ref id="B77-antibiotics-10-01254"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>N.J.</given-names></name>
<name><surname>Fu</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>G.H.</given-names></name>
<name><surname>Bao</surname><given-names>G.H.</given-names></name>
<name><surname>Xu</surname><given-names>C.F.</given-names></name>
<name><surname>He</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Isolation and structure of a new ansamycin antibiotic kanglemycin A from a <italic toggle="yes">Nocardia</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1988</year><volume>41</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.41.264</pub-id><pub-id pub-id-type="pmid">3281924</pub-id></element-citation></ref><ref id="B78-antibiotics-10-01254"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mosaei</surname><given-names>H.</given-names></name>
<name><surname>Molodtsov</surname><given-names>V.</given-names></name>
<name><surname>Kepplinger</surname><given-names>B.</given-names></name>
<name><surname>Harbottle</surname><given-names>J.</given-names></name>
<name><surname>Moon</surname><given-names>C.W.</given-names></name>
<name><surname>Jeeves</surname><given-names>R.E.</given-names></name>
<name><surname>Ceccaroni</surname><given-names>L.</given-names></name>
<name><surname>Shin</surname><given-names>Y.</given-names></name>
<name><surname>Morton-Laing</surname><given-names>S.</given-names></name>
<name><surname>Marrs</surname><given-names>E.C.L.</given-names></name>
<etal/>
</person-group><article-title>Mode of action of Kanglemycin A, an ansamycin natural product that is active against rifampicin-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>Mol. Cell.</source><year>2018</year><volume>72</volume><fpage>263</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.08.028</pub-id><?supplied-pmid 30244835?><pub-id pub-id-type="pmid">30244835</pub-id></element-citation></ref><ref id="B79-antibiotics-10-01254"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sensi</surname><given-names>P.</given-names></name>
<name><surname>Margalith</surname><given-names>P.</given-names></name>
<name><surname>Timbal</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Rifomycin, a new antibiotic; preliminary report</article-title><source>Farmaco Sci.</source><year>1959</year><volume>14</volume><fpage>146</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">13639988</pub-id></element-citation></ref><ref id="B80-antibiotics-10-01254"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Birner</surname><given-names>J.</given-names></name>
<name><surname>Hodgson</surname><given-names>P.R.</given-names></name>
<name><surname>Lane</surname><given-names>W.R.</given-names></name>
<name><surname>Baxter</surname><given-names>E.H.</given-names></name>
</person-group><article-title>An Australian isolate of <italic toggle="yes">Nocardia mediterranea</italic> producing rifamycin SV</article-title><source>J. Antibiot. (Tokyo)</source><year>1972</year><volume>25</volume><fpage>356</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.25.356</pub-id><pub-id pub-id-type="pmid">4649865</pub-id></element-citation></ref><ref id="B81-antibiotics-10-01254"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>N.J.</given-names></name>
<name><surname>Han</surname><given-names>B.L.</given-names></name>
<name><surname>Yameshita</surname><given-names>N.</given-names></name>
<name><surname>Sato</surname><given-names>M.</given-names></name>
</person-group><article-title>31-Homorifamycin W, a novel metabolite from <italic toggle="yes">Amycolatopsis mediterranei</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1994</year><volume>47</volume><fpage>613</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.47.613</pub-id><pub-id pub-id-type="pmid">8040064</pub-id></element-citation></ref><ref id="B82-antibiotics-10-01254"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Zheng</surname><given-names>H.</given-names></name>
<name><surname>Zhuo</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Complete genome sequence of <italic toggle="yes">Amycolatopsis mediterranei</italic> S699 based on de novo assembly via a combinatorial sequencing strategy</article-title><source>J. Bacteriol.</source><year>2012</year><volume>194</volume><fpage>5699</fpage><lpage>5700</lpage><pub-id pub-id-type="doi">10.1128/JB.01295-12</pub-id><pub-id pub-id-type="pmid">23012281</pub-id></element-citation></ref><ref id="B83-antibiotics-10-01254"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y.R.</given-names></name>
<name><surname>Zhang</surname><given-names>J.L.</given-names></name>
<name><surname>Tian</surname><given-names>X.Y.</given-names></name>
<name><surname>Wu</surname><given-names>X.K.</given-names></name>
<name><surname>Li</surname><given-names>T.H.</given-names></name>
<name><surname>Lu</surname><given-names>C.H.</given-names></name>
<name><surname>Shen</surname><given-names>Y.M.</given-names></name>
</person-group><article-title>Isolation of 11,12-seco-Rifamycin W derivatives reveals a cleavage pattern of the rifamycin ansa chain</article-title><source>Org. Lett.</source><year>2019</year><volume>21</volume><fpage>900</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.8b03792</pub-id><pub-id pub-id-type="pmid">30714736</pub-id></element-citation></ref><ref id="B84-antibiotics-10-01254"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>M.G.</given-names></name>
<name><surname>Khoo</surname><given-names>C.L.</given-names></name>
<name><surname>Rickards</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Oxidation processes in the biosynthesis of the tetracenomycin and elloramycin antibiotics</article-title><source>J. Antibiot. (Tokyo)</source><year>1989</year><volume>42</volume><fpage>640</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.42.640</pub-id><pub-id pub-id-type="pmid">2722677</pub-id></element-citation></ref><ref id="B85-antibiotics-10-01254"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiao</surname><given-names>X.</given-names></name>
<name><surname>Gan</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Shang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
</person-group><article-title>Tetracenomycin X exerts antitumour activity in lung cancer cells through the downregulation of cyclin D1</article-title><source>Mar. Drug.</source><year>2019</year><volume>17</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.3390/md17010063</pub-id></element-citation></ref><ref id="B86-antibiotics-10-01254"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brigham</surname><given-names>R.B.</given-names></name>
<name><surname>Pittenger</surname><given-names>R.C.</given-names></name>
</person-group><article-title><italic toggle="yes">Streptomyces orientalis</italic>, n. sp., the source of vancomycin</article-title><source>Antibiot. Chemother. (Northfield)</source><year>1956</year><volume>6</volume><fpage>642</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">24544146</pub-id></element-citation></ref><ref id="B87-antibiotics-10-01254"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boeck</surname><given-names>L.D.</given-names></name>
<name><surname>Mertz</surname><given-names>F.P.</given-names></name>
<name><surname>Wolter</surname><given-names>R.K.</given-names></name>
<name><surname>Higgens</surname><given-names>C.E.</given-names></name>
</person-group><article-title>N-demethylvancomycin, a novel antibiotic produced by a strain of <italic toggle="yes">Nocardia orientalis</italic>. Taxonomy and fermentation</article-title><source>J. Antibiot. (Tokyo)</source><year>1984</year><volume>37</volume><fpage>446</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.37.446</pub-id><pub-id pub-id-type="pmid">6547432</pub-id></element-citation></ref><ref id="B88-antibiotics-10-01254"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hunt</surname><given-names>A.H.</given-names></name>
<name><surname>Marconi</surname><given-names>G.G.</given-names></name>
<name><surname>Elzey</surname><given-names>T.K.</given-names></name>
<name><surname>Hoehn</surname><given-names>M.M.</given-names></name>
</person-group><article-title>A51568A: N-demethylvancomycin</article-title><source>J. Antibiot. (Tokyo)</source><year>1984</year><volume>37</volume><fpage>917</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.37.917</pub-id><?supplied-pmid 6548221?><pub-id pub-id-type="pmid">6548221</pub-id></element-citation></ref><ref id="B89-antibiotics-10-01254"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Qi</surname><given-names>D.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Song</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>He</surname><given-names>B.</given-names></name>
</person-group><article-title>Antibiotic activities and affinities for bacterial cell wall analogue of N-demethylvancomycin and its derivatives</article-title><source>J. Antibiot. (Tokyo)</source><year>1998</year><volume>51</volume><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.51.750</pub-id><pub-id pub-id-type="pmid">9766467</pub-id></element-citation></ref><ref id="B90-antibiotics-10-01254"><label>90.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Lapchinskaia</surname><given-names>O.A.</given-names></name>
<name><surname>Katrukha</surname><given-names>G.S.</given-names></name>
<name><surname>Pogozheva</surname><given-names>V.V.</given-names></name>
<name><surname>Ponomarenko</surname><given-names>V.I.</given-names></name>
<name><surname>Filicheva</surname><given-names>V.A.</given-names></name>
<name><surname>Kharitonova</surname><given-names>L.A.</given-names></name>
<name><surname>Lapchinskaia</surname><given-names>M.Y.</given-names></name>
<name><surname>Yakovenko</surname><given-names>A.N.</given-names></name>
<name><surname>Nifantiev</surname><given-names>N.E.</given-names></name>
<name><surname>Shashkov</surname><given-names>A.S.</given-names></name>
<etal/>
</person-group><article-title>Amycolatopsis orientalis Strain&#x02014;Producer of the Antibiotic Dimethylvancomycin and Method of the Antibiotic Preparation</article-title><source>Patent RU</source><patent>2633511</patent><day>12</day><month>October</month><year>2017</year><comment>(In Russian)</comment></element-citation></ref><ref id="B91-antibiotics-10-01254"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shashkov</surname><given-names>A.S.</given-names></name>
<name><surname>Tsvetkov</surname><given-names>D.E.</given-names></name>
<name><surname>Grachev</surname><given-names>A.A.</given-names></name>
<name><surname>Nifantiev</surname><given-names>N.E.</given-names></name>
<name><surname>Lapchinskaia</surname><given-names>O.A.</given-names></name>
<name><surname>Lavrova-Balashova</surname><given-names>M.F.</given-names></name>
<name><surname>Ponomarenko</surname><given-names>V.I.</given-names></name>
<name><surname>Katrukha</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Structural analysis of antibiotic INA 9301 from <italic toggle="yes">Amycolatopsis orientalis</italic></article-title><source>NPC</source><year>2008</year><volume>3</volume><fpage>1631</fpage><lpage>1638</lpage><pub-id pub-id-type="doi">10.1177/1934578X0800301010</pub-id></element-citation></ref><ref id="B92-antibiotics-10-01254"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
<name><surname>Lei</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Jiang</surname><given-names>B.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>Z.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>You</surname><given-names>X.</given-names></name>
<name><surname>Si</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Three structurally-related impurities in norvancomycin drug substance</article-title><source>J. Antibiot. (Tokyo)</source><year>2017</year><volume>70</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/ja.2016.115</pub-id><?supplied-pmid 27703158?><pub-id pub-id-type="pmid">27703158</pub-id></element-citation></ref><ref id="B93-antibiotics-10-01254"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Hong</surname><given-names>B.</given-names></name>
</person-group><article-title>Complete genome sequence of <italic toggle="yes">Amycolatopsis orientalis</italic> CPCC200066, the producer of norvancomycin</article-title><source>J. Biotechnol.</source><year>2017</year><volume>10</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2017.02.013</pub-id><?supplied-pmid 28216102?><pub-id pub-id-type="pmid">28216102</pub-id></element-citation></ref><ref id="B94-antibiotics-10-01254"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsunakawa</surname><given-names>M.</given-names></name>
<name><surname>Tenmyo</surname><given-names>O.</given-names></name>
<name><surname>Tomita</surname><given-names>K.</given-names></name>
<name><surname>Naruse</surname><given-names>N.</given-names></name>
<name><surname>Kotake</surname><given-names>C.</given-names></name>
<name><surname>Miyaki</surname><given-names>T.</given-names></name>
<name><surname>Konishi</surname><given-names>M.</given-names></name>
<name><surname>Oki</surname><given-names>T.</given-names></name>
</person-group><article-title>Quartromicin, a complex of novel antiviral antibiotics. I. Production, isolation, physico-chemical properties and antiviral activity</article-title><source>J. Antibiot. (Tokyo)</source><year>1992</year><volume>45</volume><fpage>180</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.45.180</pub-id><?supplied-pmid 1313409?><pub-id pub-id-type="pmid">1313409</pub-id></element-citation></ref><ref id="B95-antibiotics-10-01254"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pacey</surname><given-names>M.S.</given-names></name>
<name><surname>Jefson</surname><given-names>M.R.</given-names></name>
<name><surname>Huang</surname><given-names>L.H.</given-names></name>
<name><surname>Cullen</surname><given-names>W.P.</given-names></name>
<name><surname>Maeda</surname><given-names>H.</given-names></name>
<name><surname>Tone</surname><given-names>J.</given-names></name>
<name><surname>Nishiyama</surname><given-names>S.</given-names></name>
<name><surname>Kaneda</surname><given-names>K.</given-names></name>
<name><surname>Ishiguro</surname><given-names>M.</given-names></name>
</person-group><article-title>UK-69,753, a novel member of the efrotomycin family of antibiotics. I. Taxonomy of the producing organism, fermentation and isolation</article-title><source>J. Antibiot. (Tokyo)</source><year>1989</year><volume>42</volume><fpage>1453</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.42.1453</pub-id><pub-id pub-id-type="pmid">2808132</pub-id></element-citation></ref><ref id="B96-antibiotics-10-01254"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jefson</surname><given-names>M.R.</given-names></name>
<name><surname>Bordner</surname><given-names>J.</given-names></name>
<name><surname>Reese</surname><given-names>C.P.</given-names></name>
<name><surname>Whipple</surname><given-names>E.B.</given-names></name>
</person-group><article-title>UK-69,753, a novel member of the efrotomycin family of antibiotics. II. Structure determination and biological activity</article-title><source>J. Antibiot. (Tokyo)</source><year>1989</year><volume>42</volume><fpage>1610</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.42.1610</pub-id><pub-id pub-id-type="pmid">2584145</pub-id></element-citation></ref><ref id="B97-antibiotics-10-01254"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Box</surname><given-names>S.J.</given-names></name>
<name><surname>Elson</surname><given-names>A.L.</given-names></name>
<name><surname>Gilpin</surname><given-names>M.L.</given-names></name>
<name><surname>Winstanley</surname><given-names>D.J.</given-names></name>
</person-group><article-title>MM 47761 and MM 49721, glycopeptide antibiotics produced by a new strain of <italic toggle="yes">Amycolatopsis orientalis</italic>. Isolation, purification and structure determination</article-title><source>J. Antibiot. (Tokyo)</source><year>1990</year><volume>43</volume><fpage>931</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.43.931</pub-id><pub-id pub-id-type="pmid">2120168</pub-id></element-citation></ref><ref id="B98-antibiotics-10-01254"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Box</surname><given-names>S.J.</given-names></name>
<name><surname>Coates</surname><given-names>N.J.</given-names></name>
<name><surname>Davis</surname><given-names>C.J.</given-names></name>
<name><surname>Gilpin</surname><given-names>M.L.</given-names></name>
<name><surname>Houge-Frydrych</surname><given-names>C.S.</given-names></name>
<name><surname>Milner</surname><given-names>P.H.</given-names></name>
</person-group><article-title>MM 55266 and MM 55268, glycopeptide antibiotics produced by a new strain of <italic toggle="yes">Amycolatopsis</italic>. Isolation, purification and structure determination</article-title><source>J. Antibiot. (Tokyo)</source><year>1991</year><volume>44</volume><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.44.807</pub-id><pub-id pub-id-type="pmid">1917694</pub-id></element-citation></ref><ref id="B99-antibiotics-10-01254"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berdnikova</surname><given-names>T.F.</given-names></name>
<name><surname>Shashkov</surname><given-names>A.S.</given-names></name>
<name><surname>Katrukha</surname><given-names>G.S.</given-names></name>
<name><surname>Lapchinskaia</surname><given-names>O.A.</given-names></name>
<name><surname>Iurkevich</surname><given-names>N.V.</given-names></name>
<name><surname>Grachev</surname><given-names>A.A.</given-names></name>
<name><surname>Nifant&#x02019;ev</surname><given-names>N.E.</given-names></name>
</person-group><article-title>The structure of antibiotic eremomycin B</article-title><source>Russ. J. Bioorg. Chem.</source><year>2009</year><volume>35</volume><fpage>497</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1134/S1068162009040128</pub-id></element-citation></ref><ref id="B100-antibiotics-10-01254"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gause</surname><given-names>G.F.</given-names></name>
<name><surname>Brazhnikova</surname><given-names>M.G.</given-names></name>
<name><surname>Lomakina</surname><given-names>N.N.</given-names></name>
<name><surname>Berdnikova</surname><given-names>T.F.</given-names></name>
<name><surname>Fedorova</surname><given-names>G.B.</given-names></name>
<name><surname>Tokareva</surname><given-names>N.L.</given-names></name>
<name><surname>Borisova</surname><given-names>V.N.</given-names></name>
<name><surname>Batta</surname><given-names>G.</given-names></name>
</person-group><article-title>Eremomycin&#x02014;New glycopeptide antibiotics. Chemical properties and structure</article-title><source>J. Antibiot. (Tokyo)</source><year>1989</year><volume>42</volume><fpage>1790</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.42.1790</pub-id><pub-id pub-id-type="pmid">2621162</pub-id></element-citation></ref><ref id="B101-antibiotics-10-01254"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gauze</surname><given-names>G.F.</given-names></name>
<name><surname>Brazhnikova</surname><given-names>M.G.</given-names></name>
<name><surname>La&#x0012d;ko</surname><given-names>A.V.</given-names></name>
<name><surname>Sveshnikova</surname><given-names>M.A.</given-names></name>
<name><surname>Preobrazhenskaia</surname><given-names>T.P.</given-names></name>
</person-group><article-title>Eremomycin&#x02014;A new antibiotic from the cyclic glycopeptide group</article-title><source>Antibiot. Med. Biotekhnol.</source><year>1987</year><volume>32</volume><fpage>571</fpage><lpage>576</lpage><comment>(In Russian)</comment><?supplied-pmid 3674837?><pub-id pub-id-type="pmid">3674837</pub-id></element-citation></ref><ref id="B102-antibiotics-10-01254"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuji</surname><given-names>N.</given-names></name>
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Kamigauchi</surname><given-names>T.</given-names></name>
<name><surname>Yoshimura</surname><given-names>Y.</given-names></name>
<name><surname>Terui</surname><given-names>Y.</given-names></name>
</person-group><article-title>New glycopeptide antibiotics. I. The structures of orienticins</article-title><source>J. Antibiot. (Tokyo)</source><year>1988</year><volume>41</volume><fpage>819</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.41.819</pub-id><?supplied-pmid 3403380?><pub-id pub-id-type="pmid">3403380</pub-id></element-citation></ref><ref id="B103-antibiotics-10-01254"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuji</surname><given-names>N.</given-names></name>
<name><surname>Kamigauchi</surname><given-names>T.</given-names></name>
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Terui</surname><given-names>Y.</given-names></name>
</person-group><article-title>New glycopeptide antibiotics: II. The isolation and structures of chloroorienticins</article-title><source>J. Antibiot. (Tokyo)</source><year>1988</year><volume>41</volume><fpage>1506</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.41.1506</pub-id><?supplied-pmid 3272137?><pub-id pub-id-type="pmid">3272137</pub-id></element-citation></ref><ref id="B104-antibiotics-10-01254"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rolston</surname><given-names>K.V.</given-names></name>
<name><surname>Nguyen</surname><given-names>H.</given-names></name>
<name><surname>Messer</surname><given-names>M.</given-names></name>
</person-group><article-title>In vitro activity of LY264826, a new glycopeptide antibiotic, against Gram-positive bacteria isolated from patients with cancer</article-title><source>Antimicrob. Agents Chemother.</source><year>1990</year><volume>34</volume><fpage>2137</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1128/AAC.34.11.2137</pub-id><?supplied-pmid 2149921?><pub-id pub-id-type="pmid">2149921</pub-id></element-citation></ref><ref id="B105-antibiotics-10-01254"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kunimoto</surname><given-names>S.</given-names></name>
<name><surname>Someno</surname><given-names>T.</given-names></name>
<name><surname>Yamazaki</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Esumi</surname><given-names>H.</given-names></name>
<name><surname>Naganawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Kigamicins, novel antitumor antibiotics. II. Structure determination</article-title><source>J. Antibiot. (Tokyo)</source><year>2003</year><volume>56</volume><fpage>1012</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.56.1012</pub-id><?supplied-pmid 15015728?><pub-id pub-id-type="pmid">15015728</pub-id></element-citation></ref><ref id="B106-antibiotics-10-01254"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masuda</surname><given-names>T.</given-names></name>
<name><surname>Ohba</surname><given-names>S.</given-names></name>
<name><surname>Kawada</surname><given-names>M.</given-names></name>
<name><surname>Osono</surname><given-names>M.</given-names></name>
<name><surname>Ikeda</surname><given-names>D.</given-names></name>
<name><surname>Esumi</surname><given-names>H.</given-names></name>
<name><surname>Kunimoto</surname><given-names>S.</given-names></name>
</person-group><article-title>Antitumor effect of kigamicin D on mouse tumor models</article-title><source>J. Antibiot. (Tokyo)</source><year>2006</year><volume>59</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/ja.2006.29</pub-id><?supplied-pmid 16830887?><pub-id pub-id-type="pmid">16830887</pub-id></element-citation></ref><ref id="B107-antibiotics-10-01254"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>G.Y.A.</given-names></name>
<name><surname>Robinson</surname><given-names>S.</given-names></name>
<name><surname>Lacey</surname><given-names>E.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names></name>
<name><surname>Kim</surname><given-names>W.</given-names></name>
<name><surname>Goodfellow</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Amycolatopsis regifaucium</italic> sp. nov., a novel actinomycete that produces kigamicins</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2007</year><volume>57</volume><issue-part>Pt 11</issue-part><fpage>2562</fpage><lpage>2567</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.64974-0</pub-id><pub-id pub-id-type="pmid">17978218</pub-id></element-citation></ref><ref id="B108-antibiotics-10-01254"><label>108.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Biryukov</surname><given-names>M.V.</given-names></name>
<name><surname>Zakalyukina</surname><given-names>S.E.</given-names></name>
<name><surname>Osterman</surname><given-names>I.A.</given-names></name>
</person-group><article-title>Strain of Amycolatopsis rifamycinica&#x02014;Producer of the Antibiotic Tetracenomycin X</article-title><source>Patent RU</source><patent>2724537</patent><day>23</day><month>June</month><year>2020</year><comment>(In Russian)</comment></element-citation></ref><ref id="B109-antibiotics-10-01254"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osterman</surname><given-names>I.A.</given-names></name>
<name><surname>Wieland</surname><given-names>M.</given-names></name>
<name><surname>Maviza</surname><given-names>T.P.</given-names></name>
<name><surname>Lashkevich</surname><given-names>K.A.</given-names></name>
<name><surname>Lukianov</surname><given-names>D.A.</given-names></name>
<name><surname>Komarova</surname><given-names>E.S.</given-names></name>
<name><surname>Zakalyukina</surname><given-names>Y.V.</given-names></name>
<name><surname>Buschauer</surname><given-names>R.</given-names></name>
<name><surname>Shiriaev</surname><given-names>D.I.</given-names></name>
<name><surname>Leyn</surname><given-names>S.A.</given-names></name>
<etal/>
</person-group><article-title>Tetracenomycin X inhibits translation by binding within the ribosomal exit tunnel</article-title><source>Nat. Chem. Biol.</source><year>2020</year><volume>16</volume><fpage>1071</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-0578-x</pub-id><?supplied-pmid 32601485?><pub-id pub-id-type="pmid">32601485</pub-id></element-citation></ref><ref id="B110-antibiotics-10-01254"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwalen</surname><given-names>C.J.</given-names></name>
<name><surname>Hudson</surname><given-names>G.A.</given-names></name>
<name><surname>Kille</surname><given-names>B.</given-names></name>
<name><surname>Mitchell</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Bioinformatic expansion and discovery of thiopeptide antibiotics</article-title><source>J. Am. Chem. Soc.</source><year>2018</year><volume>140</volume><fpage>9494</fpage><lpage>9501</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b03896</pub-id><?supplied-pmid 29983054?><pub-id pub-id-type="pmid">29983054</pub-id></element-citation></ref><ref id="B111-antibiotics-10-01254"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Miao</surname><given-names>C.</given-names></name>
<name><surname>Hu</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>Echinosporin antibiotics isolated from <italic toggle="yes">Amycolatopsis</italic> strain and their antifungal activity against root-rot pathogens of the <italic toggle="yes">Panax notoginseng</italic></article-title><source>Folia Microbiol.</source><year>2019</year><volume>64</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/s12223-018-0642-z</pub-id><?supplied-pmid 30117099?><pub-id pub-id-type="pmid">30117099</pub-id></element-citation></ref><ref id="B112-antibiotics-10-01254"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>N.</given-names></name>
<name><surname>Tsuchida</surname><given-names>T.</given-names></name>
<name><surname>Umekita</surname><given-names>M.</given-names></name>
<name><surname>Kinoshita</surname><given-names>N.</given-names></name>
<name><surname>Iinuma</surname><given-names>H.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Epoxyquinomicins A, B, C and D, new antibiotics from <italic toggle="yes">Amycolatopsis.</italic> I. Taxonomy, fermentation, isolation and antimicrobial activities</article-title><source>J. Antibiot. (Tokyo)</source><year>1997</year><volume>50</volume><fpage>900</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.50.900</pub-id><?supplied-pmid 9592560?><pub-id pub-id-type="pmid">9592560</pub-id></element-citation></ref><ref id="B113-antibiotics-10-01254"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>N.</given-names></name>
<name><surname>Tsuchida</surname><given-names>T.</given-names></name>
<name><surname>Sawa</surname><given-names>R.</given-names></name>
<name><surname>Iinuma</surname><given-names>H.</given-names></name>
<name><surname>Nakamura</surname><given-names>H.</given-names></name>
<name><surname>Naganawa</surname><given-names>H.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Epoxyquinomicins A, B, C and D, new antibiotics from <italic toggle="yes">Amycolatopsis</italic>. III. Physico-chemical properties and structure determination</article-title><source>J. Antibiot. (Tokyo)</source><year>1997</year><volume>50</volume><fpage>912</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.50.912</pub-id><pub-id pub-id-type="pmid">9592562</pub-id></element-citation></ref><ref id="B114-antibiotics-10-01254"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuchida</surname><given-names>T.</given-names></name>
<name><surname>Inuma</surname><given-names>H.</given-names></name>
<name><surname>Kinoshita</surname><given-names>N.</given-names></name>
<name><surname>Ikeda</surname><given-names>T.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Hamada</surname><given-names>M.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Azicemicins A and B, a new antimicrobial agent produced by <italic toggle="yes">Amycolatopsis.</italic> I. Taxonomy, fermentation, isolation, characterization and biological activities</article-title><source>J. Antibiot. (Tokyo)</source><year>1995</year><volume>48</volume><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.48.217</pub-id><pub-id pub-id-type="pmid">7730155</pub-id></element-citation></ref><ref id="B115-antibiotics-10-01254"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuchida</surname><given-names>T.</given-names></name>
<name><surname>Sawa</surname><given-names>R.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Iinuma</surname><given-names>H.</given-names></name>
<name><surname>Sawa</surname><given-names>T.</given-names></name>
<name><surname>Naganawa</surname><given-names>H.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Azicemicins A and B, new antimicrobial agents produced by <italic toggle="yes">Amycolatopsis.</italic> II. Structure determination</article-title><source>J. Antibiot. (Tokyo)</source><year>1995</year><volume>48</volume><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.48.1148</pub-id></element-citation></ref><ref id="B116-antibiotics-10-01254"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proctor</surname><given-names>R.</given-names></name>
<name><surname>Craig</surname><given-names>W.</given-names></name>
<name><surname>Kunin</surname><given-names>C.</given-names></name>
</person-group><article-title>Cetocycline, tetracycline analog: <italic toggle="yes">In vitro</italic> studies of antimicrobial activity, serum binding, lipid solubility, and uptake by bacteria</article-title><source>Antimicrob. Agents Chemother.</source><year>1978</year><volume>13</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1128/AAC.13.4.598</pub-id><pub-id pub-id-type="pmid">666291</pub-id></element-citation></ref><ref id="B117-antibiotics-10-01254"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luke&#x0017e;i&#x0010d;</surname><given-names>T.</given-names></name>
<name><surname>Pikl</surname><given-names>&#x00160;.</given-names></name>
<name><surname>Zaburannyi</surname><given-names>N.</given-names></name>
<name><surname>Rem&#x00161;kar</surname><given-names>M.</given-names></name>
<name><surname>Petkovi&#x00107;</surname><given-names>H.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
</person-group><article-title>Heterologous expression of the atypical tetracycline chelocardin reveals the full set of genes required for its biosynthesis</article-title><source>Microb. Cell Fact.</source><year>2020</year><volume>19</volume><fpage>230</fpage><pub-id pub-id-type="doi">10.1186/s12934-020-01495-x</pub-id><pub-id pub-id-type="pmid">33341113</pub-id></element-citation></ref><ref id="B118-antibiotics-10-01254"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luke&#x0017e;i&#x0010d;</surname><given-names>T.</given-names></name>
<name><surname>Fayad</surname><given-names>A.A.</given-names></name>
<name><surname>Bader</surname><given-names>C.</given-names></name>
<name><surname>Harmrolfs</surname><given-names>K.</given-names></name>
<name><surname>Bartuli</surname><given-names>J.</given-names></name>
<name><surname>Gro&#x000df;</surname><given-names>S.</given-names></name>
<name><surname>Le&#x00161;nik</surname><given-names>U.</given-names></name>
<name><surname>Hennessen</surname><given-names>F.</given-names></name>
<name><surname>Herrmann</surname><given-names>J.</given-names></name>
<name><surname>Pikl</surname><given-names>&#x00160;.</given-names></name>
<etal/>
</person-group><article-title>Engineering atypical tetracycline formation in <italic toggle="yes">Amycolatopsis sulphurea</italic> for the production of modified chelocardin antibiotics</article-title><source>ACS Chem. Biol.</source><year>2019</year><volume>14</volume><fpage>468</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1021/acschembio.8b01125</pub-id><?supplied-pmid 30747520?><pub-id pub-id-type="pmid">30747520</pub-id></element-citation></ref><ref id="B119-antibiotics-10-01254"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>C.G.</given-names></name>
<name><surname>Mongolla</surname><given-names>P.</given-names></name>
<name><surname>Chandrasekhar</surname><given-names>C.</given-names></name>
<name><surname>Poornachandra</surname><given-names>Y.</given-names></name>
<name><surname>Siva</surname><given-names>B.</given-names></name>
<name><surname>Babu</surname><given-names>K.S.</given-names></name>
<name><surname>Ramakrishna</surname><given-names>K.V.S.</given-names></name>
</person-group><article-title>Anti-proliferative and antioxidant activities of 1-methoxy-3-methyl-8-hydroxy-anthraquinone, a hydroxyanthraquinoid extrolite produced by <italic toggle="yes">Amycolatopsis thermoflava</italic> strain SFMA-103</article-title><source>Microbiol. Biotechnol. Lett.</source><year>2017</year><volume>45</volume><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.4014/mbl.1705.05001</pub-id></element-citation></ref><ref id="B120-antibiotics-10-01254"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kishi</surname><given-names>T.</given-names></name>
<name><surname>Yamana</surname><given-names>H.</given-names></name>
<name><surname>Muroi</surname><given-names>M.</given-names></name>
<name><surname>Harada</surname><given-names>S.</given-names></name>
<name><surname>Asai</surname><given-names>M.</given-names></name>
</person-group><article-title>Tolypomycin, a new antibiotic. 3. Isolation and characterization of tolypomycin Y</article-title><source>J. Antibiot. (Tokyo)</source><year>1972</year><volume>25</volume><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.25.11</pub-id><pub-id pub-id-type="pmid">4622052</pub-id></element-citation></ref><ref id="B121-antibiotics-10-01254"><label>121.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Lapchinskaia</surname><given-names>O.A.</given-names></name>
<name><surname>Katrukha</surname><given-names>G.S.</given-names></name>
<name><surname>Terekhova</surname><given-names>L.P.</given-names></name>
<name><surname>Pogozheva</surname><given-names>V.V.</given-names></name>
<name><surname>Filicheva</surname><given-names>V.A.</given-names></name>
<name><surname>Kharitonova</surname><given-names>L.A.</given-names></name>
<name><surname>Lapchinskaia</surname><given-names>M.Y.</given-names></name>
<name><surname>Yakovenko</surname><given-names>A.N.</given-names></name>
<name><surname>Ponomarenko</surname><given-names>V.I.</given-names></name>
<name><surname>Orlova</surname><given-names>G.I.</given-names></name>
</person-group><article-title>The Amycolatopsis umgeniensis strain is a producer of the antibiotic eremomycin</article-title><source>Patent RU</source><patent>2689699 C1</patent><day>28</day><month>May</month><year>2019</year><comment>(In Russian)</comment></element-citation></ref><ref id="B122-antibiotics-10-01254"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hopmann</surname><given-names>C.</given-names></name>
<name><surname>Kurz</surname><given-names>M.</given-names></name>
<name><surname>Br&#x000f6;nstrup</surname><given-names>M.</given-names></name>
<name><surname>Wink</surname><given-names>J.</given-names></name>
<name><surname>LeBeller</surname><given-names>D.</given-names></name>
</person-group><article-title>Isolation and structure elucidation of vancoresmycin&#x02014;A new antibiotic from <italic toggle="yes">Amycolatopsis</italic> sp. ST 101170</article-title><source>Tetrahedron Lett.</source><year>2002</year><volume>43</volume><fpage>435</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(01)02171-2</pub-id></element-citation></ref><ref id="B123-antibiotics-10-01254"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kepplinger</surname><given-names>B.</given-names></name>
<name><surname>Morton-Laing</surname><given-names>S.</given-names></name>
<name><surname>Seistrup</surname><given-names>K.H.</given-names></name>
<name><surname>Marrs</surname><given-names>E.C.L.</given-names></name>
<name><surname>Hopkins</surname><given-names>A.P.</given-names></name>
<name><surname>Perry</surname><given-names>J.D.</given-names></name>
<name><surname>Strahl</surname><given-names>H.</given-names></name>
<name><surname>Hall</surname><given-names>M.J.</given-names></name>
<name><surname>Errington</surname><given-names>J.</given-names></name>
<name><surname>Allenby</surname><given-names>N.E.E.</given-names></name>
</person-group><article-title>Mode of action and heterologous expression of the natural product antibiotic vancoresmycin</article-title><source>ACS Chem. Biol.</source><year>2018</year><volume>13</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00733</pub-id><?supplied-pmid 29185696?><pub-id pub-id-type="pmid">29185696</pub-id></element-citation></ref><ref id="B124-antibiotics-10-01254"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Binda</surname><given-names>E.</given-names></name>
<name><surname>Marinelli</surname><given-names>F.</given-names></name>
<name><surname>Marcone</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Old and new glycopeptide antibiotics: Action and resistance</article-title><source>Antibiotics</source><year>2014</year><volume>3</volume><fpage>572</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.3390/antibiotics3040572</pub-id><pub-id pub-id-type="pmid">27025757</pub-id></element-citation></ref><ref id="B125-antibiotics-10-01254"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCormick</surname><given-names>M.H.</given-names></name>
<name><surname>Stark</surname><given-names>W.M.</given-names></name>
<name><surname>Pittenger</surname><given-names>G.E.</given-names></name>
<name><surname>Pittenger</surname><given-names>R.C.</given-names></name>
<name><surname>McGuire</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Vancomycin, a new antibiotic. &#x00406;. Chemical and biological properties</article-title><source>Antibiot. Annu.</source><year>1956</year><volume>3</volume><fpage>606</fpage><lpage>611</lpage></element-citation></ref><ref id="B126-antibiotics-10-01254"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rubinstein</surname><given-names>E.</given-names></name>
<name><surname>Keynan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Vancomycin revisited&#x02014;60 years later</article-title><source>Front. Public Health</source><year>2014</year><volume>2</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2014.00217</pub-id><pub-id pub-id-type="pmid">25401098</pub-id></element-citation></ref><ref id="B127-antibiotics-10-01254"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levine</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Vancomycin: A history</article-title><source>Clin. Infect. Dis.</source><year>2006</year><volume>42</volume><issue>(Suppl. 1)</issue><fpage>S5</fpage><lpage>S12</lpage><pub-id pub-id-type="doi">10.1086/491709</pub-id><pub-id pub-id-type="pmid">16323120</pub-id></element-citation></ref><ref id="B128-antibiotics-10-01254"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.Y.</given-names></name>
<name><surname>Yang</surname><given-names>S.B.</given-names></name>
<name><surname>Wu</surname><given-names>Y.J.</given-names></name>
<name><surname>Shen</surname><given-names>X.F.</given-names></name>
<name><surname>Chen</surname><given-names>S.X.</given-names></name>
</person-group><article-title>Enhancement of A82846B yield and proportion by overexpressing the halogenase gene in <italic toggle="yes">Amycolatopsis orientalis</italic> SIPI18099</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>5635</fpage><lpage>5643</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-8983-8</pub-id><pub-id pub-id-type="pmid">29728728</pub-id></element-citation></ref><ref id="B129-antibiotics-10-01254"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>R.</given-names></name>
</person-group><article-title>Enterococcal-type glycopeptide resistance genes in non-enterococcal organisms</article-title><source>FEMS Microbiol. Lett.</source><year>2000</year><volume>185</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2000.tb09032.x</pub-id><pub-id pub-id-type="pmid">10731599</pub-id></element-citation></ref><ref id="B130-antibiotics-10-01254"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sivagnanam</surname><given-names>S.</given-names></name>
<name><surname>Deleu</surname><given-names>D.</given-names></name>
</person-group><article-title>Red man syndrome</article-title><source>Crit. Care.</source><year>2003</year><volume>7</volume><fpage>119</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1186/cc1871</pub-id><pub-id pub-id-type="pmid">12720556</pub-id></element-citation></ref><ref id="B131-antibiotics-10-01254"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Z.C.</given-names></name>
<name><surname>Boger</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Maxamycins: Durable antibiotics derived by rational redesign of vancomycin</article-title><source>Acc. Chem. Res.</source><year>2020</year><volume>53</volume><fpage>2587</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.0c00569</pub-id><pub-id pub-id-type="pmid">33138354</pub-id></element-citation></ref><ref id="B132-antibiotics-10-01254"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Wei</surname><given-names>W.</given-names></name>
<name><surname>Zhong</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Ge</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Complete genome sequence and comparative genomic analyses of the vancomycin-producing <italic toggle="yes">Amycolatopsis orientalis</italic></article-title><source>BMC Genom.</source><year>2014</year><volume>15</volume><elocation-id>363</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-15-363</pub-id></element-citation></ref><ref id="B133-antibiotics-10-01254"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yim</surname><given-names>G.</given-names></name>
<name><surname>Thaker</surname><given-names>M.N.</given-names></name>
<name><surname>Koteva</surname><given-names>K.</given-names></name>
<name><surname>Wright</surname><given-names>G.</given-names></name>
</person-group><article-title>Glycopeptide antibiotic biosynthesis</article-title><source>J. Antibiot. (Tokyo)</source><year>2014</year><volume>67</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/ja.2013.117</pub-id><pub-id pub-id-type="pmid">24220108</pub-id></element-citation></ref><ref id="B134-antibiotics-10-01254"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hubbard</surname><given-names>B.K.</given-names></name>
<name><surname>Walsh</surname><given-names>C.T.</given-names></name>
</person-group><article-title>Vancomycin assembly: Nature&#x02019;s way</article-title><source>Angew. Chem. Int. Ed Engl.</source><year>2003</year><volume>42</volume><fpage>730</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1002/anie.200390202</pub-id><pub-id pub-id-type="pmid">12596194</pub-id></element-citation></ref><ref id="B135-antibiotics-10-01254"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagarajan</surname><given-names>R.</given-names></name>
</person-group><article-title>Structure-activity relationships of vancomycin-type glycopeptide antibiotics</article-title><source>J. Antibiot. (Tokyo)</source><year>1993</year><volume>46</volume><fpage>1181</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.46.1181</pub-id><?supplied-pmid 8407579?><pub-id pub-id-type="pmid">8407579</pub-id></element-citation></ref><ref id="B136-antibiotics-10-01254"><label>136.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Gause</surname><given-names>G.F.</given-names></name>
<name><surname>Preobrazhenskaya</surname><given-names>T.P.</given-names></name>
<name><surname>Laiko</surname><given-names>A.V.</given-names></name>
<name><surname>Selezneva</surname><given-names>T.I.</given-names></name>
<name><surname>Sveshnikova</surname><given-names>M.A.</given-names></name>
<name><surname>Brazhnikova</surname><given-names>M.G.</given-names></name>
<name><surname>Fedorova</surname><given-names>G.B.</given-names></name>
<name><surname>Borisova</surname><given-names>V.N.</given-names></name>
<name><surname>Tolstykh</surname><given-names>I.V.</given-names></name>
<name><surname>Proshlyakova</surname><given-names>V.V.</given-names></name>
<etal/>
</person-group><article-title>The antibiotic &#x0201c;eremomycin&#x0201d; and the method of its preparation</article-title><source>Patent</source><patent>SU 1475150 A1</patent><day>27</day><month>May</month><year>1997</year><comment>(In Russian)</comment></element-citation></ref><ref id="B137-antibiotics-10-01254"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gauze</surname><given-names>G.F.</given-names></name>
<name><surname>Brazhnikova</surname><given-names>M.G.</given-names></name>
<name><surname>Lomakina</surname><given-names>N.N.</given-names></name>
<name><surname>Gol&#x02019;dberg</surname><given-names>L.E.</given-names></name>
<name><surname>Laiko</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Eremomycin&#x02014;A new antibiotic of the polycyclic glycopeptide group</article-title><source>Antibiot. Khimioter.</source><year>1989</year><volume>34</volume><fpage>348</fpage><lpage>352</lpage><comment>(In Russian)</comment><?supplied-pmid 2742419?><pub-id pub-id-type="pmid">2742419</pub-id></element-citation></ref><ref id="B138-antibiotics-10-01254"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filippos&#x02019;iants</surname><given-names>S.T.</given-names></name>
<name><surname>Malkova</surname><given-names>I.V.</given-names></name>
<name><surname>Gol&#x02019;dberg</surname><given-names>L.E.</given-names></name>
</person-group><article-title>Glycopeptide antibiotics: Eremomycin, vancomycin, and teicoplanin. Comparison of several parameters of pharmacokinetics and antimicrobial activity</article-title><source>Antibiot. Khimioter.</source><year>1989</year><volume>34</volume><fpage>523</fpage><lpage>526</lpage><comment>(In Russian)</comment><?supplied-pmid 2530944?><pub-id pub-id-type="pmid">2530944</pub-id></element-citation></ref><ref id="B139-antibiotics-10-01254"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alduina</surname><given-names>R.</given-names></name>
<name><surname>Gallo</surname><given-names>G.</given-names></name>
<name><surname>Renzone</surname><given-names>G.</given-names></name>
<name><surname>Weber</surname><given-names>T.</given-names></name>
<name><surname>Scaloni</surname><given-names>A.</given-names></name>
<name><surname>Puglia</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Novel <italic toggle="yes">Amycolatopsis balhimycina</italic> biochemical abilities unveiled by proteomics</article-title><source>FEMS Microbiol. Lett.</source><year>2014</year><volume>351</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1111/1574-6968.12324</pub-id><?supplied-pmid 24246022?><pub-id pub-id-type="pmid">24246022</pub-id></element-citation></ref><ref id="B140-antibiotics-10-01254"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wohlleben</surname><given-names>W.</given-names></name>
<name><surname>Mast</surname><given-names>Y.</given-names></name>
<name><surname>Muth</surname><given-names>G.</given-names></name>
<name><surname>R&#x000f6;ttgen</surname><given-names>M.</given-names></name>
<name><surname>Stegmann</surname><given-names>E.</given-names></name>
<name><surname>Weber</surname><given-names>T.</given-names></name>
</person-group><article-title>Synthetic Biology of secondary metabolite biosynthesis in actinomycetes: Engineering precursor supply as a way to optimize antibiotic production</article-title><source>FEBS Lett.</source><year>2012</year><volume>586</volume><fpage>2171</fpage><lpage>2176</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2012.04.025</pub-id><?supplied-pmid 22710162?><pub-id pub-id-type="pmid">22710162</pub-id></element-citation></ref><ref id="B141-antibiotics-10-01254"><label>141.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Jordan</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Ristocetin</article-title><source>Antibiotics. Mechanism of Action</source><person-group person-group-type="editor">
<name><surname>Gottlieb</surname><given-names>D.</given-names></name>
<name><surname>Shaw</surname><given-names>P.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1967</year><volume>Volume 1</volume><fpage>84</fpage><lpage>89</lpage></element-citation></ref><ref id="B142-antibiotics-10-01254"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keesler</surname><given-names>D.A.</given-names></name>
<name><surname>Flood</surname><given-names>V.H.</given-names></name>
</person-group><article-title>Current issues in diagnosis and treatment of von Willebrand disease</article-title><source>Res. Pract. Thromb. Haemost.</source><year>2017</year><volume>2</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/rth2.12064</pub-id><?supplied-pmid 30046704?><pub-id pub-id-type="pmid">30046704</pub-id></element-citation></ref><ref id="B143-antibiotics-10-01254"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGahren</surname><given-names>W.J.</given-names></name>
<name><surname>Martin</surname><given-names>J.H.</given-names></name>
<name><surname>Morton</surname><given-names>G.O.</given-names></name>
<name><surname>Hargreaves</surname><given-names>R.T.</given-names></name>
<name><surname>Leese</surname><given-names>R.A.</given-names></name>
<name><surname>Lovell</surname><given-names>F.M.</given-names></name>
<name><surname>Ellestad</surname><given-names>G.A.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>E.</given-names></name>
<name><surname>Holker</surname><given-names>J.S.E.</given-names></name>
</person-group><article-title>Structure of avoparcin components</article-title><source>J. Am. Chem. Soc.</source><year>1980</year><volume>102</volume><fpage>1671</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1021/ja00525a036</pub-id></element-citation></ref><ref id="B144-antibiotics-10-01254"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van de Kerk-van Hoof</surname><given-names>A.</given-names></name>
<name><surname>Heck</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Interactions of &#x003b1;- and &#x003b2;-avoparcin with bacterial cell-wall receptor-mimicking peptides studied by electrospray ionization mass spectrometry</article-title><source>J. Antimicrob. Chemother.</source><year>1999</year><volume>44</volume><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1093/jac/44.5.593</pub-id><?supplied-pmid 10552974?><pub-id pub-id-type="pmid">10552974</pub-id></element-citation></ref><ref id="B145-antibiotics-10-01254"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Regev-Yochay</surname><given-names>G.</given-names></name>
<name><surname>Lipsitch</surname><given-names>M.</given-names></name>
<name><surname>Hanage</surname><given-names>W.P.</given-names></name>
</person-group><article-title>Antibiotics in agriculture and the risk to human health: How worried should we be?</article-title><source>Evol. Appl.</source><year>2015</year><volume>8</volume><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/eva.12185</pub-id><?supplied-pmid 25861382?><pub-id pub-id-type="pmid">25861382</pub-id></element-citation></ref><ref id="B146-antibiotics-10-01254"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gouliouris</surname><given-names>T.</given-names></name>
<name><surname>Raven</surname><given-names>K.E.</given-names></name>
<name><surname>Ludden</surname><given-names>C.</given-names></name>
<name><surname>Blane</surname><given-names>B.</given-names></name>
<name><surname>Corander</surname><given-names>J.</given-names></name>
<name><surname>Horner</surname><given-names>C.S.</given-names></name>
<name><surname>Hernandez-Garcia</surname><given-names>J.</given-names></name>
<name><surname>Wood</surname><given-names>P.</given-names></name>
<name><surname>Hadjirin</surname><given-names>N.F.</given-names></name>
<name><surname>Radakovic</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Genomic surveillance of <italic toggle="yes">Enterococcus faecium</italic> reveals limited sharing of strains and resistance genes between livestock and humans in the United Kingdom</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e01780-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01780-18</pub-id><pub-id pub-id-type="pmid">30401778</pub-id></element-citation></ref><ref id="B147-antibiotics-10-01254"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Birkeg&#x000e5;rd</surname><given-names>A.C.</given-names></name>
<name><surname>Gr&#x000e6;sb&#x000f8;ll</surname><given-names>K.</given-names></name>
<name><surname>Clasen</surname><given-names>J.</given-names></name>
<name><surname>Halasa</surname><given-names>T.</given-names></name>
<name><surname>Toft</surname><given-names>N.</given-names></name>
<name><surname>Folkesson</surname><given-names>A.</given-names></name>
</person-group><article-title>Continuing occurrence of vancomycin resistance determinants in Danish pig farms 20 years after removing exposure to avoparcin</article-title><source>Vet. Microbiol.</source><year>2019</year><volume>232</volume><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2019.04.007</pub-id><pub-id pub-id-type="pmid">31030850</pub-id></element-citation></ref><ref id="B148-antibiotics-10-01254"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stogios</surname><given-names>P.J.</given-names></name>
<name><surname>Savchenko</surname><given-names>A.</given-names></name>
</person-group><article-title>Molecular mechanisms of vancomycin resistance</article-title><source>Protein Sci.</source><year>2020</year><volume>29</volume><fpage>654</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1002/pro.3819</pub-id><pub-id pub-id-type="pmid">31899563</pub-id></element-citation></ref><ref id="B149-antibiotics-10-01254"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kahne</surname><given-names>D.</given-names></name>
<name><surname>Leimkuhler</surname><given-names>C.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Walsh</surname><given-names>C.</given-names></name>
</person-group><article-title>Glycopeptide and lipoglycopeptide antibiotics</article-title><source>Chem. Rev.</source><year>2005</year><volume>105</volume><fpage>425</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1021/cr030103a</pub-id><pub-id pub-id-type="pmid">15700951</pub-id></element-citation></ref><ref id="B150-antibiotics-10-01254"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boneca</surname><given-names>I.G.</given-names></name>
<name><surname>Chiosis</surname><given-names>G.</given-names></name>
</person-group><article-title>Vancomycin resistance: Occurrence, mechanisms and strategies to combat it</article-title><source>Expert. Opin. Ther. Targets.</source><year>2003</year><volume>7</volume><fpage>311</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1517/14728222.7.3.311</pub-id><?supplied-pmid 12783569?><pub-id pub-id-type="pmid">12783569</pub-id></element-citation></ref><ref id="B151-antibiotics-10-01254"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leclercq</surname><given-names>R.</given-names></name>
<name><surname>Derlot</surname><given-names>E.</given-names></name>
<name><surname>Duval</surname><given-names>J.</given-names></name>
<name><surname>Courvalin</surname><given-names>P.</given-names></name>
</person-group><article-title>Plasmid-mediated resistance to vancomycin and teicoplanin in <italic toggle="yes">Enterococcus faecium</italic></article-title><source>N. Engl. J. Med.</source><year>1988</year><volume>319</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1056/NEJM198807213190307</pub-id><?supplied-pmid 2968517?><pub-id pub-id-type="pmid">2968517</pub-id></element-citation></ref><ref id="B152-antibiotics-10-01254"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Driscoll</surname><given-names>T.</given-names></name>
<name><surname>Crank</surname><given-names>C.W.</given-names></name>
</person-group><article-title>Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management</article-title><source>Infect. Drug. Resist.</source><year>2015</year><volume>8</volume><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.2147/IDR.S54125</pub-id><?supplied-pmid 26244026?><pub-id pub-id-type="pmid">26244026</pub-id></element-citation></ref><ref id="B153-antibiotics-10-01254"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arredondo-Alonso</surname><given-names>S.</given-names></name>
<name><surname>Top</surname><given-names>J.</given-names></name>
<name><surname>McNally</surname><given-names>A.</given-names></name>
<name><surname>Puranen</surname><given-names>S.</given-names></name>
<name><surname>Pesonen</surname><given-names>M.</given-names></name>
<name><surname>Pensar</surname><given-names>J.</given-names></name>
<name><surname>Marttinen</surname><given-names>P.</given-names></name>
<name><surname>Braat</surname><given-names>J.C.</given-names></name>
<name><surname>Rogers</surname><given-names>M.R.C.</given-names></name>
<name><surname>van Schaik</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Plasmids shaped the recent emergence of the major nosocomial pathogen <italic toggle="yes">Enterococcus faecium</italic></article-title><source>mBio</source><year>2020</year><volume>11</volume><fpage>e03284-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.03284-19</pub-id><pub-id pub-id-type="pmid">32047136</pub-id></element-citation></ref><ref id="B154-antibiotics-10-01254"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shariati</surname><given-names>A.</given-names></name>
<name><surname>Dadashi</surname><given-names>M.</given-names></name>
<name><surname>Moghadam</surname><given-names>M.T.</given-names></name>
<name><surname>van Belkum</surname><given-names>A.</given-names></name>
<name><surname>Yaslianifard</surname><given-names>S.</given-names></name>
<name><surname>Darban-Sarokhalil</surname><given-names>D.</given-names></name>
</person-group><article-title>Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate <italic toggle="yes">Staphylococcus aureus</italic> clinical isolates: A systematic review and meta-analysis</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>12689</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-69058-z</pub-id><pub-id pub-id-type="pmid">32728110</pub-id></element-citation></ref><ref id="B155-antibiotics-10-01254"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartley</surname><given-names>J.</given-names></name>
</person-group><article-title>First case of VRSA identified in Michigan</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2002</year><volume>23</volume><fpage>480</fpage><pub-id pub-id-type="doi">10.1017/s0195941700082333</pub-id><pub-id pub-id-type="pmid">12186219</pub-id></element-citation></ref><ref id="B156-antibiotics-10-01254"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stegmann</surname><given-names>E.</given-names></name>
<name><surname>Frasch</surname><given-names>H.J.</given-names></name>
<name><surname>Kilian</surname><given-names>R.</given-names></name>
<name><surname>Pozzi</surname><given-names>R.</given-names></name>
</person-group><article-title>Self-resistance mechanisms of actinomycetes producing lipid II-targeting antibiotics</article-title><source>Int. J. Med. Microbiol.</source><year>2015</year><volume>305</volume><fpage>190</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2014.12.015</pub-id><pub-id pub-id-type="pmid">25601631</pub-id></element-citation></ref><ref id="B157-antibiotics-10-01254"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>C.G.</given-names></name>
<name><surname>Lessard</surname><given-names>I.A.</given-names></name>
<name><surname>Park</surname><given-names>I.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms</article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>2215</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.9.2215</pub-id><pub-id pub-id-type="pmid">9736537</pub-id></element-citation></ref><ref id="B158-antibiotics-10-01254"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sch&#x000e4;berle</surname><given-names>T.F.</given-names></name>
<name><surname>Vollmer</surname><given-names>W.</given-names></name>
<name><surname>Frasch</surname><given-names>H.J.</given-names></name>
<name><surname>H&#x000fc;ttel</surname><given-names>S.</given-names></name>
<name><surname>Kulik</surname><given-names>A.</given-names></name>
<name><surname>R&#x000f6;ttgen</surname><given-names>M.</given-names></name>
<name><surname>von Thaler</surname><given-names>A.K.</given-names></name>
<name><surname>Wohlleben</surname><given-names>W.</given-names></name>
<name><surname>Stegmann</surname><given-names>E.</given-names></name>
</person-group><article-title>Self-resistance and cell wall composition in the glycopeptide producer <italic toggle="yes">Amycolatopsis balhimycina</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>4283</fpage><lpage>4289</lpage><pub-id pub-id-type="doi">10.1128/AAC.01372-10</pub-id><pub-id pub-id-type="pmid">21690280</pub-id></element-citation></ref><ref id="B159-antibiotics-10-01254"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wehrli</surname><given-names>W.</given-names></name>
</person-group><article-title>Ansamycins. Chemistry, biosynthesis and biological activity</article-title><source>Top. Curr. Chem.</source><year>1977</year><volume>72</volume><fpage>21</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/BFb0048448</pub-id><pub-id pub-id-type="pmid">74108</pub-id></element-citation></ref><ref id="B160-antibiotics-10-01254"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farr</surname><given-names>B.</given-names></name>
<name><surname>Mandell</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Rifampin</article-title><source>Med. Clin. North Am.</source><year>1982</year><volume>66</volume><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/S0025-7125(16)31449-3</pub-id><pub-id pub-id-type="pmid">7038325</pub-id></element-citation></ref><ref id="B161-antibiotics-10-01254"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lal</surname><given-names>R.</given-names></name>
<name><surname>Khanna</surname><given-names>M.</given-names></name>
<name><surname>Kaur</surname><given-names>H.</given-names></name>
<name><surname>Srivastava</surname><given-names>N.</given-names></name>
<name><surname>Tripathi</surname><given-names>K.K.</given-names></name>
<name><surname>Lal</surname><given-names>S.</given-names></name>
</person-group><article-title>Rifamycins: Strain improvement program</article-title><source>Crit. Rev. Microbiol.</source><year>1995</year><volume>21</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3109/10408419509113532</pub-id><?supplied-pmid 7576149?><pub-id pub-id-type="pmid">7576149</pub-id></element-citation></ref><ref id="B162-antibiotics-10-01254"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peano</surname><given-names>C.</given-names></name>
<name><surname>Damiano</surname><given-names>F.</given-names></name>
<name><surname>Forcato</surname><given-names>M.</given-names></name>
<name><surname>Pietrelli</surname><given-names>A.</given-names></name>
<name><surname>Palumbo</surname><given-names>C.</given-names></name>
<name><surname>Corti</surname><given-names>G.</given-names></name>
<name><surname>Siculella</surname><given-names>L.</given-names></name>
<name><surname>Fuligni</surname><given-names>F.</given-names></name>
<name><surname>Tagliazucchi</surname><given-names>G.M.</given-names></name>
<name><surname>De Benedetto</surname><given-names>G.E.</given-names></name>
<etal/>
</person-group><article-title>Comparative genomics revealed key molecular targets to rapidly convert a reference rifamycin-producing bacterial strain into an overproducer by genetic engineering</article-title><source>Metab. Eng.</source><year>2014</year><volume>26</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2014.08.001</pub-id><?supplied-pmid 25149266?><pub-id pub-id-type="pmid">25149266</pub-id></element-citation></ref><ref id="B163-antibiotics-10-01254"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Floss</surname><given-names>H.G.</given-names></name>
</person-group><article-title>Antibiotic biosynthesis: From natural to unnatural compounds</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2001</year><volume>27</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/sj.jim.7000069</pub-id><?supplied-pmid 11780790?><pub-id pub-id-type="pmid">11780790</pub-id></element-citation></ref><ref id="B164-antibiotics-10-01254"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>F.</given-names></name>
<name><surname>Lei</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Fan</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Tang</surname><given-names>G.L.</given-names></name>
<name><surname>Xiao</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Deciphering the late steps of rifamycin biosynthesis</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2342</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04772-x</pub-id><pub-id pub-id-type="pmid">29904078</pub-id></element-citation></ref><ref id="B165-antibiotics-10-01254"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robertsen</surname><given-names>H.L.</given-names></name>
<name><surname>Musiol-Kroll</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Actinomycete-derived polyketides as a source of antibiotics and lead structures for the development of new antimicrobial drugs</article-title><source>Antibiotics</source><year>2019</year><volume>8</volume><elocation-id>157</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics8040157</pub-id></element-citation></ref><ref id="B166-antibiotics-10-01254"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bergamini</surname><given-names>N.</given-names></name>
<name><surname>Fowst</surname><given-names>G.</given-names></name>
</person-group><article-title>Rifamycin SV. A review</article-title><source>Arzneimittelforschung</source><year>1965</year><volume>15</volume><fpage>951</fpage><lpage>1002</lpage></element-citation></ref><ref id="B167-antibiotics-10-01254"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aristoff</surname><given-names>P.A.</given-names></name>
<name><surname>Garcia</surname><given-names>G.A.</given-names></name>
<name><surname>Kirchhoff</surname><given-names>P.D.</given-names></name>
<name><surname>Showalter</surname><given-names>H.D.</given-names></name>
</person-group><article-title>Rifamycins-obstacles and opportunities</article-title><source>Tuberculosis</source><year>2010</year><volume>90</volume><fpage>94</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2010.02.001</pub-id><pub-id pub-id-type="pmid">20236863</pub-id></element-citation></ref><ref id="B168-antibiotics-10-01254"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sensi</surname><given-names>P.</given-names></name>
</person-group><article-title>History of the development of rifampin</article-title><source>Rev. Infect. Dis.</source><year>1983</year><volume>5</volume><fpage>S402</fpage><lpage>S406</lpage><pub-id pub-id-type="doi">10.1093/clinids/5.Supplement_3.S402</pub-id><pub-id pub-id-type="pmid">6635432</pub-id></element-citation></ref><ref id="B169-antibiotics-10-01254"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Wan</surname><given-names>E.</given-names></name>
<name><surname>Kim</surname><given-names>C.J.</given-names></name>
<name><surname>Floss</surname><given-names>H.G.</given-names></name>
<name><surname>Mahmud</surname><given-names>T.</given-names></name>
</person-group><article-title>Identification of tailoring genes involved in the modification of the polyketide backbone of rifamycin B by <italic toggle="yes">Amycolatopsis mediterranei</italic> S699</article-title><source>Microbiology (Reading)</source><year>2005</year><volume>151</volume><issue-part>Pt 8</issue-part><fpage>2515</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.1099/mic.0.28138-0</pub-id><pub-id pub-id-type="pmid">16079331</pub-id></element-citation></ref><ref id="B170-antibiotics-10-01254"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghisalba</surname><given-names>O.</given-names></name>
<name><surname>Traxler</surname><given-names>P.</given-names></name>
<name><surname>N&#x000fc;esch</surname><given-names>J.</given-names></name>
</person-group><article-title>Early intermediates in the biosynthesis of ansamycins. I. Isolation and identification of protorifamycin I</article-title><source>J. Antibiot. (Tokyo)</source><year>1978</year><volume>31</volume><fpage>1124</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.31.1124</pub-id><pub-id pub-id-type="pmid">721708</pub-id></element-citation></ref><ref id="B171-antibiotics-10-01254"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghisalba</surname><given-names>O.</given-names></name>
<name><surname>Traxler</surname><given-names>P.</given-names></name>
<name><surname>Fuhrer</surname><given-names>H.</given-names></name>
<name><surname>Richter</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Early intermediates in the biosynthesis of ansamycins. II. Isolation and identification of proansamycin B-M1 and protorifamycin i-M1</article-title><source>J. Antibiot. (Tokyo)</source><year>1979</year><volume>32</volume><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.32.1267</pub-id><pub-id pub-id-type="pmid">396289</pub-id></element-citation></ref><ref id="B172-antibiotics-10-01254"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghisalba</surname><given-names>O.</given-names></name>
<name><surname>Traxler</surname><given-names>P.</given-names></name>
<name><surname>Fuhrer</surname><given-names>H.</given-names></name>
<name><surname>Richter</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Early intermediates in the biosynthesis of ansamycins. III. Isolation and identification of further 8-deoxyansamycins of the rifamycin-type</article-title><source>J. Antibiot. (Tokyo)</source><year>1980</year><volume>33</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.33.847</pub-id><?supplied-pmid 7000738?><pub-id pub-id-type="pmid">7000738</pub-id></element-citation></ref><ref id="B173-antibiotics-10-01254"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinelli</surname><given-names>E.</given-names></name>
<name><surname>Gallo</surname><given-names>G.G.</given-names></name>
<name><surname>Antonini</surname><given-names>P.</given-names></name>
<name><surname>White</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Structure of rifamycin W, a novel ansamycin from a mutant of <italic toggle="yes">Nocardia mediterranea</italic></article-title><source>Tetrahedron</source><year>1974</year><volume>30</volume><fpage>3087</fpage><lpage>3091</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(01)97557-X</pub-id></element-citation></ref><ref id="B174-antibiotics-10-01254"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cricchio</surname><given-names>R.</given-names></name>
<name><surname>Antonini</surname><given-names>P.</given-names></name>
<name><surname>Ferrari</surname><given-names>P.</given-names></name>
<name><surname>Ripamonti</surname><given-names>A.</given-names></name>
<name><surname>Tuan</surname><given-names>G.</given-names></name>
<name><surname>Martinelli</surname><given-names>E.</given-names></name>
</person-group><article-title>Rifamycin Z, a novel ansamycin from a mutant of <italic toggle="yes">Nocardia mediterranea</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1981</year><volume>34</volume><fpage>1257</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.34.1257</pub-id><pub-id pub-id-type="pmid">7309622</pub-id></element-citation></ref><ref id="B175-antibiotics-10-01254"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sensi</surname><given-names>P.</given-names></name>
<name><surname>Timbal</surname><given-names>M.T.</given-names></name>
<name><surname>Maffii</surname><given-names>G.</given-names></name>
</person-group><article-title>Rifomycin IX. Two new antibiotics of rifomycin family: Rifomycin S and rifomycin SV. Preliminary report</article-title><source>Experientia</source><year>1960</year><volume>16</volume><fpage>412</fpage><pub-id pub-id-type="doi">10.1007/BF02178838</pub-id><pub-id pub-id-type="pmid">13750122</pub-id></element-citation></ref><ref id="B176-antibiotics-10-01254"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lancini</surname><given-names>G.</given-names></name>
<name><surname>Hengeller</surname><given-names>C.</given-names></name>
</person-group><article-title>Isolation of rifamycin SV from a mutant <italic toggle="yes">Streptomyces mediterranei</italic> strain</article-title><source>J. Antibiot. (Tokyo)</source><year>1969</year><volume>22</volume><fpage>637</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.22.637</pub-id><pub-id pub-id-type="pmid">5367397</pub-id></element-citation></ref><ref id="B177-antibiotics-10-01254"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinelli</surname><given-names>E.</given-names></name>
<name><surname>Antonini</surname><given-names>P.</given-names></name>
<name><surname>Cricchio</surname><given-names>R.</given-names></name>
<name><surname>Lancini</surname><given-names>G.</given-names></name>
<name><surname>White</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Rifamycin R, a novel metabolite from a mutant of <italic toggle="yes">Nocardia mediterranea</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1978</year><volume>31</volume><fpage>949</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.31.949</pub-id><pub-id pub-id-type="pmid">711618</pub-id></element-citation></ref><ref id="B178-antibiotics-10-01254"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lancini</surname><given-names>G.</given-names></name>
<name><surname>Sartori</surname><given-names>G.</given-names></name>
</person-group><article-title>Rifamycin G, a further product of <italic toggle="yes">Nocardia mediterranei</italic> metabolism</article-title><source>J. Antibiot. (Tokyo)</source><year>1976</year><volume>29</volume><fpage>466</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.29.466</pub-id><?supplied-pmid 931815?><pub-id pub-id-type="pmid">931815</pub-id></element-citation></ref><ref id="B179-antibiotics-10-01254"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leitich</surname><given-names>J.</given-names></name>
<name><surname>Prelog</surname><given-names>V.</given-names></name>
<name><surname>Sensi</surname><given-names>P.</given-names></name>
</person-group><article-title>Rifomycin Y and its transformation products</article-title><source>Experientia</source><year>1967</year><volume>23</volume><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1007/BF02137934</pub-id><pub-id pub-id-type="pmid">6057725</pub-id></element-citation></ref><ref id="B180-antibiotics-10-01254"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lancini</surname><given-names>G.C.</given-names></name>
<name><surname>Thiemann</surname><given-names>J.E.</given-names></name>
<name><surname>Sartori</surname><given-names>G.</given-names></name>
<name><surname>Sensi</surname><given-names>P.</given-names></name>
</person-group><article-title>Biogenesis of rifamycins. The conversion of rifamycin B into rifamycin Y</article-title><source>Experientia</source><year>1967</year><volume>23</volume><fpage>899</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1007/BF02136207</pub-id><pub-id pub-id-type="pmid">6056996</pub-id></element-citation></ref><ref id="B181-antibiotics-10-01254"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stratmann</surname><given-names>A.</given-names></name>
<name><surname>Schupp</surname><given-names>T.</given-names></name>
<name><surname>Toupet</surname><given-names>C.</given-names></name>
<name><surname>Schilling</surname><given-names>W.</given-names></name>
<name><surname>Oberer</surname><given-names>L.</given-names></name>
<name><surname>Traber</surname><given-names>R.</given-names></name>
</person-group><article-title>New insights into rifamycin B biosynthesis: Isolation of proansamycin B and 34a-deoxy-rifamycin W as early macrocyclic intermediates indicating two separated biosynthetic pathways</article-title><source>J. Antibiot. (Tokyo)</source><year>2002</year><volume>55</volume><fpage>396</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.55.396</pub-id><pub-id pub-id-type="pmid">12061548</pub-id></element-citation></ref><ref id="B182-antibiotics-10-01254"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sensi</surname><given-names>P.</given-names></name>
<name><surname>Ballotta</surname><given-names>R.</given-names></name>
<name><surname>Greco</surname><given-names>M.</given-names></name>
</person-group><article-title>Rifomycin. V. Rifomycin O, a new antibiotic of the rifomycin family</article-title><source>Farmaco Sci.</source><year>1960</year><volume>15</volume><fpage>228</fpage><lpage>234</lpage><?supplied-pmid 13854754?><pub-id pub-id-type="pmid">13854754</pub-id></element-citation></ref><ref id="B183-antibiotics-10-01254"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanh</surname><given-names>B.T.B.</given-names></name>
<name><surname>Park</surname><given-names>J.W.</given-names></name>
<name><surname>Kim</surname><given-names>T.H.</given-names></name>
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
<name><surname>Yang</surname><given-names>C.S.</given-names></name>
<name><surname>Jang</surname><given-names>K.</given-names></name>
<name><surname>Cui</surname><given-names>J.</given-names></name>
<name><surname>Oh</surname><given-names>D.C.</given-names></name>
<name><surname>Jang</surname><given-names>J.</given-names></name>
</person-group><article-title>Rifamycin O, an alternative anti-<italic toggle="yes">Mycobacterium abscessus</italic> agent</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>1597</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25071597</pub-id></element-citation></ref><ref id="B184-antibiotics-10-01254"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cricchio</surname><given-names>R.</given-names></name>
<name><surname>Antonini</surname><given-names>P.</given-names></name>
<name><surname>Sartori</surname><given-names>G.</given-names></name>
</person-group><article-title>Thiazorifamycins. III. Biosynthesis of rifamycins P, Q and verde, novel metabolites from a mutant of <italic toggle="yes">Nocardia mediterranea</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1980</year><volume>33</volume><fpage>842</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.33.842</pub-id><?supplied-pmid 7429988?><pub-id pub-id-type="pmid">7429988</pub-id></element-citation></ref><ref id="B185-antibiotics-10-01254"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lancini</surname><given-names>G.C.</given-names></name>
<name><surname>Gallo</surname><given-names>G.G.</given-names></name>
<name><surname>Sartori</surname><given-names>G.</given-names></name>
<name><surname>Sensi</surname><given-names>P.</given-names></name>
</person-group><article-title>Isolation and structure of rifamycin L and its biogenetic relationship with other rifamycins</article-title><source>J. Antibiot. (Tokyo)</source><year>1969</year><volume>22</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.22.369</pub-id><?supplied-pmid 5345679?><pub-id pub-id-type="pmid">5345679</pub-id></element-citation></ref><ref id="B186-antibiotics-10-01254"><label>186.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Hengeller</surname><given-names>C.</given-names></name>
<name><surname>Lancini</surname><given-names>G.</given-names></name>
<name><surname>Sensi</surname><given-names>P.</given-names></name>
</person-group><article-title>27-Demethoxy-27-Hydroxyrifamycin Derivatives</article-title><source>US Patent</source><patent>3743635A</patent><day>3</day><month>July</month><year>1973</year></element-citation></ref><ref id="B187-antibiotics-10-01254"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Traxler</surname><given-names>P.</given-names></name>
<name><surname>Schupp</surname><given-names>T.</given-names></name>
<name><surname>Fuhrer</surname><given-names>H.</given-names></name>
<name><surname>Richter</surname><given-names>W.J.</given-names></name>
</person-group><article-title>3-Hydroxyrifamycin S and further novel ansamycins from a recombinant strain R-21 of <italic toggle="yes">Nocardia mediterranei</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1981</year><volume>34</volume><fpage>971</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.34.971</pub-id><pub-id pub-id-type="pmid">7319930</pub-id></element-citation></ref><ref id="B188-antibiotics-10-01254"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Portero</surname><given-names>J.-L.</given-names></name>
<name><surname>Rubio</surname><given-names>M.</given-names></name>
</person-group><article-title>New anti-tuberculosis therapies</article-title><source>Expert Opin. Ther. Patents</source><year>2007</year><volume>17</volume><fpage>617</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1517/13543776.17.6.617</pub-id></element-citation></ref><ref id="B189-antibiotics-10-01254"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomioka</surname><given-names>H.</given-names></name>
<name><surname>Namba</surname><given-names>K.</given-names></name>
</person-group><article-title>Development of antituberculous drugs: Current status and future prospects</article-title><source>Kekkaku</source><year>2006</year><volume>81</volume><fpage>753</fpage><lpage>774</lpage><comment>(In Japanese)</comment><pub-id pub-id-type="pmid">17240921</pub-id></element-citation></ref><ref id="B190-antibiotics-10-01254"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chakraborty</surname><given-names>S.</given-names></name>
<name><surname>Rhee</surname><given-names>K.Y.</given-names></name>
</person-group><article-title>Tuberculosis drug development: History and evolution of the mechanism-based paradigm</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2015</year><volume>5</volume><fpage>a021147</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a021147</pub-id><pub-id pub-id-type="pmid">25877396</pub-id></element-citation></ref><ref id="B191-antibiotics-10-01254"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Udwadia</surname><given-names>Z.F.</given-names></name>
</person-group><article-title>MDR, XDR, TDR tuberculosis: Ominous progression</article-title><source>Thorax</source><year>2012</year><volume>67</volume><fpage>286</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2012-201663</pub-id><pub-id pub-id-type="pmid">22427352</pub-id></element-citation></ref><ref id="B192-antibiotics-10-01254"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>X.-F.</given-names></name>
<name><surname>Liu</surname><given-names>X.-Q.</given-names></name>
<name><surname>Peng</surname><given-names>S.-Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Tang</surname><given-names>G.-L.</given-names></name>
</person-group><article-title>Characterization of the rifamycin-degrading monooxygenase from rifamycin producers implicating its involvement in saliniketal biosynthesis</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><fpage>971</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.00971</pub-id><pub-id pub-id-type="pmid">32582048</pub-id></element-citation></ref><ref id="B193-antibiotics-10-01254"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rothstein</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Rifamycins, alone and in combination</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a027011</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a027011</pub-id><pub-id pub-id-type="pmid">27270559</pub-id></element-citation></ref><ref id="B194-antibiotics-10-01254"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nigam</surname><given-names>A.</given-names></name>
<name><surname>Almabruk</surname><given-names>K.H.</given-names></name>
<name><surname>Saxena</surname><given-names>A.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Mukherjee</surname><given-names>U.</given-names></name>
<name><surname>Kaur</surname><given-names>H.</given-names></name>
<name><surname>Kohli</surname><given-names>P.</given-names></name>
<name><surname>Kumari</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Zakharov</surname><given-names>L.N.</given-names></name>
<etal/>
</person-group><article-title>Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>21142</fpage><lpage>21152</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.572636</pub-id><pub-id pub-id-type="pmid">24923585</pub-id></element-citation></ref><ref id="B195-antibiotics-10-01254"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Ye</surname><given-names>F.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Rifamycin W analogues from <italic toggle="yes">Amycolatopsis mediterranei</italic> S699 &#x00394;<italic toggle="yes">rif</italic>-<italic toggle="yes">orf5</italic> strain</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>920</elocation-id><pub-id pub-id-type="doi">10.3390/biom11070920</pub-id><pub-id pub-id-type="pmid">34206314</pub-id></element-citation></ref><ref id="B196-antibiotics-10-01254"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ye</surname><given-names>F.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>8-Deoxy-rifamycin derivatives from <italic toggle="yes">Amycolatopsis mediterranei</italic> S699 <italic toggle="yes">&#x00394;rifT</italic> strain</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><elocation-id>1265</elocation-id><pub-id pub-id-type="doi">10.3390/biom10091265</pub-id><?supplied-pmid 32887371?><pub-id pub-id-type="pmid">32887371</pub-id></element-citation></ref><ref id="B197-antibiotics-10-01254"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peek</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Suryavanshi</surname><given-names>S.</given-names></name>
<name><surname>Zimmerman</surname><given-names>M.</given-names></name>
<name><surname>Russo</surname><given-names>R.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Perlin</surname><given-names>D.S.</given-names></name>
<name><surname>Brady</surname><given-names>S.F.</given-names></name>
</person-group><article-title>A Semisynthetic Kanglemycin shows <italic toggle="yes">in vivo</italic> efficacy against high-burden rifampicin resistant pathogens</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>2431</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00223</pub-id><?supplied-pmid 32786275?><pub-id pub-id-type="pmid">32786275</pub-id></element-citation></ref><ref id="B198-antibiotics-10-01254"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chopra</surname><given-names>I.</given-names></name>
</person-group><article-title>Tetracycline analogs whose primary target is not the bacterial ribosome</article-title><source>Antimicrob. Agents Chemother.</source><year>1994</year><volume>38</volume><fpage>637</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1128/AAC.38.4.637</pub-id><pub-id pub-id-type="pmid">8031024</pub-id></element-citation></ref><ref id="B199-antibiotics-10-01254"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stepanek</surname><given-names>J.J.</given-names></name>
<name><surname>Luke&#x0017e;i&#x0010d;</surname><given-names>T.</given-names></name>
<name><surname>Teichert</surname><given-names>I.</given-names></name>
<name><surname>Petkovi&#x00107;</surname><given-names>H.</given-names></name>
<name><surname>Bandow</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Dual mechanism of action of the atypical tetracycline chelocardin</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1864</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2016.03.004</pub-id><?supplied-pmid 26969785?><pub-id pub-id-type="pmid">26969785</pub-id></element-citation></ref><ref id="B200-antibiotics-10-01254"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le&#x00161;nik</surname><given-names>U.</given-names></name>
<name><surname>Luke&#x0017e;i&#x0010d;</surname><given-names>T.</given-names></name>
<name><surname>Podgor&#x00161;ek</surname><given-names>A.</given-names></name>
<name><surname>Horvat</surname><given-names>J.</given-names></name>
<name><surname>Polak</surname><given-names>T.</given-names></name>
<name><surname>&#x00160;ala</surname><given-names>M.</given-names></name>
<name><surname>Jenko</surname><given-names>B.</given-names></name>
<name><surname>Harmrolfs</surname><given-names>K.</given-names></name>
<name><surname>Ocampo-Sosa</surname><given-names>A.</given-names></name>
<name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Construction of a new class of tetracycline lead structures with potent antibacterial activity through biosynthetic engineering</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2015</year><volume>54</volume><fpage>3937</fpage><lpage>3940</lpage><pub-id pub-id-type="doi">10.1002/anie.201411028</pub-id><?supplied-pmid 25650563?><pub-id pub-id-type="pmid">25650563</pub-id></element-citation></ref><ref id="B201-antibiotics-10-01254"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grandclaudon</surname><given-names>C.</given-names></name>
<name><surname>Birudukota</surname><given-names>N.V.S.</given-names></name>
<name><surname>Elgaher</surname><given-names>W.A.M.</given-names></name>
<name><surname>Jumde</surname><given-names>R.P.</given-names></name>
<name><surname>Yahiaoui</surname><given-names>S.</given-names></name>
<name><surname>Arisetti</surname><given-names>N.</given-names></name>
<name><surname>Hennessen</surname><given-names>F.</given-names></name>
<name><surname>H&#x000fc;ttel</surname><given-names>S.</given-names></name>
<name><surname>Stadler</surname><given-names>M.</given-names></name>
<name><surname>Herrmann</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Semisynthesis and biological evaluation of amidochelocardin derivatives as broad-spectrum antibiotics</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>188</volume><fpage>112005</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.112005</pub-id><pub-id pub-id-type="pmid">31911294</pub-id></element-citation></ref><ref id="B202-antibiotics-10-01254"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>N.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Mayilraj</surname><given-names>S.</given-names></name>
</person-group><article-title>Genome sequencing and annotation of <italic toggle="yes">Amycolatopsis vancoresmycina</italic> strain DSM 44592<sup>T</sup></article-title><source>Genom. Data</source><year>2014</year><volume>2</volume><fpage>16</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.gdata.2013.10.006</pub-id><?supplied-pmid 26484057?><pub-id pub-id-type="pmid">26484057</pub-id></element-citation></ref><ref id="B203-antibiotics-10-01254"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Bergeijk</surname><given-names>D.A.</given-names></name>
<name><surname>Terlouw</surname><given-names>B.R.</given-names></name>
<name><surname>Medema</surname><given-names>M.H.</given-names></name>
<name><surname>van Wezel</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Ecology and genomics of Actinobacteria: New concepts for natural product discovery</article-title><source>Nat. Rev. Microbiol.</source><year>2020</year><volume>18</volume><fpage>546</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-0379-y</pub-id><?supplied-pmid 32483324?><pub-id pub-id-type="pmid">32483324</pub-id></element-citation></ref><ref id="B204-antibiotics-10-01254"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>S.Y.</given-names></name>
<name><surname>Xiao</surname><given-names>Y.S.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Shao</surname><given-names>F.L.</given-names></name>
<name><surname>Guo</surname><given-names>Z.K.</given-names></name>
<name><surname>Zhang</surname><given-names>J.J.</given-names></name>
<name><surname>Jiao</surname><given-names>R.H.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Q.</given-names></name>
<name><surname>Tan</surname><given-names>R.X.</given-names></name>
<etal/>
</person-group><article-title>Amycolamycins A and B, two enediyne-derived compounds from a locust-associated Actinomycete</article-title><source>Org. Lett.</source><year>2017</year><volume>19</volume><fpage>6208</fpage><lpage>6211</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.7b03113</pub-id><?supplied-pmid 29090939?><pub-id pub-id-type="pmid">29090939</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antibiotics-10-01254-f001"><label>Figure 1</label><caption><p>(<bold>A</bold>). <italic toggle="yes">Amycolatopsis orientalis</italic>&#x02014;vancomycin producer. (<bold>B</bold>). Taxonomy position of the genera <italic toggle="yes">Amycolatopsis</italic>. Nomenclatural status of species: validly published [<xref rid="B18-antibiotics-10-01254" ref-type="bibr">18</xref>]. Note: *&#x02014;species that are described as antibiotics producers.</p></caption><graphic xlink:href="antibiotics-10-01254-g001" position="float"/></fig><fig position="float" id="antibiotics-10-01254-f002"><label>Figure 2</label><caption><p>Glycopeptide antibiotics: (<bold>1</bold>) vancomycin, (<bold>2</bold>) norvancomycin, (<bold>3</bold>) eremomycin, (<bold>4</bold>) balhimycin, (<bold>5</bold>) ristocetin, (<bold>6</bold>) avoparcin, and (<bold>7</bold>) keratinimicin A.</p></caption><graphic xlink:href="antibiotics-10-01254-g002" position="float"/></fig><fig position="float" id="antibiotics-10-01254-f003"><label>Figure 3</label><caption><p>Polyketide antibiotics: (<bold>1</bold>) rifamycin B, (<bold>2</bold>) kanglemycin A, (<bold>3</bold>) vancoresmycin, (<bold>4</bold>) chelocardin, (<bold>5</bold>) rifamorpholine B.</p></caption><graphic xlink:href="antibiotics-10-01254-g003" position="float"/></fig><table-wrap position="float" id="antibiotics-10-01254-t001"><object-id pub-id-type="pii">antibiotics-10-01254-t001_Table 1</object-id><label>Table 1</label><caption><p>Number of identified biosynthetic gene clusters for various genera of actinobacteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Average Total Genome Length <break/>(Mb) [<xref rid="B19-antibiotics-10-01254" ref-type="bibr">19</xref>]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Biosynthetic <break/>Gene Clusters [<xref rid="B25-antibiotics-10-01254" ref-type="bibr">25</xref>]</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Actinoplanes</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Actinomadura</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Amycolatopsis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Micromonospora</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Nocardia</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptomyces</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">637</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Streptosporangium</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td></tr></tbody></table></table-wrap><table-wrap position="float" id="antibiotics-10-01254-t002"><object-id pub-id-type="pii">antibiotics-10-01254-t002_Table 2</object-id><label>Table 2</label><caption><p>Representatives of the genus <italic toggle="yes">Amycolatopsis</italic> and the antibiotics they produce.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species, Strains</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Properties</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp. 17128</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutactimycin A, D, E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA <sup>1</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-antibiotics-10-01254" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp. Cra33g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amycolactam</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant cytotoxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-antibiotics-10-01254" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp. Hca4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamorpholines A&#x02013;E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-antibiotics-10-01254" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp.<break/>IRD-009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pradimicin-IRD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive and Gram-negative bacteria;<break/>Cytotoxic activity against cancer cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-antibiotics-10-01254" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp.<break/>&#x0041a;16-0194</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dipyrimicins A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dipyrimicin A exhibits strong antimicrobial and cytotoxic activities;<break/>Dipyrimicin B exhibits antimicrobial activity against <italic toggle="yes">Escherichia coli</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-antibiotics-10-01254" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp. LZ149</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Siderochelins A, D, E, and F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Siderochelin A exhibits antimicrobial activity against Gram-positive bacteria and <italic toggle="yes">Escherichia coli</italic>;<break/>Siderochelins A, D and E exhibit antimicrobial activity against <italic toggle="yes">Mycobacterium smegmatis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-antibiotics-10-01254" ref-type="bibr">35</xref>,<xref rid="B36-antibiotics-10-01254" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp. M39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Macrotermycins A&#x02013;D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Macrotermycins A and C had antimicrobial activity against Gram-positive bacteria (particularly staphylococcal infections);<break/>Selective antifungal activity (against a fungal parasite of the termite fungal garden)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B14-antibiotics-10-01254" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp.<break/>MI481-42F4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00410;mythiamicins A, B, C and D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MDR <sup>2</sup> strains)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-antibiotics-10-01254" ref-type="bibr">37</xref>,<xref rid="B38-antibiotics-10-01254" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amycolatopsis sp.<break/>MJM2582</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ristocetin (Ristomycin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive pathogenic infections (particularly staphylococcal infections);<break/>Applied to the in vitro diagnosis of conditions such as von Willebrand disease and Bernard&#x02013;Soulier syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-antibiotics-10-01254" ref-type="bibr">39</xref>,<xref rid="B40-antibiotics-10-01254" ref-type="bibr">40</xref>,<xref rid="B41-antibiotics-10-01254" ref-type="bibr">41</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp. <break/>ML1-hF4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00420;argamicins A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against <italic toggle="yes">Staphylococcus aureus</italic> strains (including MRSA) and <italic toggle="yes">Enterococcus faecalis, E. faecium</italic> strains (including VRE <sup>3</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-antibiotics-10-01254" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Valgamicins A, C, T and V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weak activity against Gram-positive and Gram-negative bacteria;<break/>Valgamicins A, C and T exhibit moderate cytotoxicity against human tumor cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-antibiotics-10-01254" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp.<break/>YIM 130642</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amycophthalazinone A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weak antimicrobial and antifungal activities</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-antibiotics-10-01254" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp.<break/>YIM 130687</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-carbamoyl-3-hydroxy-1,4-naphthoquinone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial (including MRSA) and antifungal activities</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-antibiotics-10-01254" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis</italic> sp. AA4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amycomicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial activity against <italic toggle="yes">Staphylococcus aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-antibiotics-10-01254" ref-type="bibr">46</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">A. alba</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1(10-aminodecyl) pyridinium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive and Gram-negative bacteria;<break/>Cytotoxic activity against cancer cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-antibiotics-10-01254" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kigamicins A-E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA); <break/>Kigamicin D is an anticancer agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-antibiotics-10-01254" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-10-01254" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maytansinoids 1&#x02013;14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Maytansinoids 7 and 13 showed antitumor activities against four human cancer cell lines
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-antibiotics-10-01254" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. australiensis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">A. azurea</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azureomycins A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial activity against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-antibiotics-10-01254" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-10-01254" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0041e;ctacosamicins A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very weak or no activity against Gram-positive and Gram-negative bacteria;<break/>Moderate activity against fungi and yeast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-antibiotics-10-01254" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-10-01254" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. balhimycina</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Balhimycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-antibiotics-10-01254" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. coloradensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoparcin (avotan)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria;<break/>Animal growth promoter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-antibiotics-10-01254" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-10-01254" ref-type="bibr">57</xref>,<xref rid="B58-antibiotics-10-01254" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. decaplanina</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decaplanin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including antibiotic-resistant enterococci and clinical isolates)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-antibiotics-10-01254" ref-type="bibr">59</xref>,<xref rid="B60-antibiotics-10-01254" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. hippodromi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amycolasporins A&#x02212;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive and Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-antibiotics-10-01254" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. japonica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ristocetin (Ristomycin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria, (particularly staphylococcal infections);<break/>Applied to the in vitro diagnosis of conditions such as von Willebrand disease and Bernard&#x02013;Soulier syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-antibiotics-10-01254" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. jejuensis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-antibiotics-10-01254" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. keratiniphila</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Keratinimicins A&#x02013;D;<break/>Keratinicyclin A&#x02013;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Keratinimicins A and C exibit strong antimicrobial activity against Gram-positive bacteria (particularly staphylococcal infections);<break/>keratinicyclin &#x00412; exibit moderate antimicrobial activity against <italic toggle="yes">Streptococcus</italic> spp. and <italic toggle="yes">Clostridium difficile</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-antibiotics-10-01254" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">A. keratiniphila</italic> subsp. <italic toggle="yes">keratiniphila</italic></td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">A. keratiniphila</italic> subsp. <italic toggle="yes">nogabecina</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nogabecin (Actinoidin B)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-antibiotics-10-01254" ref-type="bibr">64</xref>,<xref rid="B65-antibiotics-10-01254" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">A. lactamdurans</italic> *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cephamycin C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive and Gram-negative bacteria (including resistant strains); very efficient antibiotic against anaerobic microbes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-antibiotics-10-01254" ref-type="bibr">66</xref>,<xref rid="B67-antibiotics-10-01254" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-10-01254" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-10-01254" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efrotomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-antibiotics-10-01254" ref-type="bibr">68</xref>,<xref rid="B70-antibiotics-10-01254" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. lurida</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzanthrins A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria;<break/>Inhibit the growth tumor cells in tissue culture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-antibiotics-10-01254" ref-type="bibr">71</xref>,<xref rid="B72-antibiotics-10-01254" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. lurida</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ristocetin (Ristomycin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria, (particularly staphylococcal infections);<break/>Applied to the in vitro diagnosis of conditions, such as von Willebrand disease and Bernard&#x02013;Soulier syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-antibiotics-10-01254" ref-type="bibr">41</xref>,<xref rid="B73-antibiotics-10-01254" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-10-01254" ref-type="bibr">74</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">A. mediterranei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amexanthomycins A&#x02013;J</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitory activity against human DNA topoisomerases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-antibiotics-10-01254" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dethymicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA);<break/>Immunosuppressant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-antibiotics-10-01254" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kanglemycin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including rifampicin-resistant ones and <italic toggle="yes">M. tuberculosis</italic> with MDR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-antibiotics-10-01254" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-10-01254" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial activity against Gram-positive bacteria (particularly mycobacteria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-antibiotics-10-01254" ref-type="bibr">79</xref>,<xref rid="B80-antibiotics-10-01254" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-10-01254" ref-type="bibr">81</xref>,<xref rid="B82-antibiotics-10-01254" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-10-01254" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracenomycin &#x00425;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria;<break/>Showed antitumour activity <italic toggle="yes">in vivo</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-antibiotics-10-01254" ref-type="bibr">84</xref>,<xref rid="B85-antibiotics-10-01254" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. minnesotensis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. nigrescens</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. niigatensis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">A. orientalis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vancomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A last-line drug for the treatment of infections caused by almost all clinically significant Gram-positive bacteria (including MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-antibiotics-10-01254" ref-type="bibr">3</xref>,<xref rid="B86-antibiotics-10-01254" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic>&#x02013;Demethylvancomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-antibiotics-10-01254" ref-type="bibr">87</xref>,<xref rid="B88-antibiotics-10-01254" ref-type="bibr">88</xref>,<xref rid="B89-antibiotics-10-01254" ref-type="bibr">89</xref>,<xref rid="B90-antibiotics-10-01254" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>&#x02013;Demethylvancomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-antibiotics-10-01254" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Norvancomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (particularly MRSA and MRSE <sup>4</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-antibiotics-10-01254" ref-type="bibr">92</xref>,<xref rid="B93-antibiotics-10-01254" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quartromicin (the complex of at least six antibiotics components A1, A2, A3, D1, D2, and D3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral activity against herpes simplex virus type 1, influenza virus type A and human immunodeficiency virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-antibiotics-10-01254" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK-69753</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial activity <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> against the swine Gram-negative anaerobic pathogen <italic toggle="yes">Treponema hyodysenteriae</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-antibiotics-10-01254" ref-type="bibr">95</xref>,<xref rid="B96-antibiotics-10-01254" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MM 47761 and MM 4972; MM 55266, and MM 55268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-antibiotics-10-01254" ref-type="bibr">97</xref>,<xref rid="B98-antibiotics-10-01254" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eremomycin &#x00412;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-antibiotics-10-01254" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-10-01254" ref-type="bibr">100</xref>,<xref rid="B101-antibiotics-10-01254" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Orienticins A-D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against <italic toggle="yes">S. aureus</italic> (including MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-antibiotics-10-01254" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00421;hloroorienticins A-E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against <italic toggle="yes">S. aureus</italic> (including MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-antibiotics-10-01254" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LY264826</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-antibiotics-10-01254" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ECO-0501</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial activity against Gram-positive bacteria (including MRSA and VRE)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-antibiotics-10-01254" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. palatopharyngis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. regifaucium</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kigamicins A-E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including MRSA);<break/>Kigamicin D is an anticancer agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-antibiotics-10-01254" ref-type="bibr">48</xref>,<xref rid="B105-antibiotics-10-01254" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-10-01254" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-10-01254" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. rifamycinica</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracenomycin &#x00425;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate antimicrobial activity against Gram-positive organisms (including resistant strains);<break/>Activity against certain tumor cell lines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-antibiotics-10-01254" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-10-01254" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. roodepoortensis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified;<break/>Antimicrobial activity against Gram-positive (particularly mycobacteria) and Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-antibiotics-10-01254" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. rubida</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. saalfeldensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saalfelduracin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial activity against drug-resistant Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-antibiotics-10-01254" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. speibonae</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified;<break/>Antimicrobial activity against Gram-positive bacteria (particularly mycobacteria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-antibiotics-10-01254" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. speibonae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Echinosporin<break/>7-deoxyechinosporin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal activity against root-rot pathogens of the <italic toggle="yes">Panax notoginseng</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-antibiotics-10-01254" ref-type="bibr">111</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">A. sulphurea</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epoxyquinomicins A-D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epoxyquinomicins A and B exhibit antimicrobial activity against Gram-positive bacteria;<break/>Epoxyquinomicins C and D exhibit almost no antimicrobial activity and no cytotoxicity;<break/>All these antibiotics showed improvement of collagen induced arthritis <italic toggle="yes">in vivo</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-antibiotics-10-01254" ref-type="bibr">112</xref>,<xref rid="B113-antibiotics-10-01254" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azicemicins A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate antimicrobial activity against Gram-positive bacteria (particularly mycobacteria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-antibiotics-10-01254" ref-type="bibr">114</xref>,<xref rid="B115-antibiotics-10-01254" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Chelocardin</bold> (Cetocycline)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive and Gram-negative (including tetracycline-resistant pathogens and MDR pathogens)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-antibiotics-10-01254" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-10-01254" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-10-01254" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. taiwanensis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">A. thermoflava</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-methoxy-3-methyl-8-hydroxy-anthraquinone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic biosynthetic genes were identified<break/>Anticancer activity against lung cancer and lymphoblastic leukemia cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-antibiotics-10-01254" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. tolypomycina</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tolypomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong antimicrobial activities against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-antibiotics-10-01254" ref-type="bibr">65</xref>,<xref rid="B120-antibiotics-10-01254" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. tucumanensis</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. umgeniensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eremomycin &#x00412;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-antibiotics-10-01254" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">A. vancoresmycina</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vancoresmycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial activity against Gram-positive bacteria (including resistant strains)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-antibiotics-10-01254" ref-type="bibr">122</xref>,<xref rid="B123-antibiotics-10-01254" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">&#x00410;. xylanica</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antibiotic biosynthetic genes were identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-antibiotics-10-01254" ref-type="bibr">27</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Strong antimicrobial activity&#x02014;MIC &#x02264; 1 &#x000b5;g/mL, moderate&#x02014;MIC 1&#x02013;16 &#x000b5;g/mL, weak&#x02014;MIC &#x02265; 16 &#x000b5;g/mL. <sup>1</sup> MRSA&#x02014;methicillin-resistant <italic toggle="yes">S. aureus</italic>; <sup>2</sup> MDR&#x02014;multiple drug resistance; <sup>3</sup> VRE&#x02014;vancomycin-resistant enterococci; <sup>4</sup> MRSE&#x02014;methicillin-resistant <italic toggle="yes">S. epidermidis</italic>; * Nomenclatural status: not validly published.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="antibiotics-10-01254-t003"><object-id pub-id-type="pii">antibiotics-10-01254-t003_Table 3</object-id><label>Table 3</label><caption><p>Rifamycins and related metabolites produced by actinobacteria of the genus <italic toggle="yes">Amycolatopsis</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin Metabolites</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Possible Precursor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Properties</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proansamycin X</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">The first hypothetical macrocyclic intermediate of rifamycin biosynthesis has never been isolated and identified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-antibiotics-10-01254" ref-type="bibr">83</xref>,<xref rid="B169-antibiotics-10-01254" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protorifamycin I (8-deoxyansamycins W)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proansamycin X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No activity against Gram-positive bacteria or Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B170-antibiotics-10-01254" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">modified protorifamycins (derived from protorifamycin I) and defective rifamycins (8-deoxyrifamycins)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protorifamycin I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No antibiotic activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B171-antibiotics-10-01254" ref-type="bibr">171</xref>,<xref rid="B172-antibiotics-10-01254" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proansamycin X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No activity against Gram-positive bacteria or Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-antibiotics-10-01254" ref-type="bibr">173</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin Z</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No activity against Gram-positive bacteria or Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-antibiotics-10-01254" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31-Homorifamycin W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant antibacterial, antifungal, or antiviral activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-antibiotics-10-01254" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin SV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong activity<break/>against Gram-positive bacteria (particularly mycobacteria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-antibiotics-10-01254" ref-type="bibr">175</xref>,<xref rid="B176-antibiotics-10-01254" ref-type="bibr">176</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin SV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong activity<break/>against Gram-positive bacteria (particularly mycobacteria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-antibiotics-10-01254" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong activity<break/>against Gram-positive bacteria (particularly mycobacteria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B177-antibiotics-10-01254" ref-type="bibr">177</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activity against <italic toggle="yes">M. tuberculosis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B178-antibiotics-10-01254" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin Y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotically inactive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-antibiotics-10-01254" ref-type="bibr">179</xref>,<xref rid="B180-antibiotics-10-01254" ref-type="bibr">180</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin YO, YS, Isorifamycin Y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin Y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotically inactive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-antibiotics-10-01254" ref-type="bibr">179</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protorifamycin B, 34a-deoxy-rifamycin W, Rifamycin W-28-desmethyl-28-carboxy, Rifamycin W-hemiacetal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-antibiotics-10-01254" ref-type="bibr">181</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activity against <italic toggle="yes">M.</italic><italic toggle="yes">abscessus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-antibiotics-10-01254" ref-type="bibr">164</xref>,<xref rid="B182-antibiotics-10-01254" ref-type="bibr">182</xref>,<xref rid="B183-antibiotics-10-01254" ref-type="bibr">183</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thiazorifamycins:<break/>Rifamycin Q, Rifamycin P, Rifamycin Verde</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B184-antibiotics-10-01254" ref-type="bibr">184</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good antimicrobial activity against Gram-positive and Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-antibiotics-10-01254" ref-type="bibr">164</xref>,<xref rid="B185-antibiotics-10-01254" ref-type="bibr">185</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin &#x00412;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activity against Gram-positive bacteria (particularly mycobacteria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-antibiotics-10-01254" ref-type="bibr">79</xref>,<xref rid="B164-antibiotics-10-01254" ref-type="bibr">164</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27-Demethoxy-27-hydroxyrifamycin derivatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin SV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activity against several Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B186-antibiotics-10-01254" ref-type="bibr">186</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3-Hydroxyrifamycin S and further novel ansamycins S, G and W type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S and W, respectively</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ansamycins W type are devoid of any biological activity. Other ansamacins exhibit activity against Gram-positive and Gram-negative bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B187-antibiotics-10-01254" ref-type="bibr">187</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamorpholines &#x00410;-&#x00415;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Rifamorpholines B and D exhibit antimicrobial activity against methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-antibiotics-10-01254" ref-type="bibr">13</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Strong antimicrobial activity&#x02014;MIC &#x02264; 1 &#x000b5;g/mL, moderate&#x02014;MIC 1&#x02013;16 &#x000b5;g/mL, weak&#x02014;MIC &#x02265;16 &#x000b5;g/mL.</p></fn></table-wrap-foot></table-wrap></floats-group></article>